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ABSTRACT PAGE
Pax5 is a master regulator of B cell commitment and development, and regulates the 
expression of a host of genes involved in B cell maturation and activation. Previous studies on 
mice and human Pax5 have reported on alternatively spliced isoforms that have altered DNA 
binding (encoded by exons 2 and 3) and trans-activation (TA) potential (encoded by exons 
7-10). The study presented here had two goals. Our first goal was to clone and identify trout 
Pax5 isoforms. cDNA from four trout immune tissues (anterior and posterior kidney, spleen 
and blood) were screened by nested PCR to search for alternatively spliced Pax5 transcripts. 
Alternative splicing of trout Pax5 gives rise to at least six alternatively spliced transcripts with 
deletion of paired domain, trans-activation domain and/or inhibitory domain coding elements. 
Several splice forms lacking exons 2, 8 or 9 were uncovered. Our second goal was to study 
the relative expression of Pax5 isoforms during B cell activation. Using semi-quantitative 
RT-PCR, the change in relative amplification of each isoform transcript was analyzed during 
LPS activation of splenic and blood derived B cells. Our studies report that spliced Pax5 
transcripts lacking exon 2 or 8 are up-regulated during B cell activation with LPS, suggesting 
these isoforms have roles in terminal B cell differentiation. Conversely, transcripts lacking exon 
9 were relatively scarce in LPS activated splenic and blood-derived B cells and probably do not 
participate in the regulation of terminal differentiation in these tissues. Thus alternatively 
spliced Pax5 transcripts show unique tissue-specific relative expression patterns in trout B 
cells.
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Chapter 1 -  Introduction
1.1 Overview of the Pax family of proteins
The Paired-box (Pax) family of transcription factors was first identified as a group of 
proteins that control organogenesis and cell-fate specification in Drosophila. Pax 
homologs have since been described in various members of the vertebrate lineage; 
including teleosts, frogs, chicken, mice and humans. Expression of Pax genes is spatially 
and temporally regulated during embryogenesis and mutation of Pax genes leads to an 
array of lethal and sub-lethal developmental defects (Wang et al, 2008). Members of the 
Pax family possess 128 amino acids of conserved DNA binding domain at the amino- 
terminal, called the paired-box. The mammalian Pax family consists of nine members 
that have been grouped together based on the presence of three structural domains -  
Paired, Octopeptide and Homeodomain (figure 1.1) (Mansouri et al, 1999, Noll, 1993). 
Through these domains and other motifs, Pax proteins interact with DNA and other 
proteins. Pax5 is a member of the Pax family and is the master regulator of B cell 
development in the immune system.
Functional Domains: The Pax paired domain was identified as a helix-turn-helix domain 
in Drosophila paired proteins and consists of two sub-domains -  an N-terminal PAI sub- 
domain and a C-terminal RED sub-domain separated by an unstructured linker region 
(Czerny et al, 1993, Xu et al, 1999). Both PAI and RED make specific contacts on DNA
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independently, and this binding is stabilized by an N-terminal (3-turn and the linker 
region. The paired domain is encoded by exons 2, 3 and 4. The consensus DNA binding 
site for the paired domain is [(G/T)T(T/C)(C/A)(C/T)(G/C)(G/C)]. Exceptions to this are 
the DNA binding sites for Pax-6 [TTCACGC] and Pax-8 [GTCAC(G/C)C] (Jun et al, 1996, 
Czerny et al 1993, Epstein et al 1994). Interestingly, the paired domain is also reported 
to interact with the HMG domain of Sox proteins (Lang and Epstein, 2003). These 
interactions induce gene expression more robustly than either transcription factor can 
alone, as in the case of Pax-3 and Sox-10 at the M it/a n d  Ret promoters (Bondurand et 
al, 2000) and Pax-6 and Sox-2 at the 6-crystallin promoter (Kamachi et al, 2001).
Like the paired domain, the homeodomain is a sequence-specific helix-turn-helix DNA 
binding motif that binds the palindromic sequence TAAT(N)2- 3ATTA called the 
homeobox (Wilson et al, 1993). Homeodomain containing proteins are divided into two  
genetic groups. The first group comprises the Hox genes, which are further clustered on 
the vertebrate genome and their spatial and temporal expression during embryonic 
patterning. The second group, the 'orphan7 group, does not occur in genetic clusters and 
their expression is restricted to specific tissue types (Simon & Alavian, 2009). The Pax 
genes belong to the 'orphan7 group of Homeodomain-containing proteins along with the 
transcription factors POU, SIX, OCT, PITX and NKX (for a complete list of homeodomain 
proteins refer http://research.nhgri.nih.gov/homeodomain). The Pax homeodomain is 
encoded by exons 6 and 7, except in Group I and II sub-groups.
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Group# Structural Domains Pax family members
Group I 
Group II 
Group III 
Group IV
Pax 1 and Pax 9
Pax 2, Pax5 and Pax 8
Pax3 and Pax7
Pax 4 and Pax6
Paired
Domain m
Octo-
peptide
Domain
Homeo - 
Domain
Figure 1.1 Sub-families of Pax proteins classified by presence of structural domains. The nine members 
of mammalian Pax family are classified into four sub-groups based on presence of paired domain (PD - 
blue cylinder), octopeptide segment (OD - red box) and homeodomain (HD - grey cylinder). Group I 
members Pax 1 and 9 have PD and OD but lack HD. Group 2 members Pax 2, 5 and 8 have PD and OD but 
only partial HD. Group 3 members Pax 3 and 7 have all three structural domains. Group 4 members Pax 4 
and 6 have PD and HD, but lack OD.
Members of the Pax family also possess an eight amino acid octopeptide motif encoded 
by exon 5, except Pax-4 and Pax-6 (Noll, 1993). This motif functions as a transcriptional 
inhibitor, through direct interaction with the Groucho family of transcriptional 
repressors (Eberhard et al, 2000). Pax 3 and 5 interact with GRG4 (a member of the 
groucho family) and Lymphoid Enhancer binding factor (LEF-1) to form a repression 
complex (Jin et al, 2002). Through this complex, Pax proteins are thought to participate 
in the W nt signaling pathway, the dysregulation of which is responsible for the 
development of several types of cancers (Behrens, 2005).
Pax proteins also contain a potent trans-activation domain (TD) at the carboxy-terminus 
which is rich in proline-serine-threonine (PST) residues. The TD is encoded by exon 8 and 
partly by exon 9. Most Pax proteins show dose-dependent trans-activation through the
3
TD, as in Pax-5 and Pax-6 where transcriptional activation is high low concentrations and 
decreases at higher concentrations (Glasner et al, 1994, Dorfler & Busslinger, 1996). 
Additionally, Pax-2, Pax-3, Pax-4, Pax-5 and Pax-6 can inhibit transcription through an 
inhibitory domain (ID) located adjacent to the TD at the carboxy-terminus (Chi & 
Epstein, 2002, Dorfler & Busslinger, 1996). The inhibitor domain is encoded by part of 
exon 9 and exon 10. The transcriptional activity of Pax proteins is the result of relative 
activity between activation and repression functions.
1.2 Role of Pax genes in embryonic development and oncogenesis:
Pax proteins influence cell-fate decisions of multi-potent stem cells. For example, Pax-5 is 
essential for the commitment of lymphoid progenitors to the B cell lineage (Cobaleda et 
al, 2007). Pax5 knockout mice show a complete loss of B cell phenotype and an increase 
in cells of the T cell and natural killer cell lineage, suggesting Pax5 represses the 
differentiation of uncommitted progenitor cells into non-B lineages (Mikkola et al, 2002, 
Cobaleda et al, 2007). Similarly, lack of Pax-6 in mice and humans shows complete loss 
of eye development as the gene is required for the specification of multiple ocular 
lineages (Marquardt et al, 2001). Interestingly, loss of Pax-7 does not lead to any 
developmental defects in Pax-7^ mice, probably because Pax-3 can substitute loss of 
expression of Pax-7 in skeletal muscle (Seale et al, 2000). However, Pax-7 null mice die 
shortly after birth, due the inability of skeletal muscles to regenerate. A complete list of 
Pax proteins and their tissue specific expression is listed in table 1.1.
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Pax proteins promote cellular survival and inhibit apoptotic signals during cellular 
development. Pax 2, 5 and 8 demonstrate anti-apoptotic activity by directly inhibiting 
p53 expression through a highly conserved enhancer region (Stuart et al, 1995). The p53 
family of transcription factors are well known tumor suppressors and are important 
inhibitors of the cell cycle. Loss of Pax-2 expression by siRNA induces apoptosis in renal 
carcinoma cells (Gnarra and Dressier, 1995). Similarly, oligonucleotide inhibition of Pax- 
3 mRNA transcripts leads to increased cell death in rhabomyosarcoma cells (Bernasconi 
et al, 1996).
Down-regulation o f Pax genes is vital fo r terminal differentiation. Pax5 expression is 
down-regulated in terminally differentiating B cells. The down-regulation of Pax5 by B 
lymphocyte inducing factor (Blimpl) allows for the expression of terminal differentiation 
genes and the re-expression of Pax5-inhibited genes in mature B cells (Shaffer et al, 
2002, Delogu et al, 2006). Similarly, Pax3 and Pax7 expression is extinguished prior to 
terminal differentiation of embryonic myoblasts during myogenesis (Williams et al, 
2000, Buckingham et al, 2003).
Table 1.1
Pax gene Sub-group Expressed in tissue Associated Mutation/Disease
Pax -1 1 Skeleton, Sclerotome, 
Thymus
Kippel-Fell syndrome, Jarcho-Levin 
syndrome, Salivary gland tumor
Pax-2 ii CNS, Kidney Papillorenal syndrome, Renal cell 
carcinoma, Wilms' Tumor, Breast 
cancer, Kaposi Sarcoma
Pax-3 III CNS, Neural crest, 
skeletal muscle
Waardenberg's syndrome, RMS, 
Eming's sarcoma
Pax-4 IV Pancreas Silver-Russell syndrome, Wolcott- 
Rallison syndrome, Diabetes, 
Insulinoma
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Pax-5 II CNS, B cells Large cell lymphoma, Lymphocytic 
leukemia, Medulloblastoma, 
Neuroblastoma, Astrocytoma
Pax-6 IV CNS, Eye, Pancreas Aniridia, Cataract, Glioblastoma 
multiform, anaplastic glioblastoma, 
astrocytic glioma
Pax-7 III CNS, Cranio-facial, 
skeletal muscle
RMS, Eming's sarcoma, melanoma, 
squamous cell lung carcinoma
Pax-8 II CNS, Kidney, Thyroid Thyroid dysplasia, Thyroid follicular 
carcinoma, Wilms' tumor, placental 
cancer, ovarian serous tumors
Pax-9 1 Skeleton, Cranio-facial, 
tooth
No thymus, teeth, parathyroid glands, 
cranio-facial and limb defects
Table 1.1 Tissue-specific expression of Pax genes during embryogenesis and associated defects due to 
mutations/mis-expression of Pax genes (adapted from Wang et al, 2008).
In summary, Pax proteins have important roles in commitment of multi-potent 
progenitors to specific cell fates, the survival of developing cells and down-regulation of 
Pax genes is essential for proper terminal differentiation of these cells. Mutations in Pax 
genes, either due to chromosomal aberration or mis-expression, often leads to 
cancerous phenotype and/or complete loss of specific cell lineages (see table 1.1 for 
associated diseases).
1.3 Role of Pax-5 in B cell development
Commitment of hematopoietic progenitors to the mammalian B cell lineage:
Since B cell development has been studied thoroughly in the mammalian system, an 
overview of mammalian B cell development is provided prior to that in trout. B 
lymphocytes arise from a pool of multi-potent hematopoietic progenitors that have 
undergone a strict gene regulatory cascade in order to commit to the B cell lineage. 
Early stages of hematopoiesis involve the loss of unlimited differentiation potential 
through the down-regulation of pluri-potency marker c-kit in hematopoietic stem cells
(HSC) and the generation of multi-potent progenitors (MPP). MPPs can give rise to 
either lymphoid lineage or myeloid lineage in the form of early lymphoid progenitors 
(ELP) or common myeloid progenitors (CMP) (Kondo et al, 1997, Akashi et al, 2003). Loss 
of long-term self renewal is marked by the up-regulation of the tyrosine kinase Flt3 in 
MPP cells (Adolfsson et al, 2001, Christensen et al, 2001). Consequently, MPPs 
differentiate into ELPs, where the expression of RAG1 and RAG2 coincides with the 
recombination of Dh-Jh at the immunoglobulin heavy chain (IgH) locus (Igarashi et al, 
2002). Recent evidence has shown that ELPs can give rise to both early T-cell 
progenitors (ETP) in the thymus and /common lymphoid progenitors (CLP) in the bone 
marrow (Allman et al, 2003).
Myeloid 
r Lineage
NKcell9"  v  \rDendritic cell Pre-BCR signaling
© - © - © - @ - © - © - © * © - ® - r »Differentiation
Lin- Lin- Lin - Lin - B220+ CD19* CD25* igM*
c-Kit High High High Low Low Low Low - -
F!t3 + + + + - - - -
Dh'Jh - - + + + + ■f
v h-dj„ - - - - + + +
VL-JL - - - - - - + +
Pax-5 - - - + + + +
EBF-1 - - - + •+ + + •+
E2a - - + + + + + -
RAG-
1/2
- . + + + + + + +
Figure 1.2 Commitment of muiti-potent progenitors to the B cell lineage in the bone marrow. The figure 
highlights the expression of various cell surface markers, transcription factors and Ig gene rearrangement 
during B cell development in the bone marrow. +/- symbols are not quantitative. Legend: HSC -  
hematopoietic stem cell, MPP -  multi-potent progenitor cell, ELP -  early lymphoid progenitor, CLP -  
common lymphoid progenitor, CMP -  common myeloid progenitor, ETP -  early T cell progenitor, Pro-B -  B 
cell progenitor cell, Pre-B -  B cell precursor cell, Lin -  negative for expression of lineage-specific markers. 
(Adapted from  Busslinger, M., 2004)
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In the presence of appropriate cytokine cues, CLPs can give rise to B cell, T cell, Natural 
Killer and Dendritic cell lineages (Kondo et al, 1997, Traver et al, 2000). Expression of the 
B220 receptor in CLPs marks the transition into CLP-2 cells (Martin et al, 2003). 
Completion of Dh-Jh re-arrangement and the expression of CD19 promote the 
conversion of CLP-2 cells to early pro-B cells (Li et al, 1996, Tudor et al, 2000, Hardy et 
al, 1991). Completion of VH-DJH recombination in late pro-B cells induces the expression 
of Igp at the cell surface as part of the pre-B cell receptor, which marks the transition 
into precursor-B cells (pre-B cell) stage. Signaling at the pre-B cell receptor promotes 
allelic exclusion at the IgH locus, proliferation and cell expansion, and differentiation in 
to small pre-B cells where light chain recombination occurs (Meffre et al, 2000). 
Completion of light chain recombination heralds the emergence of immature lgM+ B 
cells which migrate from the sterile environment of the bone marrow to peripheral 
lymphoid organs. (See figure 1.2 for overview of B cell development).
Transcriptional regulation of mammalian B cell development:
The generation of lymphoid progenitors from the HSC depends on at least two main 
transcription factors: Ikaros and PU.l. The Zn-finger family of transcription factors 
Ikaros, Helios and Aiolos influence the cell fate decisions of HSC's during hematopoiesis 
(Georgopoulos, 2002) and is expressed in all hematopoietic lineages, including stem 
cells and MPPs. Mice that possess a dominant negative allele of Ikaros, generated 
through the targeted deletion of the N-terminal Zn finger, are unable to give rise to any 
B, T, NK and DC cells (Georgopoulos et al, 1994, Wu et al, 1997). Thus expression of
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Ikaros and its family of transcription factors is essential for the normal development of 
lymphocytes.
PU.l, a member of the Ets family of transcription factors, is also expressed in many 
hematopoietic lineages and is thought to work in parallel with Ikaros to regulate 
lymphocyte development. Retroviral reconstitution experiments have shown that low 
level of PU .l induce B cell development in P U .l^  progenitors, while high level of PU.l 
inhibit B cell development and support myeloid cell development (DeKoter et al, 2000). 
Thus PU.l regulates the decision of lymphoid versus myeloid fate in multipotent 
myeloid-lymphoid progenitors.
The regulation of pro-B cell development and survival is regulated by the transcription 
factors E2a, EBF and Pax-5. The E2a gene is alternatively spliced during B cell 
development, and gives rise to two basic helix-loop-helix transcription factors E12 and 
E47 (Murre et al, 1989). E2a/ mice show B cell arrest in the earliest stages of 
development with lack of Dh-Jh rearrangements and no detectable Pax-5 (Bain et al, 
1994, Zhuang et al, 1994, Bain et al, 1997). The EBF gene (Early B cell factor) is expressed 
in pro-B cell, pre-B cells and mature B cells (Lin et al, 1995). EBF/_ mice also display a 
phenotype similar to E2a7 mice, with early developmental arrest in B cells with no 
detectable levels of Pax5 (O' Riordan et al, 1999). Thus, EBF and E2a are expressed 
upstream of Pax5 in the B cell program. Interestingly, ectopic expression of EBF and E2a 
in non-B lymphoid cell lines induces the expression of B cell specific genes (Schlissel et 
al, 1991, Choi et al, 1996, Kee et al, 1998). Molecular analyses have shown that E2a and
9
EBF bind the promoters of genes involved in B cell signaling (VpreB, A5) and surrogate 
light chain (Iga, Ig3) (Sigvardsson et al, 1997, Sigvardsson, 2000, Gissler and Sigvardsson, 
2002).
Commitment of MPPs to the B cell lineage is not complete without Pax5 expression, 
since Pax-57 mice show a developmental arrest in the pro-B cell stage (Urbanek et al, 
1994). Culturing Pax-57 pro-B cells in the presence of IL-7 showed that these cells retain 
the ability to develop in to cells of the lympho-myeloid lineage. In the presence of 
appropriate cytokine signals, these cells can develop into NK cell, macrophages, 
dendritic cells, osteoclasts and granulocytes (Nutt et al, 1999). Retroviral reconstitution 
of Pax5 expression in Pax-57 pro-B cells restricted the multi-lineage potential and could 
rescue mature B cell phenotype (Nutt et al, 1999).
Pax5 is first expressed in the hematopoietic system at the pro-B cell stage, and is 
thought to be downstream of E2a and EBF in the B cell program (Adams et al, 1992). 
Conditional inactivation of Pax5 leads to loss of identity and function of B cells, and such 
cells trans-differentiate into macrophage and T cell lineages (Horcher et al, 2001). Cre- 
mediated gene deletion of Pax5 in committed pro-B cells showed Pax5 is required for 
both initiation of B cell commitment and maintenance of B cell identity (Mikkola et al, 
2002). At the transcriptional level, Pax5 has dual roles as a transcriptional repressor of 
lineage inappropriate genes and a transcriptional activator of linage appropriate genes. 
For example, Pax5 based repression of the macrophage lineage factor M-CSFR and the 
T-cell commitment factor Notch-1, renders committed pro-B cells unresponsive to
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myeloid cytokine M-CSF and Notch ligands (Nutt et al, 1999, Souabni et al, 2002). 
Alternatively, Pax5 activated a host of B cell specific genes involved in pre-BCR signaling, 
receptor signaling chain (Iga), the co-stimulatory receptor (CD19) and the central 
adapter protein BLNK (Nutt et al, 1997, Fitzsimmons et al, 1996, Kozmik et al, 1992, 
Schebesta et al, 2002). Pax5 also facilitates VH-DJH recombination via long scale 
contraction of the IgH locus (Nutt et al, 1999, Reynaud et al, 2008).
The transcriptional activity of Pax5 is modulated by its interaction with other 
transcription factors in a gene context dependent manner. For example, Pax5 is 
converted into a transcriptional repressor via interaction with Grg4 (a member of the 
groucho family of transcriptional co-repressors) (Eberhard et al, 2000). The leading 
hypothesis states the Pax5 trans-activation domain is effectively masked, thus leading to 
repressor-like function. Conversely, Pax5 functions as a transcriptional activator of mb-1 
when it interacts with the Ets family of transcription factors (Garvie et al, 2001).
Activation of mature B cells and terminal differentiation in mammalian sytems:
Immature B cells migrate from an antigen-free environment in the bone marrow to 
peripheral lymphoid organs for maturation and activation. Naive resting B cells express 
membrane IgM and are locked in the GO phase of the cell cycle. B cell activation takes 
place in a Thymus independent (Tl) or thymus dependent (TD) manner. TD activation 
occurs through interaction of the B cell receptor with membrane molecules on helper T 
cells and associated cytokines. On the other hand, Tl activation takes place completely 
independent of T cell stimulation and cytokines. Lipopolysaccharide (LPS) is a Tl antigen
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that is polyclonal in nature and induces activation of mature B cells. Activated B cells
undergo rapid proliferation in the germinal center and are called centroblasts. Densely 
packed regions of proliferating centroblasts appear darker than the surrounding region 
of the germinal center (Dark Zone). In the light zone, high affinity non-dividing 
centrocytes that can bind antigen-antibody complexes on follicular dendritic cells are 
selected during affinity maturation, while low affinity centrocytes undergo apoptosis.
Resting naive 
Bcetl
BLIMP1
MITF
PAX5
BCL-6
MTA3
BACH 2
IRF4
XBP1
ND
Apoptosis Apoptosis
Memory
cellUn-selected
Affinity
Short lived 
Plasma cellPlasmablast
Proliferating Non-dividing Proliferating Short Lived Plasma Long Lived Plasma
Germinal center Germinal center 
(Dark Zone) (Light Zone)
ND
plasmablast Cell /  Memory cell
(Antibody secreting) (Antibody secreting)
ND
Figure 1.3 Terminal differentiation of B cell to plasma cells. The figure highlights the expression of 
various transcription factors involved in B cell development and terminal differentiation during plasma 
cell development. +/- symbols are not quantitative. ND implies that the expression patterns are not 
determined.
Positively selected centrocytes undergo immunoglobulin class-switching and mature 
into plasmablasts or memory cells. Plasmablasts possess membrane bound 
immunoglobulin and show tell-tale signs of an enlarged endoplasmic reticulum to 
accommodate the production of massive amounts of immunoglobulin. The terminally 
differentiated plasma cell lacks membrane bound form of immunoglobulin but produces
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secreted form of immunoglobulin and is generally short-lived unless it migrates to an 
antigen-free niche and receives growth factors the promotes its survival.
Transcriptional regulation of B cell terminal differentiation in mammalian systems:
While Pax5 expression is required for the commitment and identity of B cells, transition 
of B cells to plasma cells requires the down-regulation of Pax5 (Lin et al, 2002). 
Activation of activation-induced cytidine deaminase (AID) by Pax5 is an essential part of 
germinal-center B cells maturation as it initiates somatic hyper-mutation and class- 
switch recombination processes (Gonda et al, 2003). Pax5 based repression of terminal 
differentiation genes X-box protein (Xbp-1), J-chain prevents the premature onset of 
terminal differentiation in maturing B cells (Reimold et al, 1996, Rinkenberger et al, 
1996). Interestingly, loss of Pax5 expression alone is not sufficient for the induction of 
plasma cell fate through Blimpl (B lymphocyte inducing maturation factor) expression 
(Horcher et al, 2001). Blimpl is a Zinc finger transcription factor (Keller and Maniatis, 
1992) that interacts with histone de-acetylases (Yu et al, 2000), hGroucho (Ren et al,
1999) and a G9a histone methyltransferase (Gyory et al, 2004) as part of its 
transcriptional repressive function. Expression of Blimpl is first detectable in the 
plasmablast stage of B cell differentiation, where it is thought to be the master regulator 
of plasma cell differentiation (Martin et al, 2001). Blimpl expression alone is enough to 
induce plasmacytic differentiation both in vitro as well as in B cell lines (Shapiro-Shelef, 
2003, Shaffer et al, 2002, Turner et al, 1994, Schliephake and Schimpl, 1996). It does this 
by both inducing the expression of genes involved in plasmacytic differentiation and
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suppressing genes involved in B cell identity: Pax5, the proliferative program: c-myc (Lin 
et al, 1997) and indirectly rescues the expression of Xbpl through repression of Pax5. 
Xbpl acts downstream of Blimpl in the regulatory cascade and helps expand the 
secretory apparatus to initiate Ig secretion by plasma cells (Harding et al, 2002). Unlike 
Blimpl, Xbpl expression is not enough to initiate differentiation to plasma cell fate.
A host of other transcription factors are involved in the successful production of 
antibody secreting plasma cells. Notable among these are MITF (Micropthalmia 
associated transcription factor), BCL-6 (B cell lymphoma protein -6), MTA-3 (metastasis- 
associated 1 family, member 3), BACH2 and IRF4 (Interferon-regulatory factor 4). MITF is 
an inhibitor of plasma cell and is crucial for maintaining germinal B cells in resting state. 
Down regulation of MITF, by IRF4 leads to the expression of Blimpl in activated B cells 
(Lin et al, 2004). Like MITF, BCL-6 is also a crucial repressor of Blimpl and aids in the 
development of germinal centers of B cell development (Shaffer et al, 2000). BCL-6 
based repression of Blimpl is thought to occur indirectly through the repression of 
STAT3 which is an inducer of Blimpl expression (Vasanwala et al, 2002, Reljic et al,
2000). MTA3 interacts directly with BCL-6 to mediate its repressive effects (Fujita et al, 
2004). BACH2 is also required for the proper establishment of germinal centers (Muto et 
al, 2004).
In summary, extinguishing Pax5 expression and up-regulation of Blimpl and Xbpl in 
activated B cells are the major regulatory events surrounding plasmacytic
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differentiation. Plasma cells are non-proliferative cells that clonally secrete antibodies, 
thus completing the B cell humoral immune response.
B cell development and activation in Trout
The stages of B cell development and activation in trout are not well defined but may 
occur in a manner similar to mammalian B cells. Trout do not possess bone marrow or 
typical lymph-nodes (Zapata et al, 1995, Zapata et al, 1990). The organs used for B 
lymphogenesis are different from mammalian B cell genesis. Unlike the bone marrow in 
mammals, it is suggested that trout use the anterior kidney as a site of primary 
lymphogenesis (Zapata et al, 1990, Fange et al, 1986). The trout kidney is a ventrally 
located unpaired organ that extends from cranium at the anterior end of the body to 
the caudal end. Additionally, the anterior kidney lacks renal function and provides a 
sterile environment for B cell development. Studies from our lab suggest that trout 
anterior kidney house proliferating B cell precursors and plasma cells. The presence of 
antibody secreting cells in the anterior kidney is unexpected and may represent a subset 
of B1 cells that are characterized by low-levels of Ig secretion even in the absence of 
activation (Berland & Wortis, 2002).
15
Activated B cell
AK Plasma cell PlasmablastMature Bcell
Plasrr.ablast
Blood Activated Be ell
Plasmablast
SpleenPlasma ceil
Figure 1.4 Model for the development, migration and activation of B cells in the trout. The anterior 
kidney houses a repertoire o f developing B cells that migrate to  the posterior kidney and spleen, where 
they get activated. Activated B cells terminally differentiate into plasmablasts and antibody secreting 
plasma cells. It is thought that a small percentage of plasmablasts and plasma cells migrate to  the anterior 
kidney, (adapted from Zwollo et al, 2005)
Developing mature B cells migrate from the anterior kidney to sites of activation at the 
posterior kidney and spleen via the blood. Unlike the anterior kidney, the posterior 
kidney possesses renal function and provides an environment for antigen encounter by 
migrating mature cells (Fange et al, 1986). The posterior kidney was found to contain 
partially activated B cells and plasmablasts, suggesting it functions as a secondary 
immune organ. Trout spleen and blood were shown to contain resting B cells with low Ig 
secretion (Zwollo et al, 2008).
Similar to the posterior kidney, mature B cells get activated and terminally differentiate 
into plasmablasts and short-lived immunoglobulin secreting plasma cells in the spleen. 
LPS activation of splenic-B cells showed these cells could produce both membrane and 
secreted form of IgM, detectable by real-time PCR and flow-cytometric analyses (Zwollo 
et al, 2008). Conversely, LPS activated blood-derived B cells showed low propensity for 
generating antibody secreting plasma cells. Taken together, the posterior kidney, spleen 
and blood serve as secondary immune sites and lack developing B cells. Subsets of
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short-lived plasma cells may migrate to the anterior kidney and become long-lived 
plasma cells. Thus trout kidney serves as a diverse and multifunctional organ for both 
hematopoiesis and B lymphogenesis.
Although, the predominant immunoglobulin isotypes produced by trout B cells is IgM 
and IgD, a novel immunoglobulin isotype have been recently reported in a smaller 
subset of trout B cells -  IgT (Hansen et al, 2005). Another novel isotype (IgZ) was 
recently reported in zebrafish (Flajnik, 2005), suggesting a diverse potential of isotype 
production in the teleost lineage. Taken together, trout immune tissues contain 
developmentally diverse and tissue-specific subsets of B cells .
1.4 Alternative splicing of Pax-5 and evolutionary conservation of 
isoforms
In eukaryotes, nuclear pre-mRNA transcripts contain non-protein coding sequences 
called introns interspersed between protein coding exons. Formation of functional 
mature mRNA transcript involves the removal of introns by a mechanism called RNA 
splicing. Eukaryotic introns are classified as group III introns and their removal is 
mediated by a large RNA-protein complex called the spliceosome (reviewed by Black, D., 
2003). Little is known about the exact composition of the spliceosome, though the main 
subunits include 5 small uridine rich nuclear ribonucleoprotein particles (U l, U2, U4, U5 
and U6) (Nilsen, 2002), seven Sm-like core proteins and over 200 accessory proteins that 
are added or removed during complex assembly and mRNA splicing. Classically, the 
intron possesses a GU nucleotide at the 5' splice site, and AG 3' splice site, a conserved
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branch point and a polypyrimidine tract. The initial steps of splicing involve the 
association of U1 snRNP to the GU di-nucleotide and a U2 snRNP associated factor to 
the polypyrimidine tract. Subsequent recruitment of snRNPs U4, U5, U6 and other core 
components initiates the assembly of the pre-spliceosome complex. Following 
assembly, the 2 -O H  of an Adenine residue at the branch point attacks the phosphate 
group at the 5' splice site in a trans-esterification reaction. This leads to the cleavage of 
the 5' exon and the formation of a lariat structure involving ligation of the 5' end of the 
intron with the adenine residue at the branch point. The free 3 -O H  of the 5' exon then 
attacks the phosphate group at the 3' end of the intron in a second trans-esterification 
reaction. This allows for excision of the intron and ligation of the two exons.
Changes in splice site choice arise from changes in the assembly of the spliceosome or 
functional mutations in the original splice site (Berget, S., 1995, Black, D., 1995). 
Alternative splicing is a mechanism by which a single gene encodes several unique 
mRNA products and is a mode by which genes can obtain a high degree of proteomic 
diversity. Almost 90% of human genes are now known to encode at least two isoforms 
(Pan et al, 2008, Wang et al, 2008). It is thought that increase in proteomic diversity by 
alternative splicing serves to augment gene regulatory networks through three main 
mechanisms: the removal of interaction and localization domains, production of mRNA 
transcripts with shorter/longer half-lives and production of non-functional mRNA that 
are targeted for non-sense mediated degradation (Lareau et al, 2004).
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Alternative splicing involves the selective inclusion/skipping of nucleotides on an mRNA 
transcript by way of alternative 5' and 3' splice donor/acceptor sites. There are five 
main forms of alternative splicing: exon skipping (38% of common alternative splicing 
events), alternative 3' and 5' splice sites (18% and 8%), intron retention (less than 3%) 
and other complex events such as mutually exclusive exons, alternative promoter usage 
and multiple polyadenylation sites (remaining 33%) (Ast, 2004). Regulation of 
alternative splicing occurs through the interaction of trans-acting splicing regulators 
present on the spliceosome (>200 subunit ribonucleoprotein) and the cis-acting splice 
enhancer/silencer sequences on the mRNA transcript (Caceres and Kornblihtt, 2002). 
Alternative exons often have sub-optimal splice sites and length when compared to 
constitutive exons (Ast, 2004). Thus regulation of alternative splicing allows for spatial, 
temporal and tissue specific expression of isoforms.
Alternative spliced Pax5 isoforms were first reported by Zwollo et al in mouse B cells, 
where four major isoforms are produced: Pax-5a which represents the full-length form, 
Pax5-b which has deletion of exon 2, Pax-5d which has deletion of exons 6-10 and Pax5- 
e which contains deletions of both exons 2 and 6-10 (Zwollo et al, 1997). Short and 
Holland (2008) reported several N-terminal and C-terminal isoforms of the Pax2/5/8  
gene, a precursor of vertebrate Pax5, in whole adult amphioxus (a basal chordate) 
cDNA. Human Pax5 isoforms were first reported by Borson et al (2002) in B cells of 
multiple myeloma patients, with deletion of exon 2, 8, 9, 7-8 and 7-9. Robichaud et al
(2004), confirmed the detection of multiple Pax5 C-terminal isoforms using RT-PCR in 
normal B cells and lymphoma cells, along with the mutually exclusive use of exon lb
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(Robichaud et al, 2008). Further studies by Arseneau et al (2009), Sekine et al (2007), 
Oppezzo et al (2005) and Lowen et al (1999) discuss the prevalence, expression and 
functional studies performed for different isoforms and have been addressed in the 
discussion section.
Table 1.2
1 la
Not
defined + + +
All B cells
2 lb
Not
defined + +
- All B cells
3 laA2
Partial
Paired
domain
+ + +
B-cell lymphoma, CLL, 
mouse spleen, MM, 
Adult amphioxus 
(whole)
4 lbA2
Partial
Paired +
Normal B cells, BCL, 
CLL
domain
5 A2/3
Paired
domain +
- - Normal B cells, BCL, 
CLL
6 A2/4 Partial PD + - -
Normal B cells, BCL, 
CLL
7 A 2/8 /9
Partial PD, 
TA and ID +
- -
Normal B cells, BCL, 
CLL
8 A3 Partial PD - - +
Adult amphioxus 
(whole)
9 A3/4a Partial PD - - +
Adult amphioxus 
(whole)
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10 A3/8
Partial PD 
and TA +
- - Normal B cells, BCL, CLL
11 A4
OD and 
Partial PD
- - +
Adult amphioxus 
(whole)
12 A5
Not J. Normal B cells, BCL,
defined
T CLL
13 A5/9 Partial ID + = - Normal B cells, BCL, CLL
14 A6-9 TA and ID + - - CLL
15 A6-10 TA and ID - + - Mouse spleen
16 A 6/7 /8 HD and TA + - - CLL
17 A7
Not ■ Normal B cells, BCL,
defined T CLL, M M
18 A7/8 TA domain + - -
Normal B cells, BCL, 
CLL, M M
19 A7-9 TA domain + - -
Normal B cells, BCL, 
CLL
20 A7-9
TA and 
partial ID +
- - Normal B cells, BCL, CLL
21 A7-10 Partial ID - - +
Adult amphioxus 
(whole)
22 A 7 -p ll TA and ID - - +
Adult amphioxus 
(whole)
23 A 7 /1 0 /p ll
Not
defined
- - +
Adult amphioxus 
(whole)
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24 A7/10b
Not
defined
- - +
Adult amphioxus 
(whole)
25 A 7 /1 0 b /p ll
Not
defined
- - +
Adult amphioxus 
(whole)
26 A 7 /p l l
Not
defined
- - +
Adult amphioxus 
(whole)
27 A7b
Not
defined
- - +
Adult amphioxus 
(whole)
28 A8
Partial TA I Normal B cells, BCL,
domain T CLL, M M
29 A9
Partial TA l Normal B cells, BCL,
and ID
T CLL, MM
30 A8/9
Partial
TA/ID +
- - Normal B cells, BCL, CLL, M M
Table 1.2 List of alternatively spliced Pax-5 transcripts reported in different organisms. +/- indicates 
presence absence, NA -  data not available. PD -  paired domain, TA -  trans-activation domain, ID -  
Inhibitory domain, HD -  homeodomain, OD -  Octopeptide segment, Not defined -  deleted amino acids 
encode no known functional domains, Ap-indicates partial deletion, CLL-Chronic Lymphoblastic 
Leukemia (human), BCL -  B-cell Lymphoma (human), MM -M u ltip le  Myeloma B-cells (human).
With the growing number of reports for alternative splicing of Pax5 in different 
organisms, it is now feasible to focus on cross species conservation of alternative 
splicing in vertebrates. Evolutionary conservation of isoforms over long periods of time 
suggests that these isoforms may be positively selected for and implies conserved 
function (Lareau et al, 2004).
Table 1.2 lists all the alternatively spliced isoforms that have been reported thus far for 
Pax5. Clearly, human and amphioxus Pax5 yield the most diverse splicing patterns in the 
vertebrate lineage, where most splicing occurs at the C-terminal end of Pax-5. Human
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Pax5 isoforms represent 63% (19 of 30) of total isoforms reported and amphioxus Pax5 
isoforms represent 40% (12 of 30) of total isoforms reported. However, between the 
basal chordate amphioxus and humans, only 2 isoforms are conserved -  namely, full- 
length Pax5 and laA2. This exon 2 skipping is also conserved in mouse B cells. 
Conserved Pax5 isoforms represent only 10% (3 of 30) of the reported isoforms for 
these three organisms. The remaining isoforms are not conserved and represent 
novel/rare isoforms. The conservation of particular isoforms implies that these 
sequences have functional roles in vertebrate B cell development. In summary, multiple 
isoforms of Pax5 have been detected with deletions in the PD, TA and ID. These 
isoforms possess a wide range of trans-activities and potentially contribute to the 
intricate regulatory function of Pax5 in B cells.
1.5 Significance of alternative splicing
The regulatory role of alternatively spliced genes in cellular processes like cell 
cycle/proliferation, differentiation, lineage commitment and apoptosis has previously 
been under-appreciated. With growing evidence for widespread alternative splicing of 
genes and evolutionary conservation of alternatively spliced isoforms, alternative 
splicing has been recognized as an important means of genetic regulation at the post­
transcription and translation levels.
Apart from expanding the proteomic diversity of genes, alternative splicing of genes can 
produce proteins with whole functional domains removed or added. Alternatively 
spliced isoforms usually function as dominant negative inhibitors and block the function
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of the wild-type (Brinkman et al, 2004). For example, alternative splicing of the 
apoptosis genes Bcl-x, Caspase-9 and Ced-4 yields variants with either pro or anti- 
apoptotic activity (Wu et al, 2003, Syken et al, 1999). Alternative splicing can also alter 
protein localization, for example alternative splicing of the fibroblast growth factor 
receptor gene produces a switch from membrane bound to soluble protein form (Jang, 
2002).
Also, alternative promoter usage can alter mRNA translation rate. In vitro experiments 
performed by switching promoter sequence on the fibronectin 1 gene showed its 
expression was almost 10-times higher when paired with its endogenous promoter than 
with a 3-globin promoter (Cramer et al, 1997). Similarly, mRNA transcripts with 
alternatively spliced 3' un-translated sequence have altered stability and susceptibility 
to degradation. Additionally, spliced transcripts which generate a premature 
termination codon are often subject to nonsense-mediated decay. Thus alternatively 
spliced transcripts may have variant half-lives in an intracellular environment.
Alternatively spliced transcripts are also known to be involved in auto-regulation of gene 
expression. For example, constitutive splicing of the poly-pyrimidine tract binding 
protein (PTB) gene produces PTB, which is a regulator of alternative splicing. Increase in 
PTB protein levels favors the production of un-productive alternatively spliced transcript 
with a premature-termination codon in exon 11 and is subject to nonsense mediated 
decay (Wollerton et al, 2004).
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Variation in the intracellular level of splicing regulatory factors influence the mode of 
mRNA splicing and is one explanation for tissue specificity and developmental regulation 
of alternatively spliced isoforms. A classic example of this was illustrated by Stickeler et 
al (1999) where stepwise increase in splicing regulator (SR) protein levels correlated 
with increased alternative splicing of the CD44 gene in mammary tumor cells.
Given its vital role in the regulation of cellular processes, aberrant expression of 
alternatively spliced isoforms has been implicated in various diseases and cancers. For 
example, the neurofibromatosis gene (NF1) has one of the highest mutation rates of all 
human genes and aberrant expression of NF1 leads to the formation of neurofibromas. 
Almost 32% of neurofibroma cases can be attributed to irregular splicing of NF1 (Ars et 
al, 2000).
Alternatively spliced isoforms of Pax5 contain selective deletions of one or more 
functional domains. These isoforms have been tested in functional assays, where they 
show altered DNA binding and trans-activity when compared to full-length. Isoforms 
with deletion of DNA binding domain coding exon 2, are unable to bind DNA as shown in 
EMSA studies for mouse B cells (Zwollo et al, 1997, Lowen et al, 2001). Pax5 isoforms 
with deletion of trans-activation domain coding exon 8 and 9 have also been shown to 
have DNA binding ability and trans-activity different from full-length in human normal 
and multiple myeloma B cells (Robichaud et al, 2004). In one report, human Pax5/A8 
isoform was shown to bind to the AID promoter and induce AID expression in chronic
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lymphoblastic leukemia cell in vitro (Oppezzo et al, 2005). Thus Pax-5 isoforms have 
different and unique trans-activation potentials.
Pax5 trans-activates multiple target genes that are cell surface receptors and involved in 
pre-BCR signaling. B cell signaling processes are tightly regulated by complex regulatory 
cascades. Pax5 isoforms can potentially provide a wide range of regulatory control 
during stages of B cell development and activation, by influencing the expression of 
Pax5 target genes.
Recently, it has been proposed the alternatively spliced isoforms can be used as 
biomarkers of cancerous phenotype (Brinkman, 2004). Altered expression of Pax5 
isoforms has been reported in B cells from multiple myeloma and lymphoma patients 
(Borson et al, 2005). Thus Pax5 isoforms may also be used as biomarkers of lymphocytic 
cancers. Since alternatively spliced transcripts are tissue, stimulus and disease specific, 
there remains a large scope for using Pax5 isoforms as biomarkers of cancerous 
phenotype. Detection strategies can include PCR using primers that specifically amplify 
an alternatively spliced variant or microarrays for detection of a large number of 
markers in parallel. Since alternatively spliced transcripts are often translated, antibody 
based strategies may also be used to detect isoform expression (Brinkman et al, 2004). 
Finally, our study of alternative splicing of Pax5 in trout B cells completes the 
evolutionary picture of isoform conservation in vertebrates.
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1.6 Research aims and hypotheses
The primary aim of this project was to identify and clone alternatively spliced Pax5 
transcripts in trout B cells which contain deletions of exons that encode various 
functional domains, using nested-PCR.
The secondary goal of this project was to study potential changes in the expression of 
each alternatively spliced transcript versus full-length Pax5 upon activation of splenic 
and blood-derived B cells. Evaluation of the relative amplification of alternatively spliced 
Pax5 would implicate the involvement of Pax5 isoforms in the regulatory processes that 
surround B cell activation.
Based on observed exon skipping patterns of alternatively spliced trout Pax5, we 
hypothesized that:
1) Alternatively spliced isoforms of Pax5 that skip exon 2, encoding part of the DNA 
binding domain, would function as dominant negative repressors of Pax5 activity 
and are expressed in relatively higher quantities during splenic and blood- 
derived B cell activation.
2) Alternatively spliced isoforms of Pax5 that skip exon 8, encoding part of the 
trans-activation domain, function as repressors of Pax5 activity and are 
expressed in relatively higher quantities during splenic and blood-derived B cell 
activation.
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3) Alternatively spliced isoforms of Pax5 that skip inhibitor domain coding exon 9 
function as strong trans-activators and their expression is relatively low during 
splenic and blood-derived B cell activation.
These hypotheses were tested using semi-quantitative PCR analysis of LPS activated 
cells.
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Chapter 2: Materials and Methods
2.1 Overview of Methods
Harvesting trout immune tissues and activating B cells in culture: The following 
immune tissues were collected from three to five adult rainbow trout (8-12 inches long; 
obtained from Casta Line Trout farms) - the anterior kidney (AK or Kl), posterior kidney 
(PK or K5), spleen and peripheral blood (PBL). Tissues were collected in 5mls of Hank's 
balanced salt solution (HBSS - 137mM NaCI, 5.6m M D-glucose, 5mM KCI, 8.1m M  
Na2HP04.2H20  and 20m M Hepes at pH 7.05) and blood was collected in heparinized 
tubes. Single cell suspensions were obtained by repeated aspiration of tissues with a 
10ml syringe followed by passing through a 40nm cell strainer (Falcon/BD biosciences). 
Erythrocytes were removed from the cell suspension through layering onto histopaque 
1077 gradient (Sigma Aldrich) followed by centrifugation at 500g at 4°C for 40 minutes. 
W hite blood cells were removed from the interface and washed in 50mls of HBSS prior 
to being cultured in trout complete medium (TCM) consisting of R P M I1640 with 10 mM  
L-glutamine, 10% FCS, 50 g/ml gentamycin, 50 M 2-ME, and the nucleosides adenosine, 
uracil, cytosine, and guanosine (10 mg/ml; Sigma-Aldrich) at a concentration of 10 million 
cells per ml of medium, as described in Yui, M.A. & Kaattari S.L. (1987). Cells were 
activated in culture with the B cell mitogen LPS (055:B5 from E. coli; Sigma) at lOOpg/ml. 
The cells were fed every other day with one-tenth of the culture volume of a lOx tissue 
culture cocktail containing 500 mg/m gentamycin, 10 mg/ml essential amino acids, 10 
mg/ml non-essential amino acids, 70 mM L-glutamine, 70 mg/ml dextrose, 10 mg/ml
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nucleosides, and 33% FBS. Cells were harvested on days 0-7, pelleted at lOOOrpm in a 
clinical centrifuge and frozen at -80°C until RNA extraction.
RNA isolation and cDNA synthesis: Total cellular RNA was extracted from frozen pellets 
of approximately 5 to 10 million human, mouse or trout B cells (either freshly isolated or 
activated with LPS in culture) using RNeasy mini kit (Qiagen), according to the 
manufacturer's instructions. Total RNA was quantified on nanodrop ND-1000 
spectrophotometer (Thermo Scientific). 0.5pg or lp g  of total RNA was used to generate 
cDNA using iScript cDNA synthesis kit (Bio-Rad) according to the manufacturer's 
instructions.
Nested Polymerase Chain Reaction fo r screening o f O. mykiss alternatively spliced 
Pax5: Nested PCR was conducted to screen for each alternatively spliced transcript of 
trout Pax5 on a Perkin-Elmer GeneAmp PCR system 2400. 1.5p! to 3pl of cDNA template 
was used in the first round of PCR using PCR primers (generated by Integrated DNA 
Technologies) that externally flank the exons being tested and using Vent® DNA 
polymerase (New England Biotech) under the following conditions: 1 minute at 94°C, 1 
minute at 56-58°C and 1 minute at 72°C for 35 cycles. l-2p l of amplified product from  
the first round was then used as template for the second round of PCR using an 
independent set of internal primers under the following conditions: 1 minute at 94°C, 1 
minute at 60-62°C and 1 minute at 72°C for 35 cycles. lOpI of second round PCR product 
was run on a 2% agarose gel containing Ethidium bromide (O.lpg/ml) and with 0.5pg of
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lOObp DNA ladder (New England Biotech) as size marker. A list of primers used in the 
nested PCR screen can be found under Table 2.1.
Nested Polymerase Chain Reaction fo r  screening o f human and mouse Pax5/A2-8: This 
method used to isolate alternatively spliced transcripts has been used before by Gorlov 
and Saunders (2002). Nested PCR was conducted to screen for alternatively spliced 
Pax5/A2-8 in human bone marrow and tonsil cDNA samples, and mouse spleen cDNA on 
a Perkin-Elmer GeneAmp PCR system 2400. PCR primers were designed based on the 
published full length cDNA sequence of human Pax5/BSAP (GenelD: 9951919, Ensembl: 
ENSG00000196092) and Mus musculus Pax5 (GenelD: 118130642, Ensembl:
ENSMUSG00000014030). 1.5pl to 3pl of cDNA template was used in the first round of 
PCR using PCR primers (generated by Integrated DNA Technologies) that externally 
flank the exon being tested and using Vent® DNA polymerase (New England Biotech) 
under the following conditions: 1 minute at 94°C, 1 minute at 56-58°C and lm inute at 
72°C for 35 cycles. Amplified product from the first round was then used as template for 
the second round of PCR using an independent set of internal primers under the 
following conditions: 1 minute at 94°C, 1 minute at 60-62°C and 1 minute at 72°C for 35 
cycles. lOpI of second round PCR product was run on a 2% Agarose gel containing 
ethidium bromide (O.lpg/ml) and with 0.5pg of lOObp DNA ladder (New England 
Biotech) as size marker. A list of primers used in the nested PCR analysis can be found 
under Table 2.3.
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DNA extraction from low melt agarose: This technique has been adapted from Chory et 
al (1999). 50-100|il of nested PCR product was electrophoretically separated in a 1% low 
melt agarose gel and the potential alternatively spliced Pax5 amplicons were excised 
and stored in TEN buffer (1M Tris pH 8, 0.5M  EDTA, 5M NaCI) at 4°C overnight. The 
mixture was melted at 67°C, added to 1 volume of phenol (pre-warmed to 37°C) and 
vortex mixed. Samples were spun at 10,000 rpm for 5 minutes at room temperature in a 
tabletop centrifuge. The upper aqueous layer was harvested and transferred to another 
aliquot of phenol and the extraction was performed 2 more times. In the last extraction, 
the upper aqueous layer was added to 1 volume of chloroform (pre-warmed to 37°C) 
and vortex mixed. Samples were spun at 10,000 rpm for 5 minutes at room temperature 
in a tabletop centrifuge. The upper aqueous layer was collected and precipitated at - 
20°C overnight in l /1 0 th volume 3M sodium acetate and two volumes of ice-cold 100% 
Ethanol (molecular grade). DNA was precipitated by spinning at 10,000 rpm for 30 
minutes at 4°C and removing the supernatant. The DNA pellet was washed with one 
volume of ice-cold 70% ethanol and air dried before re-suspending in TE buffer (lOm M  
Tris, Im M  ED TA -pH  8).
Cloning of alternatively spliced isoforms: 5-50ng of round 2 nested PCR product was 
ligated into pSC-A-amp/kan cloning vector (Strataclone PCR cloning kit, Stratagene), 
transformed into Strataclone Solopack™ competent bacterial cells according to the 
manufacturer's instructions and grown on LB plates (containing 50pg/ml Ampicillin) at 
37°C for 16-20 hours. Single colonies were selected and individually re-grown in 5ml of 
LB broth (containing 50pg/ml Ampicillin) at 37°C for 16-20 hours.
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Small scale boiling lysis plasmid preps: Plasmid DNA was extracted from E. coli cultures 
using small-scale boiling lysis plasmid preps (Ehrt & Schnappinger, 2003) as described 
below. 5mls of E. coli culture was pelleted at 5000rpm and 4°C for 10 minutes in a 
clinical centrifuge. The supernatant was discarded and the bacterial cell pellet was 
resuspended in 70pl of STET buffer (0.1M NaCI, lOmM Tris Cl, Im M  EDTA, 5% Triton X- 
100) and 5pl of lysozyme (lm g/m l). Cells were lysed by incubating at 95°C for 1 minute 
followed by centrifugation at lOOOOrpm for 10 minutes in a microfuge at room 
temperature. The pellet containing proteins, genomic DNA and cell debris were 
removed using sterile toothpicks. Plasmid DNA in the supernatant was precipitated by 
adding one volume of 2- propanol and centrifuging at 10,000 rpm for 15 minutes at 4°C. 
The supernatant was discarded and DNA pellet was washed with 2 volumes of 70% 
ethanol. Excess ethanol was removed and the pellet was air dried before resuspending 
in 40pl of TE buffer (lOm M  Tris, Im M  EDTA -  pH 8).
Restriction digestion with EcoRI: lOpI of plasmid DNA was digested with 200 units of 
EcoRI restriction enzyme (New England Biotech) at 37°C for 1 hour, lp l of RNase A 
(lOm g/m l) was added to the reaction mix and the sample was incubated for another 15 
minutes at 37°C to remove RNA. lOpI of the digested product was run on a 2% agarose 
gel with (containing O.lpg/m l ethidium bromide) to check for requisite DNA insert.
Selection o f clones: Clones containing a DNA insert were re-grown overnight in 5mls of 
LB (containing 50pg/ml Ampicillin) at 37°C and plasmid DNA was extracted using
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QIAprep spin miniprep kit (Qiagen), as per the manufacturer's instructions, lp g  of 
plasmid DNA was digested with EcoRI enzyme (New England Biotech) and run on 2% 
Agarose gel (containing O.lpg/m l Ethidium bromide) to re-test for requisite insert, as 
described above.
Sequencing and analysis: 2-3pg of plasmid DNA, containing the target DNA insert, was 
shipped for sequencing by the Iowa State University DNA sequence facility (Applied 
Biosystems 3730x1 DNA Analyzer). The DNA insert region was sequenced using T3 
universal primers. 3-5 independent clones of each alternatively spliced transcript were 
sequenced to confirm sequence identity. Alternatively splicing of Pax5 exons was 
confirmed by aligning the sequenced clone with published full length cDNA sequence of 
O. mykiss Pax5 (NCBI Gene ID: 185135003) in a Pustell DNA matrix (and ClustalW 
alignment) using the alignment program MacVector® version 7.2.3.
Semi-quantitative RT-PCR and ratio analysis: RNA was isolated from trout immune 
tissues as previously described (page 33). A single round of PCR was performed to 
obtain a relative ratio of alternatively spliced Pax5 isoform to full length Pax5 cDNA 
using PBL and spleen cDNA. Two sense direction PCR primers were used, that flanked 
exon boundaries of full length and alternatively spliced Pax5 respectively, along with a 
common anti-sense PCR primer. PCR was performed using Vent® DNA polymerase (New 
England Biotech) under the following conditions: lm inute at 94°C, lm inute at 60-62°C 
and lm inute at 72°C for 32 cycles on a Perkin-Elmer GeneAmp PCR system 2400. lOpI of 
PCR product was run on a 2% Agarose gel containing Ethidium bromide (O.lpg/ml) and
46
with 0.5pg of lOObp DNA ladder (New England Biotech) as size marker. PCR amplicons 
were visualized and recorded on a gel documenting apparatus (Bio-Rad Gel Doc XR 
CFW1312M) under UV light. Gel images were recorded at 0.5 (± 0.3) seconds UV 
exposure and band intensities measured using Quantity One® software version 4.6.1 
(Discovery Series/Bio-Rad). A list of primers used in the semi-quantitative PCR analysis 
can be found under Table 2.2.
The ratio of relative intensity of alternatively spliced to full-length* Pax5 amplicon or 
secreted to membrane IgM and IgT amplicons was calculated and the ratio at each day 
of LPS activation was then normalized against day 0. All experiments were performed in 
triplicate, the mean of the resulting values were plotted in a trend line graph with days 
after LPS activation on the x-axis and relative ratio on the y-axis. Standard deviations 
from the mean were incorporated for each data point per day.
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Table 2.2: Primers used in nested PCR analysis of alternatively spliced Pax5 transcripts.
Primer Name Direction Sequence (5' to 3') Location
Target
isoform
Round
of
nested
PCR
tPax5/5'end.S Sense
ATG TGC GGC CGC ATG 
GAA GTA GAG GCC GAG 
GG
Pax5 exonla 
(ATG)
Pax5/la A2 
isoform 1
tPax5/528.AS Antisense
AGC CGA GTC ACT GGA 
CACC Pax5 exon 5
Pax5/la A2 
isoform 1
tPax5/elwt.S Sense
AGT AGA GGC CGA GGG 
TCATG
Pax5 exon 
la
Pax5/la A2 
isoform 2
tPax5/E4.AS Antisense
CTG ACC CGG AGG CTG 
ATG G Pax5 exon 4
Pax5/la A2 
isoform 2
tPax5b/5'UT.S Sense
GAT GGA GTC GGC GAA 
CTAG
Pax5 exon 
lb  (5'UTR)
Pax5/lb A2 
isoform 1
tPax5/3'UT.AS Antisense
CAT CGT TGA TGG GTG 
GGG TCA Pax5 3'UTR
Pax5/lb A2 
isoform 1
tPax5/5'end.S Sense
ATG GAG ATA GAG AAT 
ATA GTC GCC
Pax5 exon 
lb(ATG)
Pax5/lb A2 
isoform 2
tPax5/618.S Sense
ATG TGC GGC CGC GCT 
ACC CCC CAC ACG TCC 
CCC Pax5 exon 6
Pax5/A8
isoform 1
tPax5/1104.AS Antisense
CAT CTG TCC CGT CTG 
GCT GG
Pax5 exon 
10
Pax5/A8
isoform 1
tPax5/764.S Sense
ATG TGC GGC CGC ACC 
AAT CTG GCC AAT CCA 
GGG TCA Pax5 exon 7
Pax5/A8 
Pax5/A9a, 
9b and 9c 2
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tPax5/964.AS Antisense
AGG GTG GGA ATA GCA 
G Pax5 exon 9
Pax5/A8
isoform 2
tPax5/3'end2.
AS Antisense
ATG TGC GGC CGC TCA 
GTG GCG GTC GTA GGC 
GG
Pax5 exon 
10 (TGA)
Pax5/A9a, 
9b and 9c 1
tPax5/860.S Sense
ATG TGC GGC CGC GCT 
ACC CCC CAC ACG TCC 
CCC Pax5 exon 8
Pax5/A9a, 
9b and 9c 2
tPax5/1104.AS Antisense
CAT CTG TCC CGT CTG 
GCT GG
Pax5 exon 
10
Pax5/A9a, 
9b and 9c 2
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Table 2.3: Primers used to obtain the relative ratio of alternatively spliced Pax5 transcript to 
full-length* transcript using semi-quantitative RT-PCR analysis.
Primer Name Direction Sequence (5' to 3') Location
Target
isoform
tPax5/El-2.S Sense
GAC GAG CAG GAG GAC 
ATG G
Pax5 exon la /2  
boundary
FL*Pax5 
(containing 
exons la  
and 2)
tPax5/El-3.S Sense
CGA GCA GGT ACT ATG 
AGA CAG G
Pax5 exon la /3  
boundary
Pax5/la A2 
isoform
tPax5/e3sp2.AS Antisense
GAT CGC GGC CGC GTC 
TCG TAT CTC CCA GGC G Pax5 exon 3
Pax5/la A2 
and
FL*Pax5 
(containing 
exons la  
and 2)
tPax5B/El-2.S Sense
TGA AGG CGA GAG AAG 
GAC ATG
Pax5 exon lb /2  
boundary
FL*Pax5 
(containing 
exon lb  
and 2)
tPax5/lB2/3.S Sense
AAG GCG AGA GGT ACT 
ATG AG
Pax5 exon lb /3  
boundary
Pax5/lb A2 
isoform
tPax5/7/8.S Sense
CCA CTG CCA GGT CGA 
GAC CTC
Pax5 exon 7/8 
boundary
FL*Pax5 
(containing 
exon 8)
tPax5/7/9.S Sense
TCCACTGCCAGGAGGAGAT 
1 1 1 1C
Pax5 exon 7/9 
boundary
Pax5/A8
isoform
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tPax5/9/10(101 
8). AS Antisense
TGTTGG AAC ACTAAC 
AGG CTG
Pax5 exon 9/10 
boundary
Pax5/A8 
isoform & 
FL*Pax5 
(containing 
exon 8)
tPax5/8/9.S Sense
GTA TGG TAC CCG GAG 
GAG ATTTTTC
Pax5 exon 8/9 
boundary
FL*Pax5 
(containing 
exon 9)
tPax5/8(931)/l
0(1018).S Sense
TAT GGT ACC CGT GTT 
CCA ACA G
Pax5 exon 8/10 
boundary Pax5/A9a
tPax5/8(920)/l
0(1018).S Sense
CTC ACT GAC TGT GTT 
CCA ACA G
Pax5 exon 8/10 
boundary Pax5/A9b
tPax5/8(920)/l
0{1072).S Sense
CTC ACT GAC TGG GCT 
CTTCACC
Pax5 exon 8/10 
boundary Pax5/A9c
tPax5/3'end2.A
S Antisense
ATG TGC GGC CGC TCA 
GTG GCG GTC GTA GGC 
GG
Pax5 exon 10 
(TGA)
Pax5/A9a, 
A9b, A9c & 
FL*Pax5 
(containing 
exon 9)
tHC.S Sense
CCT TAA CCA GCC GAA 
AGG G IgM
secreted & 
membrane 
IgM
transcript
tHCm.AS Antisense
CCA ACG CCA TAC AGC 
AGAG
IgM trans­
membrane 
segment coding 
region
membrane
IgM
transcript
tHCs.AS2 Antisense
TGA GGT TCT ATG AAT 
GGTTCTC
IgM secretory 
tail coding 
region
secreted
IgM
transcript
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tlgT.S Sense
GAG GAC AGT GGC GAG 
TAC C IgT
secreted
and
membrane
IgT
transcript
tlgtTmem.AS Antisense
GCT GCC GAA CTC ATC 
CTC
IgT trans­
membrane 
segment coding 
region
membrane
IgT
transcript
tlgTsec.AS Antisense
GGC AGC AAC ACA AGA 
CTG AC
IgT secretory tail 
coding region
secreted
IgT
transcript
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Table 2.4: Primers used to clone human and mouse Pax5/A2-8 transcript.
Primer Name Direction Sequence (5' to 3X) Location
Round of
nested
PCR
hPax5/5'UT.S Sense
GTG GAA ACT TTT CCC TGT 
CC
human Pax5 
exon la  (5'UTR) 1
hPax5/3'end.AS Antisense
GTG CCA TCA GTG TTT GGT 
GCC
human Pax5 
3'end (TGA) 1/2
SD664.S Sense
ATG GAT TTA GAG AAA AAT 
TAT CCG
human Pax5 
exon la  (ATG) 2
mPax5/5'UT.S Sense
CCT CGC TGT CCA TTT CAT 
CAA GTC C
mouse Pax5 exon 
la  (5'UTR) 1
mPax5/3'UT.AS Antisense
GTA AGT GCT TGG CAC CCG 
TGG
mouse Pax5 exon 
10 ( 3'UTR) 1
Pax5.ATGl.S Sense ATG GAT TTA GAG AA
mouse Pax5 exon 
la  (ATG) 2
PP8.S Sense
AAA TGG ATT TAG AGA AAA 
ATT AC
mouse Pax5 exon 
la  (ATG) 2
mPax5/3'end.AS Antisense
TCA GTG ACG GTC ATA GGC 
GGTGGC
mouse Pax5 
3'end (TGA) 2
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Chapter 3: Results
3.1 Screening for alternatively spliced isoforms of Pax5 with deletion of the paired 
domain:
The N-terminal DNA-binding paired domain is a strongly conserved feature among 
members of the Pax family and is encoded by the second and third exons of the Pax5 
gene (figure 3.1) (Czerny, Schaffner and Busslinger, 1993). Alternatively spliced 
transcripts of Pax5 that lack a paired domain are hypothesized to have low DNA binding 
ability and may function as dominant transcriptional co-repressors of Pax5 downstream  
targets. To screen for alternatively spliced isoforms of Pax5 that lack the paired domain 
coding region (either exon 2 or exon 3), two independent sets of primers were designed 
based on the published complete cDNA sequence of Oncorhynchus mykiss Pax5 
(Genbank accession number NM 001124682) that flank the 5' end of the transcript.
O.mytos? PaxScPNA
5 T T
Pax 5 protein
N-terminal
Legend:
I N  I i 1 i
L H N C-terminal
m  Paired Domain Trans-activation domain
,— . |7~i Trans-activation/Inhibitory
□  Octopept.de Segment I D  domain overlap
Partial homeodomain T t y  I Inhibitory domain
sjs 561 ox; 'o ;  **»  » » 9 9 4  im xn
531 TGA
47 216 414 479 60.' 70S 830 932 1019 l l» l
Figure 3.1: Schematic of Pax5 cDNA exon structure and conserved functional domains on the Pax5 
protein. O. mykiss Pax5 cDNA is 1191 nucleotides long and consists of 10 exons that encode 5 conserved 
functional domains. The exon boundaries of O. mykiss Pax5 cDNA was determined by aligning the
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published full-length Pax5 sequences of mouse, human and O. mykiss. Nucleotides 46-432 (Exons 2, 3 and 
partial 4) code for the DNA binding paired domain, 538-561 (partial Exon 5) code for the octopeptide 
segment, 682-703 (partial Exon 6) code for the partial homeodomain, 829-993 (Exon 8 and partial 9) code 
for the trans-activation domain and 994-1188 (partial Exon 9 and 10) code for the inhibitory domain.
Using a nested PCR approach (figure 3.2), the first set of primers which externally flank
exons 2 and 3 was used to screen for alternatively spliced Pax5 in cDNA from freshly
isolated anterior kidney cells (as described in methods). Both rounds of PCR product
were electrophoretically separated and DNA bands obtained corresponded to a longer
paired domain containing Pax5 amplicon of size 450 nucleotides and a smaller 281
nucleotide long amplicon (see figure 3.2). A 190 nucleotide long amplicon (indicated by
an asterisk in figure 3.2) was also obtained, which upon sequence analysis was found to
be not related to Pax5.
la
Q.
5 ' la 2 3 4 5 6 -1 0 3* °  J O
4— tH
Amplicon g»»450n-
Round 1 PCR
1la 2 3 4 5 ||
Amplican sizes 52Snts
3 liil
tPax5/E4AS ; tP axS /elw tS
Round 2 PCR
Full length* Pax5 amplicon
tPax5/E4.A5
Amplicon size« 281
FL Pax5 
(450 nt)
>  Pax5/laA 2  
(281 nt)
* (approx. 190 nt)
Alternatively spliced Pax5/laA2 amplicon
Figure 3.2: Nested PCR strategy for Pax5/laA2 transcript. The first round o f nested PCR on AK day 0
cDNA used primers that flank exons 2 to 4. The product from this round was then used in a second round 
of PCR with an independent set of internal primers that flank exons 2 and 3. The product was 
electrophoretically separated on a 2% agarose gel w ith (O.lpg/m l Ethidium bromide). The first lane 
contains a 0.5pg o f lOObp ladder (New England Biotech) and the second lane contains lOpI of second 
round PCR product. Two amplicons of sizes 450 nucleotides and 281 nucleotides was obtained, 
corresponding to  exon 2 containing and exon 2 deleted Pax5 transcripts. Also, a 190 nucleotide amplicon
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was obtained (indicated by * in gel picture). Sequence analysis showed that this amplicon was not Pax5 
related. BLAST searches performed for this amplicon showed no sequence homology w ith genes in the 
NCBI database.
Subsequent cloning and sequencing of both amplicons revealed that the longer 
amplicon (clone # 350E2-U461207) was paired domain containing Pax5 (with exons 2 
and 3) and the shorter amplicon (clone # E23A0a_T3_492426) was an alternatively 
spliced transcript of Pax5. A pustel DNA matrix alignment of the paired domain 
containing Pax5 clone with the published full-length Pax5 cDNA sequence showed 
complete homology, corresponding to full length Pax5 containing exons 2 and 3. A 
pustel DNA matrix alignment of the alternatively spliced Pax5 clone with the published 
full length Pax5 cDNA sequence showed homology in regions corresponding to exons la , 
3 and 4 with a 169 nucleotide gap between nucleotides 47 to 216 (See Appendix I 
alignment 2), corresponding to a deletion of exon 2.
Three more independent clones (clone # C02_E56D5_R-2__497304, A02_E2A0a3_R- 
2_497311 and C02_E2A0a6_R-2_497313) were sequenced to confirm the identity of 
alternative spliced Pax5 with deleted exon 2 [Pax5/laA2]. A total of seven clones 
sequenced displayed a splicing pattern distinctive of Pax5/laA2, suggesting that this 
alternatively spliced transcript may be relatively abundant to full-length Pax5 in B cells. 
Clones containing tPax5 sequence are listed in table 3.1.
In a previous study by Zwollo et al (un-published data), a cDNA library screen for full- 
length O. mykiss Pax5 lead to the discovery o f putative alternate exon lb . We designed 
a nested PCR strategy to test if Pax5 transcripts with exon lb  also deleted exon 2. The
58
first set of primers flank the entire Pax5 (with exon lb ) transcript and was used to 
screen for all alternatively spliced transcripts of Pax5 in AK day 0 cDNA from freshly 
isolated anterior kidney cells. Amplicons of size 300-500 and less than 300 nucleotides 
were extracted separately from low melt agarose. This DNA was then used as template 
in the nested round using an independent set of internal primers that flank exons 2 
(figure 3.3). Both rounds of PCR product were electrophoretically separated and DNA 
bands were obtained corresponding to a longer paired domain containing Pax5 
amplicon of size 358 nucleotides and a smaller 189 nucleotide amplicon (see figure 3.3). 
A 240 nucleotide amplicon was obtained that was found to be not-Pax5 related 
(indicated with an * in figure 3.3).
Cloning and sequence analysis of the potential Pax5/lbA2 amplicon is yet to be 
performed. The difference in size between the longer 358 nucleotide amplicon and the 
shorter 189 nucleotide amplicon correspond to the size of deleted exon 2 (179 
nucleotides and supports the conclusion that the shorter amplicon is indeed Pax5/lbA2.
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oin
I lb 2 3 4 i i l lbk . 3 4 8
A !'C3TI ;*= 453 Ampf'cpo i : i  = 2S3 nts.
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Amp.icon i  rftc SSSnts Am piico fti. : •«  ISdnts
Full length" Pax5 ( lb )  amplicon Alternatively spliced Pax5/lbA2 amplicon
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(358 nts)
* (approx 240 nts)
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Figure 3.3: Nested PCR strategy for Pax5/lbA2 transcript. The first round o f nested PCR on AK day 0
cDNA used primers that flank the entire Pax5/lb transcript. The product from this round was then 
separated electrophoretically on a 1% low melt agarose gel (O.lpg/m l Ethidium bromide). Amplicons of 
size 500-300 nucleotides and less than 300 nucleotides were extracted and used as template in a second 
round of PCR w ith an independent set o f internal primers that flank exons 2. The products were 
electrophoretically separated on a 2% agarose gel w ith (O.lpg/m l Ethidium bromide). The first lane 
contains a 0.5pg o f lOObp ladder (New England Biotech); the second lane contains lOpI o f nested PCR 
product using round 1 amplicons o f size 500-300 as template; the th ird lane contains lOpI o f nested PCR 
product using round 1 amplicons less than 300 nucleotides in size as template. Two amplicons o f sizes 358 
nucleotides and 189 nucleotides were obtained, corresponding to  exon 2 containing and exon 2 deleted 
Pax5/lb transcripts. Also, a 240nt amplicon was obtained that was not Pax5 related. BLAST searches 
performed for this amplicon showed no sequence homology w ith genes in the NCBI database.
3.2 Screening for alternatively spliced isoforms of Pax5 with deletion of the trans­
activation domain:
The trans-activation domain of Pax5 has been described as a region rich in proline, 
serine and threonine residues (PST rich) (Dorfler and Busslinger, 1996) and its position 
on the Oncorhynchus mykiss (Rainbow trout) Pax5 cDNA sequence was determined 
based on ClustalW alignments with published mouse (Genbank ID: 118130642) and 
human Pax5 cDNA (Genbank ID: 9951919) (Alignment 2.1). Exons 7, 8 and exon 9 
encode the trans-activation domain of O. mykiss Pax5 (See figure 3.1). An alternatively 
spliced isoform of Pax5 that lacks the trans-activation domain will have an intact 
inhibitory domain at its carboxy-terminal and may function as a dominant 
transcriptional repressor of Pax5 downstream targets. To screen for alternatively spliced 
isoforms of Pax5 containing a deletion of the trans-activation domain coding region, two  
independent sets of primers were designed that flank exons 7, 8 and 9 externally (see 
Figure 3.4). This work was done together with an undergraduate student Alice Harman.
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Using a nested PCR approach, the first set of primers which flank exons 7, 8 and 9 
broadly was used to screen for alternatively spliced Pax5 transcripts in cDNA obtained 
from posterior kidney cells that had been stimulated with LPS for 7 days. Product from  
this round of PCR was then used as template in the second round using an independent 
set of internal primers that flanks exon 8. Nested PCR product was electrophoretically 
separated and the DNA bands obtained corresponded to a longer exon 8 containing 
Pax5 amplicon of size 200 nucleotides and another amplicon that was roughly 102 
nucleotides smaller (figure 3.4).
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tF j«S ; 1134.AS
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Round 2 PCR
Amplicon si2**200n
Full length' Pax5 amplicon
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Alternatively spliced Pax5/u8 amp!icon
* (>200nts)
-  / / FL Pax5 
  >(200 nts)
^  Pax5/A 8 
(98 nts)
Figure 3.4: Nested PCR strategy for Pax5/A8 transcript. The first round of nested PCR on AK day 7 cDNA 
used primers that flank exons 7 to 9. The product from this round was then used in a second round of PCR 
with an independent set o f internal primers that flank exons 8. The product was electrophoretically 
separated on a 2% agarose gel w ith (O.lpg/m l Ethidium bromide). Lane 0 contains 0.5pg of lOObp ladder 
(New England Biotech) and lane 1 contains lOpI o f second round PCR product. Two amplicons o f sizes 200 
nucleotides and 98 nucleotides (faintly visible) were obtained, corresponding to exon 8 containing and 
exon 8 deleted Pax5 transcripts. Two additional amplicons greater than 200 nucleotides were also 
obtained, consequent sequencing of which revealed that they were not related to  Pax5 (indicated with an 
asterisk symbol).
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The shorter amplicon of size 98 nucleotides was barely discernable suggesting that it is 
present at lower relative levels than full-length Pax5 transcript.
Subsequent cloning and sequencing of both amplicons revealed that the longer 
amplicon was exon 8 containing Pax5 and the shorter amplicon (clone # A6_T3_504023) 
was an alternatively spliced transcript of Pax5 with deleted exon 8. A Pustel DNA matrix 
alignment of the Pax5/A8 clone with the published Pax5 cDNA sequence showed 
homology of exons 7 and 9, with a 102 nucleotide long gap between nucleotides 830 to 
931 on FL* Pax5 (See Appendix I : Alignment 4), corresponding to a deletion of exon 8.
Another independent clone (clone # A5_T3_504022) was sequenced to confirm the 
identity of alternative spliced Pax5 with deleted exon 8 [Pax5/A8]. (For a fu ll list of 
sequenced clones see table 3.1)
3.3 Screening for alternatively spliced isoforms of Pax5 with deletion of the inhibitory 
domain:
The inhibitory domain of Pax5 is located at the C-terminal end of the protein and is 
encoded by exons 9 and 10 (minimal inhibitory domain by nucleotides 994-1188, 
complete inhibitory domain by nucleotides 931-1188; see figure 3.1) (Dorfler and 
Busslinger, 1996). Alternatively spliced isoforms of Pax5 that lack the inhibitory domain 
will have an intact trans-activation domain at the carboxy-terminal and may function as 
more potent transcriptional activators of Pax5 downstream targets. To screen for 
alternatively spliced transcripts of O. mykiss Pax5 that contain a deletion of the 
inhibitory domain coding region, two independent sets of primers were designed that
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flank the 3' end of the transcript, specifically exons 9 and 10 (see Figure 3.5). This work 
was done together with an undergraduate student Alice Harman.
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Figure 3.5: Nested PCR strategy for Pax5/A9 transcript. The first round of nested PCR on AK day 7 cDNA 
uses primers that flank exons 8 and 9. The product from this round was then used in a second round of 
PCR with an independent set o f internal primers that flank exon 9. The product was electrophoretically 
separated on a 2% Agarose gel w ith (O.lpg/m l Ethidium bromide). Lane 1 contains a 0.5pg of lOObp 
ladder (New England biotech) and lane 2 contains 10pl o f second round PCR product. Two amplicons of 
sizes 268 nucleotides and 182 nucleotides were obtained, corresponding to exon 9 containing and exon 9 
deleted Pax5 transcripts.
Using a nested PCR approach, the first set of primers which flank exons 9 and 10 broadly 
was used to screen for alternatively spliced Pax5 in cDNA obtained from day 7 anterior 
kidney cDNA. Product from this round of PCR was then used as template in the second 
round using an independent set of internal primers that flank exons 9. Round II PCR 
product was electrophoretically separated and the DNA bands obtained corresponded 
to a longer inhibitory domain containing Pax5 amplicon of size 268 nucleotides and 
another amplicon of size 182 nucleotides (see figure 3.5).
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Subsequent cloning and sequencing of both amplicons revealed that the longer 
amplicon (clone# E9500a2_T3_407321) contains complete exon 9 and the shorter 
amplicon (clone# E9180a3_R-2_497320) was an alternatively spliced transcript of Pax5 
that lacked exon 9 (Pax5/A9a). A Pustel DNA matrix alignment of the Pax5/A9a clone 
with the published Pax5 cDNA sequence showed homology of exons 8 and 10, with an 
86 nucleotide gap between nucleotides 932 to 1018 (See alignment 5), corresponding to  
a deletion of exon 9.
An independent clone (clone # A9_T3_504026) was sequenced from AK day 0 and 
Spleen day 0 cDNA to confirm the identity of alternative spliced Pax5 with deleted exon 
9 [Pax5 A9a] as listed in table 3.1.
Two other clones were sequenced that used alternative splice donor and acceptor sites, 
and were different from those at the exon 8 /9  and exon 9 /10  junctions. The first 
cryptically spliced clone (A10_T3_504027) uses a 5' splice donor site at nucleotide 920 
inside exon 8 and 3' splice acceptor site at the classical exon 9 /10  boundary (see 
alignment 6). This clone was called Pax5 A9b and has a truncation off an additional 11 
nucleotides from the TD coding region.
The other cryptically spliced clone (clone # D02_E56D56_T3_497305) uses a 5' splice 
donor site at nucleotide 920 in exon 8 and a 3' splice acceptor site at nucleotide 1072 
inside exon 10 (see alignment 6). This clone was called Pax5 A9c and has a deletion of an 
additional 11 nucleotides from the TD coding region and 54 nucleotides from the ID 
coding region.
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2 more independent clones of Pax5 A9b and 9 more independent clones of Pax5 A9c 
(clone IDs: G01_E56D56_R-2_497305, E02_E56D5x_T3_497306, D02_E9100a5_R- 
2 497314, E02_E9100a7_R-2_497315 and G02_E9160al_R-2_497317) were sequenced 
from AK day 0, day 7 and Spleen day 0 cDNA to confirm the identity of cryptically spliced 
transcripts Pax5 A9b and Pax5 A9c. All clones are listed in table 3.1.
In summary, six alternatively spliced transcripts of O. mykiss Pax5 were isolated from  
several immune tissues with deletions of regions that encode the paired domain, trans­
activation domain and inhibitory domain. A schematic of all the alternatively spliced 
transcripts and the position of their deletions can be found in figure 3.18.
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3.4 Summary of cloned alternatively spliced Pax5 transcripts:
In total, six novel alternatively spliced transcripts of trout Pax5 were cloned and 
sequenced in this study (figure 3.6).
Figure 3.6
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Figure 3.6 Summary of alternatively spliced transcripts of trout Pax5 cloned in this study. The panel 
schematically shows cDNA transcripts o f the six common alternatively splice variants of O. mykiss Pax5. 
The full-length form of Pax5 contains 10 exons and spans over 1191 nucleotides (with exon la). 
Nucleotides 46-432 encode a DNA binding paired domain (light grey), nucleotides 538-561 encode the 
octopeptide segment (black), nucleotides 682-702 encode the partial homeodomain (striated box), 
nucleotides 829-930 and 829-993 encode the minimal and maximal trans-activation domains (medium 
grey), nucleotides 931- 1188 and 994 to  1188 encode the maximal and minimal inhibitory domains (dark 
grey). Deletion o f an exon on the alternatively spliced transcripts results in the truncation of a respective 
functional domain encoding region. The lower panel shows an alternatively spliced transcript o f Pax5 
with mutually exclusive use o f exon lb  and deletion of exon 2.
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3.5 Relative ratio of alternatively spliced Pax5 isoforms to full length* Pax5 in 
the Spleen
Previous studies (Zwollo et al, 2008) suggest that O. mykiss spleen lacks developing B 
cells and houses mostly resting, mature B cells. The same study showed that LPS 
activation of splenic cells shows a high capacity of producing plasma cells. This suggests 
that the spleen might serve as a secondary immune organ and during infections 
produces a diverse population of terminally differentiating B cells. In our study, the 
relative abundance of each Pax5 isoform was estimated in splenic B cells using a semi- 
quantitative RT-PCR approach. Freshly collected splenic B cells were cultured in the 
presence of the B cell mitogen lipopolysaccharide (LPS) and collected from days 0 to 7 
for total RNA extraction and cDNA synthesis. LPS polyclonal activated B cells by cross- 
linking the IgM receptor on B cells and inducing activation of B cells.
Sense primers were designed that flank the exon-exon boundary of full length* or 
alternatively spliced Pax5, allowing for the individual amplification of each transcript. A 
standard RT-PCR reaction was performed using both sets of sense primers and a 
common antisense primer. The relative ratio of the alternatively spliced Pax5 isoform 
(with a deleted exon) to full length* Pax5 isoform (in which the alternatively spliced 
exon is retained in the transcript) was obtained semi-quantitatively. A similar approach 
was also used to estimate the relative ratio of secreted to membrane IgM and IgT across 
7 days of activation with LPS. The comparison of both data sets were used to study the
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change in relative amounts of alternative spliced to full length isoform during B cell 
activation.
3.5.1 Relative ratio of secreted to membrane IgM in the spleen:
As described above, secreted and membrane IgM transcripts were amplified in triplicate 
RT-PCR reactions using spleen cDNA from LPS activated cells between Days 0 and 7. Two 
amplicons were obtained: 598 nucleotide amplicon corresponding to secreted IgM and 
373 nucleotide amplicon corresponding to membrane IgM transcripts (figure 3.7a).
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Figure 3.7b
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Figure 3.7 Relative ratio of secreted to membrane IgM in spleen, (a) Semi-quantitative PCR strategy to 
amplify secreted and membrane IgM transcripts using a common sense primer and antisense primers that 
recognize either the trans-membrane (TM) segment coding region or the secretory tail (ST) coding region. 
The product is electrophoretically separated on a 2% agarose gel (O.lpg/ml Ethidium bromide). Two 
amplicons o f sizes 598 nucleotides and 373 nucleotides are obtained corresponding to secreted IgM and 
membrane IgM transcripts respectively, (b) The left panel shows the relative ratio of secreted to 
membrane IgM transcript in cDNA from splenic cells that have been stimulated w ith LPS for 0-7 days in 
culture. The right panel shows electrophoretically separated secreted and membrane IgM transcripts on a 
2% agarose gel; lane 1 = 0.5pg lOObp DNA ladder (New England Biotech), Lanes 2-9 = cDNA from splenic 
cells that have been LPS activated from 0-7 days respectively.
At day 0 the ratio of secreted to membrane IgM is less than 1, indicating that there is 
greater membrane IgM transcript amplification than secreted IgM transcript 
amplification in freshly isolated splenic B cells (figure 3.7b). Upon activation with LPS, 
the relative ratio of secreted to membrane IgM increases between Day 0 and Day 1; 
with a small overall increase from days 1 through 7. This is consistent with known 
effects of LPS activation in trout B cells, which shifts IgM transcript levels from  
membrane to secreted IgM in terminally differentiating B cells. However, it is interesting
Relative ratio of secreted to membrane IgM
in Spleen 9.24.08 Days a fter LPS activation
Days aftsr activation with LPS
 ^Sec igM 
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69
to note that the relative ratio of secreted to membrane IgM does not exceed 1, 
indicative of a fairly high level of IgM in the cells.
3.5.2 Relative ratio of secreted to membrane IgT in the spleen:
The immunoglobulin molecule IgT has been discovered quite recently and is reported to 
be unique to the teleost B cell lineage (Hansen et al, 2005). We sought to use IgT 
expression as a comparative method of studying the expression of alternatively spliced 
isoforms of Pax5 during B cell activation. As previously described for IgM expression 
study, secreted and membrane IgT transcripts were amplified in triplicate RT-PCR 
reactions using spleen cDNA from LPS activated cells between day 0 (freshly isolated) 
and day 7. Two amplicons were obtained: 451 nucleotide amplicon corresponding to 
secreted IgT and 271 nucleotide sized amplicon corresponding to membrane IgT (see 
figure 3.8a).
At day 0 (no LPS activation), the relative ratio of secreted to membrane IgT is marginally 
greater than 1, indicating that both transcripts are almost equally amplified in freshly 
isolated splenic B cells (see figure 3.8b). Upon LPS activation, the relative ratio of 
secreted to membrane IgT increases and is highest between days 6 and 7. It is 
interesting to note that the relative ratio of secreted to membrane IgT drops to around 
1 at day 5 of LPS activation. Although the reason for this is unknown, possible 
explanations have been offered in the discussion section.
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Figure 3.8 Relative ratio of secreted to membrane IgT in spleen, (a) Semi-quantitative PCR strategy to 
amplify secreted and membrane IgT transcripts using a common sense primer and antisense primers that 
recognize either the trans-membrane (TM) segment coding region or the secretory tail (ST) coding region. 
The product is electrophoretically separated on a 2% agarose gel (O.lpg/ml Ethidium bromide). Lane 1 
contains 0.5pg of lOObp ladder (New England Biotech), Lane 2 contains lOpI o f IgT in blood day 4 cDNA. 
Two amplicons o f sizes approx 451 nucleotides and 271 nucleotides are obtained corresponding to 
secreted IgT and membrane IgT respectively, (b) The left panel shows the relative ratio o f secreted to 
membrane IgT transcript in cDNA from splenic cells that have been stimulated w ith LPS for 0-7 days in 
culture. The right panel shows electrophoretically separated secreted and membrane IgT transcripts on a 
2% agarose gel; lane 1 = 0.5pg lOObp DNA ladder (New England Biotech), Lanes 2-9 = cDNA from splenic 
cells that have been LPS activated for days 0, 1, 4, 5, 6 and 7 respectively. An asterisk symbol denotes
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unidentified amplicons, approx 350 nts in size which are not specific to IgT and have been excluded from 
the analysis. Further sequence analysis is required to determine the identity of these amplicons.
3.5.3 Relative ratio of Pax5/laA2 to full-length* Pax5 in the spleen:
Pax5/laA2 is an alternatively spliced isoform of Pax5 that lacks the paired domain 
coding region exon 2 and contains the alternative exon la . In order to study the 
expression of this alternatively spliced transcript relative to full-length* Pax5 in the 
spleen, triplicate RT-PCR reactions were performed using cDNA from splenic B cells that 
had been activated with LPS in culture between 0 and 7 days. Two amplicons were 
obtained of sizes 399 nucleotides and 230 nucleotides, corresponding to full- 
length*Pax5 and Pax5/laA2 respectively (See figure 3.9a).
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Figure 3.9 (b)
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Figure 3.9 Relative ratio of Pax5/laA2 to FL*Pax5 in the spleen, (a) Semi-quantitative PCR strategy to 
amplify Pax5/laA2 and FL*Pax5 transcripts using a common antisense primer and sense primers that 
recognize either the exon la -2  junction of FL*Pax5 or the exon la-3 junction of Pax5/laA2. The product is 
electrophoretically separated on a 2% agarose gel (O.lpg/m l Ethidium bromide). Lane 1 contains 0.5pg of 
lOObp ladder (New England Biotech), Lane 2 contains lOpI o f PCR product in spleen day 2 cDNA. Two 
amplicons o f sizes approx 399 nucleotides and 230 nucleotides are obtained corresponding to FL*Pax5 
and Pax5/laA2 respectively, (b) The left panel shows the relative ratio o f Pax5/laA2 to FL*Pax5 
transcripts in cDNA from splenic cells that have been stimulated w ith LPS for 0-7 days in culture. The right 
panel shows the PCR product that has been electrophoretically separated on a 2% agarose gel; lane 1 = 
0.5pg lOObp DNA ladder (New England Biotech), Lanes 2-9 = cDNA from splenic cells that have been LPS 
activated for days 0-7 respectively.
At day 0 (no LPS activation), the relative ratio of Pax5/laA2 to full-length* Pax5 is 
approximately 0.36 (less than 1), indicating that the alternatively spliced transcript is 
present at much lower relative levels than full-length* Pax5 (see figure 3.9b). Upon 
activation with LPS, there is a steady increase in the relative ratio of Pax5/laA2 to full- 
length* PaxS until day 6 where it is almost double that at day 0. This suggests that there 
is a shift towards using more of the alternative isoform Pax5/laA2 during later stages of 
B cell activation.
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3.5.4 Relative ratio of Pax5/lbA2 to full-length* Pax5 in the spleen:
Pax5/lbA2 is an alternatively spliced isoform of Pax5 that lacks the paired domain 
coding region exon 2 and contains the alternative exon lb . In order to study the 
expression of this alternatively spliced transcript relative to full-length* Pax5 in the 
spleen, triplicate RT-PCR reactions were performed using cDNA from splenic B cells that 
had been activated with LPS in culture between 0 and 7 days. Two amplicons were 
obtained of sizes 330 nucleotides and 161 nucleotides, corresponding to full- 
length*Pax5 and Pax5/lbA2 respectively (See figure 3.10a).
At day 0 (no LPS activation), the relative ratio of Pax5/lbA2 to full-length* Pax5 is 
approximately 0.36 (less than 1), indicating that the alternatively spliced transcript is 
present at much lower amounts relative to full-length* Pax5 (figure 3.10b). Upon 
activation with LPS, there is an increase in the relative ratio of Pax5/lbA2 to full-length* 
Pax5 until day 3; where it almost doubles. This suggests that there is a shift towards 
using the alternative isoform Pax5/lbA2 in the initial stages of LPS activation.
Figure 3.10 (a)
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Figure 3.10 (b)
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Figure 3.10 Relative ratio of Pax5/lbA2 to FL*Pax5 in the spleen, (a) Semi-quantitative PCR strategy to 
amplify Pax5/lbA2 and FL*Pax5 transcripts using a common antisense primer and sense primers that 
recognize either the exon lb -2  junction o f FL*Pax5 or the exon 1-3 junction of Pax5/lbA2. The product is 
electrophoretically separated on a 2% agarose gel (O.lpg/ml Ethidium bromide). Lane 1 contains 0.5pg of 
lOObp ladder (New England Biotech), Lane 2 contains lOpI o f PCR product in spleen day 2 cDNA. Two 
amplicons of sizes approx 330 nucleotides and 161 nucleotides are obtained corresponding to FL*Pax5 
and Pax5/lbA2 respectively, (b) The left panel shows the relative ratio of Pax5/lbA2 to FL*Pax5 
transcripts in cDNA from splenic cells that have been stimulated w ith LPS for 0-7 days in culture. The right 
panel shows the PCR product that has been electrophoretically separated on a 2% agarose gel; lane 1 = 
0.5pg lOObp DNA ladder (New England Biotech), Lanes 2-9 = cDNA from splenic cells that have been LPS 
activated for days 0-7 respectively.
At day 0 (no LPS activation), the relative ratio of Pax5/lbA2 to full-length* Pax5 is 
approximately 0.36 (less than 1), indicating that the alternatively spliced transcript is 
present at much lower amounts relative to full-length* Pax5 (figure 3.4b). Upon 
activation with LPS, there is an increase in the relative ratio of Pax5/lbA2 to full-length* 
Pax5 until day 3; where it almost doubles. This suggests that there is a shift towards
using the alternative isoform Pax5/lbA2 in the initial stages of LPS activation.
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3.5.5 Relative ratio of Pax5/A8 to full-length* Pax5 in the spleen:
Pax5/A8 is an alternatively spliced isoform of Pax5 that lacks a part of the trans­
activation domain encoded by exon 8. In order to study the expression of this isoform 
changes relative to full-length* Pax5 in the spleen, triplicate RT-PCR reactions were 
performed using cDNA from splenic B cells that had been activated with LPS in culture 
between 0 and 7 days. Two amplicons were obtained of sizes 228 nucleotides and 126 
nucleotides, corresponding to full-length*Pax5 and Pax5/A8 respectively (See figure 
3.11a).
At Day 0 (no LPS activation) the relative ratio of Pax5/A8 to full-length* Pax5 is 
approximately 0.37 (less than 1), indicating that the alternatively spliced transcript is 
present at much lower amounts relative to full-length* Pax5 (figure 3.11b). Upon 
activation with LPS, the relative ratio of Pax5/A8 to full-length* Pax5 increases gradually 
and is highest around day 6. This may suggest a role for Pax5/A8 during later stages of B 
cell activation.
Figure 3.11a
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Figure 3.11b
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Figure 3.11 Relative ratio of Pax5/A8 to FL*Pax5 in the spleen, (a) Semi-quantitative PCR strategy to 
amplify Pax5/A8 and FL*Pax5 transcripts using a common antisense primer and sense primers that 
recognize either the exon 7-8 junction o f FL*Pax5 or the exon 7-9 junction o f Pax5/lbA2. The product is 
electrophoretically separated on a 2% agarose gel (O.lpg/m l Ethidium bromide). Lane 1 contains 0.5pg of 
lOObp ladder (New England Biotech), Lane 2 contains lOpI of PCR product in spleen day 0 cDNA. Two 
amplicons of sizes approx 228 nucleotides and 126 nucleotides are obtained corresponding to  FL*Pax5 
and Pax5/lbA2 respectively, (b) The left panel shows the relative ratio o f Pax5/A8 to FL*Pax5 transcripts 
in cDNA from splenic cells that have been stimulated w ith LPS for 0-7 days in culture. The right panel 
shows the PCR product that has been electrophoretically separated on a 2% agarose gel; lane 1 = 0.5pg 
lOObp DNA ladder (New England Biotech), Lanes 2-9 = cDNA from splenic cells that have been LPS 
activated for days 0-7 respectively.
3.5.6 Relative ratio of Pax5/A9a, Pax5/A9b and Pax5/A9c to full length* Pax5 in the 
spleen:
The alternatively spliced transcripts of Pax5 that lack complete or part of exon 9 encode 
Pax5 protein isoforms with truncated C-terminal inhibitory domains. In order to study 
the expression of these isoform changes relative to full-length* Pax5 in the spleen, 
triplicate RT-PCR reactions were performed using cDNA from splenic B cells that have
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been activated with LPS in culture between 0 and 7. A PCR for the relative ratio of 
Pax5/A9a to full-length* Pax5 should yield two amplicons of sizes 269 nucleotides and 
183 nucleotides, corresponding to full-length*Pax5 and Pax5/A9a respectively (See 
figure 3.12a).
Only 1 amplicon of size 269 nucleotides was detected corresponding to full-length*Pax5, 
where the amplicon corresponding to Pax5/A9a was undetectable for most days of LPS 
activation (See figure 3.12b). This suggests that the alternatively spliced transcripts of 
Pax5 with deletion of complete exon 9 occur in minute relative quantities when 
compared to the full-length* Pax5 transcript.
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Figure 3.12b
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Figure 3.12 Relative ratio of Pax5/A9a to FL*Pax5 in the spleen, (a) Semi-quantitative PCR strategy to 
amplify Pax5/A9a and FL*Pax5 transcripts using a common antisense primer in exon 10 and sense primers 
that recognize either the exon 8-9 junction for FL*Pax5 or the exon 8-10 junction for Pax5/A9a transcripts. 
The product was electrophoretically separated on a 2% agarose gel (O.lpg/ml Ethidium bromide). Lane 1 
contains 0.5pg of lOObp ladder (New England Biotech), Lane 2 contains lO jil o f PCR product in spleen day 
3 cDNA. Two amplicons o f sizes approx 269 nucleotides and 183 nucleotides are obtained corresponding 
to FL*Pax5 and Pax5/A9a respectively, (b) The left panel shows the relative ratio o f Pax5/A9a to FL*Pax5 
transcripts in cDNA from splenic cells that have been stimulated with LPS for 0-7 days in culture. The right 
panel shows the PCR product that has been electrophoretically separated on a 2% agarose gel; lane 1 = 
0.5pg lOObp DNA ladder (New England Biotech), Lanes 2-9 = cDNA from splenic cells that have been LPS 
activated for days 0-7 respectively.
The same approach was used to measure the relative ratio of Pax5/A9b or Pax5/A9c vs. 
full-length* Pax5, using sense primers that recognize the exon 8-10 junctions unique to 
each alternatively spliced transcript. In both cases, amplification of alternatively spliced 
transcript was not detected (data not shown).
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3.5.7 Summary of the relative ratio of alternatively spliced Pax5 transcripts to full- 
length Pax5 in the Spleen:
Figure 3.13 outlines the different relative amplification of each alternatively spliced Pax5 
transcript with respect to their full-length counterparts during LPS activation of splenic B 
cells. During activation, both IgM and IgT shift toward an increase in relative secreted 
transcript, suggesting that splenic B cells are responsive to LPS treatm ent which is in 
agreement with previous studies (Zwollo et al, 2008). This increase in relative secreted 
Ig levels can be correlated with an increase in alternative isoform expression during LPS 
activation as can be observed in the case of Pax5/laA2, Pax5/lbA2 and Pax5/A8 for the 
spleen. This correlation suggests a link between the expression of alternatively spliced 
isoforms during splenic B cell activation, and will discussed in later sections.
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Figure 3.13 Summary of the relative ratio of alternatively spliced Pax5 transcripts to full-length Pax5 in
the spleen.
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3.6 Relative ratio of alternatively spliced Pax5 isoforms to full-length* Pax5 in 
the blood
Previous studies in O. mykiss have demonstrated that the blood contains populations of 
resting/non-lg secreting B cells and lacks terminally differentiated B cells or plasma cells 
(Zwollo et al, 2008). Even with LPS activation the blood had a lower propensity of 
generating activated B cells, plasmablasts or plasma cells. In our study, the relative 
abundance of each Pax5 isoform was estimated in the blood using a semi-quantitative 
RT-PCR approach. Freshly collected blood-derived B cells were cultured in the presence 
of the B cell mitogen lipopolysaccharide (LPS) and collected from days 0 to 7 for total 
RNA extraction and cDNA synthesis. LPS polyclonal activated B cells by cross-linking the 
IgM receptor on B cells and inducing activation of B cells.
Sense primers were designed that span the exon-exon boundary of full length* or 
alternatively spliced Pax5, allowing for the individual amplification of each transcript. A 
standard RT-PCR reaction was performed using both sets of sense primers and a 
common antisense primer. The relative ratio of the alternatively spliced Pax5 isoform 
(with a deleted exon) to full length* Pax5 isoform (in which the alternatively spliced 
exon is retained in the transcript) was obtained semi-quantitatively. A similar approach 
was also used to estimate the relative ratio of secreted to membrane IgM and IgT across 
7 days of activation with LPS. The comparison of both data sets were used to study the 
change in relative amounts of alternative spliced to full length isoform during B cell 
activation.
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3.6.1 Relative ratio of secreted to membrane IgM in the blood:
As described above, secreted and membrane IgM transcripts were amplified in triplicate 
RT-PCR reactions using cDNA from blood-derived B cell that have been activated with 
LPS for 7 days. Two amplicons were obtained: 598 nucleotide amplicon corresponding 
to secreted IgM and 373 nucleotide amplicon corresponding to membrane IgM (see 
figure 3.14a).
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Figure 3.14 Relative ratio of secreted to membrane IgM in blood, (a) Semi-quantitative PCR strategy to 
amplify secreted and membrane IgM transcripts using a common sense primer and antisense primers that 
recognize either the trans-membrane (TM) segment coding region or the secretory tail (ST) coding region. 
The product is electrophoretically separated on a 2% agarose gel (O.lpg/ml Ethidium bromide). Two 
amplicons of sizes approx 600 nucleotides and 280 nucleotides are obtained corresponding to secreted 
IgM and membrane IgM respectively, (b) The left panel shows the relative ratio of secreted to membrane 
IgM transcript in cDNA from PBL cells that have been stimulated w ith LPS for 0-7 days in culture. The right 
panel shows electrophoretically separated secreted and membrane IgM transcripts on a 2% agarose gel; 
lane 1 = 0.5pg lOObp DNA ladder (New England Biotech), Lanes 2-9 = cDNA from PBL cells that have been 
LPS activated from 0-7 days respectively, (c) The left panel shows the relative ratio of secreted to 
membrane IgM transcript in cDNA from PBL cells that have been stimulated w ith LPS between 0-14 days 
in culture. The right panel shows electrophoretically separated secreted and membrane IgM transcripts 
on a 2% agarose gel; lane 1 = 0.5pg lOObp DNA ladder (New England Biotech), Lanes 2-9 = cDNA from PBL 
cells that have been LPS activated on even days from 0,2,4,6,8,10,12,14 days respectively.
At day 0 (no LPS activation), the relative ratio of secreted to membrane IgM is
approximately 0.38 (less than 1), indicating that there is greater membrane IgM
transcript than secreted IgM transcript in un-activated blood B cells. Immediately after
activation, the relative ratio of secreted to membrane IgM increases slightly at day 1.
After day 1, the relative ratio of membrane to secreted IgM progressively reduces
towards later days of LPS activation. This is consistent with the Zwollo et al (2008) study
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where blood derived B cells showed low potential for generating plasma cells upon 
activation with LPS.
To further investigate if blood derived B cells get activated by LPS beyond the resolution 
of 7 days, an independent sample of blood derived B cells were activated with LPS in 
culture for 14 days. Using the same experimental setup, semi-quantitative RT-PCR 
analysis of the independent blood sample (figure 3.14c) revealed:
1) The relative ratio of secreted to membrane IgM is always less than 1 for all days 
of LPS activation observed.
2) The difference in the relative ratio of secreted to membrane IgM between the 
lowest at day 0 and the highest at day 14 is almost negligible.
This supports the hypothesis that blood derived B cells have low potential for terminal 
differentiation during LPS activation.
3.6.2 Relative ratio of secreted to membrane IgT in the blood
As in the splenic B cell study, we sought to use IgT expression as a comparative method 
of studying the expression of alternatively spliced isoforms of Pax5 during B cell 
activation. As previously described for IgM expression study, secreted and membrane 
IgT transcripts were amplified in triplicate RT-PCR reactions using spleen cDNA from LPS 
activated cells between days 0 and 7. Two amplicons were obtained: 451 nucleotide 
amplicon corresponding to secreted IgT and 271 nucleotide amplicon corresponding to 
membrane IgT (see figure 3.15a).
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Figure 3.15 Relative ratio of secreted to membrane IgT in blood, (a) Semi-quantitative PCR strategy to 
amplify secreted and membrane IgT transcripts using a common sense primer and antisense primers that 
recognize either the trans-membrane (TM) segment coding region or the secretory tail (ST) coding region. 
The product is electrophoretically separated on a 2% agarose gel (O.lpg/ml Ethidium bromide). Lane 1 
contains 0.5pg of lOObp ladder (New England Biotech), Lane 2,3 and 4 contains 10pl each o f membrane, 
secreted and both membrane and secreted IgT from blood day 0 cDNA. Two amplicons of sizes approx 
451 nucleotides and 271 nucleotides are obtained corresponding to  secreted IgT and membrane IgT 
respectively, (b) The left panel shows the relative ratio o f secreted to  membrane IgT transcript in cDNA 
from blood cells that have been stimulated with LPS for 0-7 days in culture. The right panel shows 
electrophoretically separated secreted and membrane IgT transcripts on a 2% agarose gel; lane 1 = 0.5pg 
lOObp DNA ladder (New England Biotech), Lanes 2-9 = cDNA from blood cells that have been LPS 
activated for days 0, 1, 4, 5, 6 and 7 respectively, (c) The left panel shows the relative ratio o f secreted to 
membrane IgT transcript in cDNA from PBL cells that have been stimulated w ith LPS between 0-14 days in 
culture. The right panel shows electrophoretically separated secreted and membrane IgT transcripts on a 
2% agarose gel; lane 1 = 0.5pg lOObp DNA ladder (New England Biotech), Lanes 2-9 = cDNA from PBL cells 
that have been LPS activated on even days from 0,2,4,6,8,10,12,14 days respectively.
At day 0, the relative ratio of secreted to membrane IgT is approximately 1.69 (greater
than one) indicating that the secreted transcript is present at greater levels than the
membrane transcript in un-activated blood-derived B cells. Amplification of membrane
IgT was detectable in very low relative levels. After activation with LPS, the relative ratio
remains unchanged until day 3, but then increases rapidly to greater than 2 fold higher
at day 7 (figure 3.15b).
The same trend was observed when the relative ratio of secreted to membrane IgT was 
obtained from an independent sample of blood derived B cells that were activated with 
LPS for 14 days (See figure 3.15c). The relative ratio of secreted to membrane IgT 
remains unchanged in the initial days of activation with LPS, but almost doubles after 
day 6. Once again the secreted IgT transcript seems to be present at greater levels than
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the membrane IgT transcript throughout activation -  the lowest relative ratio being 2.08 
at day 0.
3.6.3 Relative ratio of Pax5/laA2 to full-length* Pax5 in the blood:
Pax5/laA2 is an alternatively spliced isoform of Pax5 that lacks the paired domain 
coding region exon 2 and contains the alternative exon la . In order to study the 
expression of this isoform relative to full-length* Pax5 in the blood, triplicate RT-PCR 
reactions were performed using cDNA from blood-derived B cells that had been 
activated with LPS in culture between 0 and 7 days. Two amplicons were obtained of 
sizes 399 nucleotides and 230 nucleotides, corresponding to full-length*Pax5 and 
Pax5/laA2 respectively (See figure 3.16a).
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Figure 3.16 Relative ratio of Pax5/laA2 to FL*Pax5 in the blood, (a) Semi-quantitative PCR strategy to 
amplify Pax5/laA2 and FL*Pax5 transcripts using a common antisense primer and sense primers that 
recognize either the exon la-2  junction of FL*Pax5 or the exon la-3 junction of Pax5/laA2. The product is 
electrophoretically separated on a 2% agarose gel (O.lpg/ml Ethidium bromide). Lane 1 contains 0.5pg of 
lOObp ladder (New England Biotech), Lane 2 contains lOpI o f PCR product in blood day 2 cDNA. Two 
amplicons of sizes approx 399 nucleotides and 230 nucleotides are obtained corresponding to FL*Pax5 
and Pax5/laA2 respectively, (b) The left panel shows the relative ratio of Pax5/laA2 to FL*Pax5 
transcripts in cDNA from PBL cells that have been stimulated w ith LPS for 0-7 days in culture. The right
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panel shows the PCR product that has been electrophoretically separated on a 2% agarose gel; lane 1 = 
0.5pg lOObp DNA ladder (New England Biotech), Lanes 2-9 = cDNA from PBL cells that have been LPS 
activated for days 0-7 respectively, (c) The left panel shows the relative ratio of Pax5/laA2 to FL*Pax5 
transcript in cDNA from PBL cells that have been stimulated with LPS between 0-14 days in culture. The 
right panel shows electrophoretically separated Pax5/laA2 and FL*Pax5 transcripts on a 2% agarose gel; 
lane 1 = 0.5|ig lOObp DNA ladder (New England Biotech), Lanes 2-9 = cDNA from PBL cells that have been 
LPS activated on even days from 0,2,4,6,8,10,12,14 days respectively.
At day 0 (no LPS added), the relative ratio of Pax5/laA2 to full-length* Pax5 is 
approximately 0.89 indicating that the full length transcript is only slightly more than 
the alternatively spliced isoform. Following activation with LPS, the ratio remains 
unchanged until after day 6 (figure 3.16b). This suggests that Pax5/laA2 may have a 
contributing role in later stages of blood-derived B cell activation.
To test this hypothesis, we replicated this experiment in an independent sample of 
blood derived B cells that were activated with LPS for 14 days (See figure 3.16c). 
Analysis of the data from this experiment revealed a trend where although the relative 
ratio of Pax5/laA2 to full-length* Pax5 remained unchanged during initial days of LPS 
activation, a downward trend forms towards later stages of activation. Also, this 
experiment showed almost twice as much full length* Pax5 than Pax5/laA2 isoform on 
most days of LPS activation.
3.6.4 Relative ratio of Pax5/lbA2 to full-length* Pax5 in the blood:
Pax5/lbA2 is an alternatively spliced isoform of Pax5 that lacks the paired domain 
coding region exon 2 and contains the alternative exon lb . In order to study the 
expression of this isoform relative to full-length* Pax5 in the blood, triplicate RT-PCR
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reactions were performed using cDNA from blood-derived B cells that have been 
activated with LPS in culture between 0 and 7 days. Two amplicons were obtained of 
sizes 330 nucleotides and 161 nucleotides, corresponding to full-length*Pax5 and 
Pax5/lbA2 respectively (See figure 3.17a).
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Figure 3.17 (c)
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Figure 3.17 Relative ratio of Pax5/lbA2 to FL*Pax5 in blood (a) Semi-quantitative PCR strategy to  amplify 
Pax5/lbA2 and FL*Pax5 transcripts using a common antisense primer and sense primers that recognize 
either the exon lb -2  junction o f FL*Pax5 or the exon 1-3 junction of Pax5/lbA2. The product is 
electrophoretically separated on a 2% agarose gel (O.lpg/m l Ethidium bromide). Lane 1 contains 0.5pg of 
lOObp ladder (New England Biotech), Lane 2 contains lOpI o f PCR product in blood day 0 cDNA. Two 
amplicons o f sizes approx 330 nucleotides and 161 nucleotides are obtained corresponding to FL*Pax5 
and Pax5/lbA2 respectively, (b) The left panel shows the relative ratio of Pax5/lbA2 to FL*Pax5 
transcripts in cDNA from PBL cells that have been stimulated w ith LPS for 0-7 days in culture. The right 
panel shows the PCR product that has been electrophoretically separated on a 2% agarose gel; lane 1 = 
0.5pg lOObp DNA ladder (New England Biotech), Lanes 2-9 = cDNA from PBL cells that have been LPS 
activated for days 0-7 respectively, (c) The left panel shows the relative ratio of Pax5/lbA2 to FL*Pax5 
transcript in cDNA from PBL cells that have been stimulated with LPS between 0-14 days in culture. The 
right panel shows electrophoretically separated Pax5/lbA2 and FL*Pax5 transcripts on a 2% agarose gel; 
lane 1 = 0.5pg lOObp DNA ladder (New England Biotech), Lanes 2-9 = cDNA from PBL cells that have been 
LPS activated on even days from 0,2,4,6,8,10,12,14 days respectively.
At day 0 (no LPS added), the relative ratio of Pax5/lbA2 to full-length* Pax5 is 
approximately 1.15, indicating that the alternatively spliced isoform is present in slightly 
greater relative quantities than the full-length* transcript in blood-derived B cells (figure 
3.17b). Following activation with LPS, there is an increase in the relative ratio of 
Pax5/lbA2 to full-length* Pax5 with highest levels at days 2 and 7.
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This trend was observed again when the experiment was repeated in an independent 
sample of blood-derived B cells that had been activated with LPS for 14 days in culture 
(see figure 3.17c). The relative ratio of Pax5/lbA2 to full-length* Pax5 is highest around 
days 10 and 12 of PBL stimulation with LPS, suggesting that Pax5/lbA2 may participate 
in late stages of B cell activation.
3.6.5 Relative ratio of Pax5/A8 to full-length Pax5 in the blood:
Pax5/A8 is an alternatively spliced isoform of Pax5 that lacks a part of the trans­
activation domain coding region exon 8. In order to study the expression of this isoform 
changes relative to full-length* Pax5 in the blood, triplicate RT-PCR reactions were 
performed using cDNA from blood-derived B cells that have been activated with LPS in 
culture between 0 and 7 days. Two amplieon were obtained of size 198 nucleotides and 
98 nucleotides, corresponding to full-length* Pax5 and Pax5/A8. (See figure 3.18a)
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Figure 3.18 Relative ratio of Pax5/A8 to FL*Pax5 in the blood, (a) Semi-quantitative PCR strategy to 
amplify Pax5/A8 and FL*Pax5 transcripts using a common antisense primer and sense primers that 
recognize either the exon 7-8 junction of FL*Pax5 or the exon 7-9 junction of Pax5/lbA2. The product is 
electrophoretically separated on a 2% agarose gel (O.lpg/ml Ethidium bromide). Lane 1 contains 0.5pg of 
lOObp ladder (New England Biotech), Lane 2 contains lOpI o f PCR product from PBL day 0 cDNA. Two 
amplicons of sizes approx 198 nucleotides and 98 nucleotides are obtained corresponding to  FL*Pax5 and 
Pax5/lbA2 respectively, (b) shows a semi-quantitative PCR for Pax5/A8 and FL*Pax5 transcripts in cDNA 
from PBL; the PCR products have been electrophoretically separated on a 2% agarose gel; lane 1 = 0.5pg 
lOObp DNA ladder (New England Biotech), Lanes 2-9 = cDNA from PBL cells that have been LPS activated 
for days 0-7 respectively. Pax5/A8 transcripts were undetectable, (c) The left panel shows the relative 
ratio o f Pax5/A8 to FL*Pax5 transcript in cDNA from PBL cells that have been stimulated with LPS between 
0-14 days in culture. The right panel shows electrophoretically separated Pax5/A8 and FL*Pax5 transcripts 
on a 2% agarose gel; lane 1 = 0.5pg lOObp DNA ladder (New England Biotech), Lanes 2-9 = cDNA from PBL
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cells that have been LPS activated on even days from 0,2,4,6,8,10,12,14 days respectively. An asterisk 
denotes amplified product greater than 250 nts that are not Pax5 products.
Pax5/A8 was undetectable in cDNA from a set of PBL that had been stimulated with LPS 
for 7 days in culture 9 (Figure 3.18b), but the FL*Pax5 transcript was abundant. This 
suggests that Pax5/A8 transcript is present in very low relative quantities in the blood.
In an independent set of PBL cells that have been stimulated in culture with LPS for 14 
days, the Pax5/A8 transcript was detectable (figure 3.18c), though once again FL*Pax5 
transcript were better amplified. At day 0, the relative ratio of Pax5/A8 to full-length* 
Pax5 is approximately 0.49 (less than 1), indicating that there is twice as much full 
length than alternatively spliced Pax5/A8 transcript in blood B cells. Upon activation 
with LPS the relative ratio gradually increases and is highest at day 14.
3.6.6 Relative ratio of Pax5/A9a to full-length* Pax5 in the blood:
The alternatively spliced transcripts of Pax5 that lack complete or part of exon 9 encode 
Pax5 protein isoforms with truncated C-terminal inhibitory domains. In order to study 
the expression of these isoform changes relative to full-length* Pax5 in the blood, 
triplicate RT-PCR reactions were performed using cDNA from blood-derived B cells that 
have been activated with LPS in culture between 0 and 7 days. Two amplieon of sizes 
269 nucleotides and 183 nucleotides was detected corresponding to full-length*Pax5 
and Pax5/A9a (See figure 3.19a).
95
Figure 3.19 (a)
1-8 9 10
tPax5/E£/3.S tPax5/3'sn22.AS
I
8 9 io  i
Amplieon size = 259 nts
Full-length* Pax5
8 10
tPa«5/£i331)/10il01S).S tPax5/3er.a2.AS
I
I s ! 10
Amplieon size* IS S nts
Alternatively spliced Pax5/A9a
inS “
to nj 2
FL* Pax5 
(2 6 9  nts)
*Pax5/A9a 
(183 nts)
Figure 3.19 (b)
Relative Ratio of Pax5A9a to FL*Pax5 in 
Blood 9 /3 /0 8
in
I
U.
0.35
-
c
iA
I■5
.a
se
0.25
0.20
0.15-
is 70 1 2 3 5 54
Days after activation with LPS
ajjo
2 Days after LPS activation
« - n O  r*  n  w ^  in 'A rs 
fo S ra *  l* r» <8 <8 »- j J E o O Q O Q O  0 0
FL* Pax5 
(269 nts)
Pax5/49a 
(183 nts)
Figure 3.19 (c)
Days a fte r L P S  activation
m "** S'.2  JS Q
i  g || | |  ' Sv J  •
\
FL* P a x 5  
( 2 6 9  nts)
*  ( 2 5 0  nts)
P a x 5 /A 9 a  
(1 8 3  nts)
96
Figure 3.19 Relative ratio of Pax5/A9a,b or c to FL*Pax5 in the blood, (a) Semi-quantitative PCR strategy 
to amplify Pax5/A9a, 9b or 9c and FL*Pax5 transcripts using a common antisense primer and sense 
primers that recognize either the exon 8-9 junction o f FL*Pax5 or the exon 8-10 junction of Pax5/A9 
transcripts. The product is electrophoretically separated on a 2% agarose gel (O.lpg/m l Ethidium 
bromide). Lane 1 contains 0.5pg of lOObp ladder (New England Biotech), Lane 2 contains 10pl o f PCR 
product in pbl day 3 cDNA. Two amplicons o f sizes approx 269 nucleotides and 183 nucleotides are 
obtained corresponding to FL*Pax5 and Pax5/A9a respectively, (b) The left panel shows the relative ratio 
o f Pax5/A9a to FL*Pax5 transcripts in cDNA from splenic cells that have been stimulated with LPS for 0-7 
days in culture. The right panel shows the PCR product that has been electrophoretically separated on a 
2% agarose gel; lane 1 = 0.5pg lOObp DNA ladder (New England Biotech), Lanes 2-9 = cDNA from splenic 
cells that have been LPS activated for days 0-7 respectively. An asterisk denotes PCR product or size 240 
nts that is not-Pax5. (c) The left panel shows the relative ratio o f Pax5/A9a to FL*Pax5 transcript in cDNA 
from PBL cells that have been stimulated w ith LPS between 0-14 days in culture. The right panel shows 
electrophoretically separated Pax5/A9a and FL*Pax5 transcripts on a 2% agarose gel; lane 1 = 0.5pg lOObp 
DNA ladder (New England Biotech), Lanes 2-9 = cDNA from PBL cells that have been LPS activated on even 
days from 0,2,4,6,8,10,12,14 days respectively, (c) shows the electrophoretic separation o f Pax5/A9a and 
FL*Pax5 transcripts on a 2% agarose gel; lane 1 = 0.5pg lOObp DNA ladder (New England Biotech), Lanes 
2-9 = cDNA from PBL cells that have been LPS activated on even days from 0,2,4,6,8,10,12,14 days 
respectively. Pax5/A9a transcripts were undetectable.
At day 0 (not LPS activated), the relative ratio of Pax5/A9a to full-length* Pax5 is 
approximately 0.18 (<1) (Figure 3.19b). This suggests that the alternatively spliced 
transcripts with deleted exon 9 occur in very small relative quantities when compared to 
the full-length* Pax5 transcript in PBL cells. Upon activation, the relative ratio increases 
and peaks at Day 3.
In a repeat of the experiment in an independent PBL sample that had been activated 
with LPS for 14 days in culture, Pax5/A9a transcripts were undetectable while the 
FL*Pax5 transcripts were measurable (figure 3.19c). This suggests that Pax5/A9a 
transcripts are present in relatively lower amounts in PBL cells.
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3.6.7 Relative ratio of cryptically spliced Pax5 isoforms Pax5/A9b and Pax5/A9c to full- 
length* Pax5 in the blood:
Semi-quantitative RT-PCR experiments performed to measure the relative ratio of 
cryptically spliced Pax5 isoforms (Pax5/A9b and Pax5/A9c) to full-length* Pax5 were 
unable to detect alternatively spliced product in both un-activated and LPS activated 
blood-derived B cells (data not shown). This suggests that these isoforms are expressed 
in minute relative quantities in the blood when compared to the full-length* Pax5 
transcript.
In both independent sets of experiments on blood B cells, the relative amount of 
secreted IgM is lower than membrane IgM and decreases or remains unchanged during 
LPS activation. This is in agreement with previous reports (Zwollo et al, 2008) where 
blood derived B cells do not elicit a strong activation response when treated with LPS. It 
is interesting to note that there is a relative increase of secreted IgT with respect to 
membrane IgT. Reasons for different response for these Ig isotype have been discussed 
in later sections. Even though a strong secreted Ig amplification was absent during LPS 
activation of blood B cells, the relative amplification of alternatively spliced transcript to 
full-length Pax5 seem to increase following activation, as was observed in splenic B cells. 
This supports the hypothesis that alternatively spliced isoforms of Pax5 are involved in B 
cell activation and progression of activated mature B cells towards terminally 
differentiated plasma cells.
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3.6.8 Summary of the relative ratio of alternatively spliced Pax5 transcripts in the  
blood
Figure 3.20 (a)
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Figure 3.20 (b)
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Figure 3.20 Relative ratios of alternatively spliced transcripts to full length Pax5 in the Blood (a) The
relative ratio of secreted to membrane IgM and IgT, alternatively spliced transcript to  full length Pax5 for 
laA2, lbA2 and A8 between Days 0 to  7 o f LPS activation, (b) The relative ratio of secreted to membrane 
IgM and IgT, alternatively spliced transcript to  full length Pax5 for laA2, lbA2 and A8 between Days 0 to 
14 of LPS activation.
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3.7 Using nested PCR to detect Pax5/A2-8 in human and mouse immune tissues
A novel alternatively spliced transcript of O. mykiss Pax5 was cloned (Alice Harman, 
unpublished data) that contained only exons la , 9 and 10, and contained an in-frame 
deletion of 885 nucleotides (exons 2 through 8). The deleted exons encode the paired 
domain, the octopeptide segment, the partial homeodomain and the trans-activation 
domain (figures 3.1 and 3.4). The resulting transcript solely encodes the maximal 
inhibitory domain. Based on this analysis, we predict that Pax5/A2-8 may function as a 
co-repressor and contribute to Pax5's inhibitory role in the B cell program. Since 
predominant alternatively spliced variants of genes with in-frame deletions are often 
conserved across the vertebrate lineage (Lareau et al, 2004) we sought to identify 
human and mouse analogues of Pax5/A2-8.
Figure 3.21
Human PaxS
Hypothetical 
Pax5/&2 8
ATG TGA
Exon |  1 j 2 | 3 | ** | S | 6 1 7 | 8 1 9 | 1 0 |
Nucleotide 1 47 213 411 476 605 781 911 1013 1100 1176
Figure 3.21 Hypothetical human and mouse Pax5/A2-8 transcript. Mouse and human Pax5 show a high 
degree of homology and consist o f 10 exons spread over 1176 nucleotides. Human and mouse Pax5/A2-8 
analogues would encode a complete inhibitory domain but would lack all other conserved functional 
domains of full-length Pax5.
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Human and mouse Pax5/A2-8 sequence variants were artificially generated in silico 
from the published cDNA sequenced of human Pax5 (Genbank ID: 9951919) and mus 
musculus Pax5 (Genbank ID: 118130642). PCR primers that span the exon 1-9 junction 
of human and mouse Pax5 were generated and two sets of independent PCR Primers 
were designed for each organism that flank exons 1-10. Primer sequences are provided 
in table 3.
A nested RT-PCR strategy was employed to screen human bone marrow and tonsil 
cDNA, and mouse spleen cDNA for alternatively spliced transcript Pax5/A2-8 (see figure 
3.22a). Amplified product from the first round was electrophoretically separated on a 
1% low melt agarose gel and amplicons less than 0.5kb were extracted using standard 
phenol: chloroform extraction (see Methods). This product was then used as template 
for the nested round of PCR with an independent set of internal primers. Two strategies 
were used to detect alternatively spliced Pax5/A2-8: The first strategy used internal 
primers that flank exon 1 through 10 of human and mouse Pax5, while the second 
strategy used a sense primer that spans the exon 1-9 junction of mouse Pax5/A2-8 and 
an antisense at the 3' end of exon 10. Figure 3.21b shows the electrophoretically 
separated nested products of Pax5 in human bone marrow and tonsil cDNA; figure 3.20c 
shows nested products of Pax5 in mouse spleen. DNA bands were visible with sizes 
corresponding to human Pax5/A2-8 (247 nts) and mouse Pax5/A2-8 (210 nts).
Nested PCR fragments that corresponded with human and mouse analogues of 
alternatively spliced Pax5/A2-8 transcript were cloned into pSC vectors (Strataclone). 13
102
clones of the hypothetical human Pax5/A2-8 amplieon and 7 clones of the hypothetical 
mouse Pax5/A2-8 amplieon were sequenced (For a complete list of clones refer table 
3.2). Unfortunately none of these clones contained expected Pax5/A2-8 sequence. A 
BLAST analysis of these sequences revealed no homology with known genes in the NCBI 
database.
One mouse clone (ID: B10_T3_567252) was of particular interest as it possessed parts of 
exon 1 and complete exon9, specifically: 10 nucleotides of the 3' end of exon 1 was 
ligated to the 5' end of exon 9. This was determined by aligning the clone with both 
artificially generated mouse Pax5/A2-8 sequence and the published mouse Pax5 cDNA 
sequence (See appendix I : Alignment 8). Although this initially seemed like evidence for 
the usage of exon 1 to 8 splicing in mouse Pax5, it was noted that the clone lacked exon 
10. Also only one version of this clone was obtained, despite repeated attempts to 
sequence independent clones. This clone was generated using a nested strategy with 
exon 1-9 spanning primer; raising the question if the clone was the result of the exon 1- 
9 junction primer annealing to the 5' end of exon 9. Hence this was not sufficient 
evidence for Pax5/A2-8 in mouse cells.
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Figure 3.22a
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Figure 3.22 Nested PCR for human and mouse Pax5/A2-8. (a) Nested PCR strategy for detecting Pax5/A2- 
8 analogues in human and mouse cDNA. (b) Nested PCR products were electrophoretically separated on a 
2% agarose gel (O.lpg/ml Ethidium bromide) Lane 1 contains 0.5pg o f lOObp ladder (NEB), Lanes 2 and 3
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contain round 1 nested PCR product from human BM and tonsil cDNA respectively, Lane 4 and 5 contain 
round 2 nested PCR product (using product <0.5kb from lanes 2 and 3 as template respectively). Several 
amplicons o f size around 247 nucleotides were visible in lane 5, corresponding to  predicted human 
Pax5/A2-8 amplification, (c) Nested PCR products were electrophoretically separated on a 2% agarose gel 
(O.lpg/ml Ethidium bromide) Lane 1 contains 0.5pg of lOObp ladder (NEB), lanes 2 and 3 contain round 1 
nested PCR product from 2 independent samples of mouse splenic cDNA, lanes 3 and 4 contains round 2 
nested PCR product (using product <0.5kb from lanes 6 and 7 as template respectively). Several 
amplicons of size around 210 nucleotides were visible in lane 5, corresponding to  predicted mouse 
Pax5/A2-8 amplification.
Other mouse and human clones (see table 3.2 for a complete list of clones) contained 
only small regions of homology (usually exon 9) with human Pax5 when aligned with the 
published human Pax5 cDNA and artificially generated human Pax5/A2-8 sequences. 
These regions correspond to PCR primers and are often fused with sequences of DNA 
that were non-Pax5. A BLAST of these unknown sequences against the database of 
human, mouse and other nucleotides was inconclusive.Further efforts are required to 
clone these novel and seemingly rare transcripts of alternatively spliced Pax5/A2-8 in 
mouse and human cDNA.
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Table 3.1: List of clones sequenced to screen for trout Pax-5 isoforms.
# Exon Clone ID S primer AS primer Isoform
result
Tissue Sequence
Date
1 2 350E2-
U461207
tPax5/elwt.S
tpax5/e3sp2.
AS
FL* Pax5 
with Exon 
la  and 2
PK
Day 5
6/2/08
2 A2 E23A0a_
T3_492426
tPax5/elwt.S tPax5/E4.AS
Pax5/la
A2
AK
Day 0
6/2/08
3 A2 E2A0b_
T3_497310 tPax5/elwt.S tPax5/E4.AS
Pax5/la
A2
AK
Day 0
6/23/08
4 A2 E2A0a3_
T3497311 tPax5/elwt.S tPax5/E4.AS
Pax5/la
A2
AK
Day 0
6/23/08
5 A2 E2A0a5_
T3497312 tPax5/elwt.S tPax5/E4.AS
Pax5/la
A2
AK
Day 0
6/23/08
6 A2 E2A0a6_
T3_497313 tPax5/elwt.S tPax5/E4.AS
Pax5/la
A2
AK
Day 0
6/23/08
7 A2 6_T3_
531756 tPax5/562.S tPax5/909.AS
Pax5/la
A2
AK
Day 7
12/8/08
8 A2 7_T3_
531757 tPax5/562.S tPax5/909.AS
Pax5/la
A2
AK
Day 7
12/8/08
9 8 A7_T3_
504024
tPax5/764.S tPax5/1104.AS
FL* Pax5 
with exon 
8
Spl 
Day 0
7/23/08
10 A8 A5_T3_
504022 tPax5/764.S tPax5/1104.AS
Pax5/A8 Spl 
Day 0 7/23/08
11 A8 A6_T3_
504023 tPax5/764.S tPax5/1104.AS
Pax5/A8 Spl 
Day 0
7/23/08
12 9
E9500a2_ 
T3 497321 tPax5/764.S tPax5/1104.AS
FL*Pax5 
with Exon 
9
Spl 
Day 0
6/23/2008
13 9
E9500a7_ 
T3 497322 tPax5/764.S tPax5/1104.AS
FL*Pax5 
with Exon 
9
Spl 
Day 0
6/23/2008
14 9
E9500a9_ 
T3 497323 tPax5/764.S tPax5/1104.AS
FL*Pax5 
with Exon 
9
Spl 
Day 0
6/23/2008
15 A9 E9180a3_
T3_497320
tPax5/764.S tPax5/1104.AS
Pax5/A9a Spl 
Day 0
6/23/2008
16 A9 A9_
T3_504026
tPax5/764.S tPax5/1104.AS
Pax5/A9a Spl 
Day 0
7/23/08
17 A9 A10_T3_50
4027
tPax5/764.S tPax5/1104.AS
Pax5/A9b Spl 
Day 0
7/23/08
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18 A9 E9160al_ 
T3 497317 tPax5/764.S tPax5/1104.AS
Pax5/A9c Spl 
Day 0
6/23/08
19 A9 E9100a5_ 
T3 497314 tPax5/764.S tPax5/1104.AS
Pax5/A9c Spl 
Day 0
6/23/08
20 A9 E9100a7_ 
T3 497315 tPax5/764.S tPax5/1104.AS
Pax5/A9c Spl 
Day 0
6/23/08
21 A9 E56D56_ 
T3 497305 tPax5/764.S tPax5/1104.AS
Pax5/A9c Spl 
Day 0
6/23/08
22 A9 E56D5X_ 
T3 497306 tPax5/764.S tPax5/1104.AS
Pax5/A9c Spl 
Day 0
6/23/08
23 A9 E9S6_
T3 492437 tPax5/764.S tPax5/1104.AS
Pax5/A9c AK 
Day 7 6/2/2008
24 A9 E9S7_
T3_492438 tPax5/764.S tPax5/1104.AS
Pax5/A9c AK 
Day 7 6/2/2008
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Table 3.2: List of clones sequenced to screen for mouse and human Pax5/A2-8.
# Clone ID Size
nts
Cloning 
Sense Primer
Cloning 
Antisense Primer
Tissue Sequence
date
1 H6_a2_T3_5826
04 248 SD664.S hPax5/3'end.AS
human
Tonsil 7/28/2009
2 H6al6_T3_5826
05 248 SD664.S hPax5/3'end.AS
human
Tonsil 7/28/2009
3 H6a5_T3_58260
6 150 SD664.S hPax5/3'end.AS
human
Tonsil 7/28/2009
4 H6al3_T3_5826
07 150 SD664.S hPax5/3'end.AS
human
Tonsil 7/28/2009
5 H6al4_T3_5826
08 150 SD664.S hPax5/3'end.AS
human
Tonsil 7/28/2009
6
Hlal2_T3_5826
09 292 hPax5/5'UT.S hPax5/3'end.AS
human
Bone
Marrow 7/28/2009
7
Hlal3_T3_5826
10 292 hPax5/5'UT.S hPax5/3'end.AS
human
Bone
Marrow 7/28/2009
8
Hlal5_T3_5826
11 292 hPax5/5'UT.S hPax5/3'end.AS
human
Bone
Marrow 7/28/2009
9
Hla9_T3_58261
2 190 hPax5/5'UT.S hPax5/3'end.AS
human
Bone
Marrow 7/28/2009
10
Hlall_T3_5826
13 190 hPax5/5'UT.S hPax5/3'end.AS
human
Bone
Marrow 7/28/2009
11
R1 T3 577845 350 hPax5/5'UT.S hPax5/3'end.AS
human
Bone
Marrow 7/7/2009
12
R2 T3 577846 300 hPax5/5'UT.S hPax5/3'end.AS
Human
Bone
Marrow 7/7/2009
13
A1 T3 577847 270 PP8.S mPax5/3'end.AS
Mouse
spleen
M I-3 ) 7/7/2009
14
A2 T3 577848 270 PP8.S mPax5/3'end.AS
Mouse
spleen
(-11-3) 7/7/2009
15
A3 T3 577849 270 PP8.S mPax5/3'end.AS
Mouse
spleen
(-11-3) 7/7/2009
16
H1T3J577860 270 PP8.S mPax5/3'end.AS
Mouse
spleen 7/7/2009
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(-l|-3 )
17
B7 T3 567249 100
mPax5/El/E9
.S mPax5/1110.AS
Mouse
spleen
(-l|-3 ) 5/28/2009
18
B8 T3 567250 100
mPax5/El/E9
.S mPax5/1110.AS
Mouse
spleen
(-l|-3 ) 5/28/2009
19
B9 T3 567251 600
mPax5/El/E9
.S mPax5/1110.AS
Mouse
spleen
(-11-3) 5/28/2009
20
B10_T3_567252 160
mPax5/El/E9
.S mPax5/1110.AS
Mouse
spleen
(-l|-3 ) 5/28/2009
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Chapter 4: Discussion
The transcription factor Pax-5 is known as the master regulator of B cell development, 
as it is responsible for the commitment of lymphoid progenitors to the B cell lineage 
(Delogu et al, 2006) and its sustained expression is essential for B cell identity (Cobaleda 
et al, 2007). This is evidenced in the expression pattern of Pax-5 during B cell 
development, where it is first turned on in the progenitor B cell stage and remains 
expressed until terminal differentiation of B cells into plasma cells (Busslinger et al, 
2004). As a transcription factor, Pax5 serves a primary purpose of inducing the 
expression of a number of secondary transcription factors that further reinforce the B 
cell program, such as Irf8 and Ikxf3 (Aiolos) (Nera et al, 2006), as well as those involved 
in adhesion and pre-BCR signaling like CD19, CD79a and BLNK (Kozmik et al, 1992, 
Fitzsimmons et al, 1996, Schebesta et al, 2002). Pax-5 also serves a secondary function 
of inhibiting the expression of lineage inappropriate genes, such as the T-lineage 
receptor Notch-1 (Souabni et al, 2002), the macrophage lineage commitment factor 
csflr (Tagoh et al, 2006), genes associated with multi-potency like flt3 (Holmes et al, 
2006) and plasmacytic differentiation gene Xbp-1 (Dent et al, 1997, Reimold et al, 2001).
The basis for Pax5's dual function as a transcription activator and a repressor has been 
attributed to the presence of two distinct modular domains at its C-terminus: a potent 
trans-activation domain (TA) that is rich in proline, serine and threonine (PST) residues 
and an adjacent inhibitory domain (ID) that exerts a negative influence on the trans­
activation domain (Dorfler and Busslinger, 1996). It is thought that gene context-
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dependent trans-activity of Pax5 is the result of masking of inhibitory domain elements 
through interactions with other co-factors present at the gene promoter or enhancer 
locus. The same may then be true for Pax-5's inhibitory activity, where masking of TA 
domain elements abrogates trans-activation ability.
Here, we present an alternative scenario in which alternatively spliced protein products 
of Pax5 in trout may selectively impose trans-activating or inhibitory effects on the 
transcription of downstream target genes. Alternative splicing of Pax5 can yield a host of 
isoforms with varying degrees of TA potentials. Combined expression of these isoforms 
permits Pax5 to exert subtle changes in gene expression that are necessary to ensure B- 
lineage commitment, identity and terminal differentiation.
In this study, we cloned and sequenced several alternatively spliced transcripts of trout 
Pax5 with deletion of exons that code for the DNA-binding paired domain, the TA 
domain and the inhibitory domain. Using semi-quantitative PCR analysis, we then 
studied the relative amplification of each isoform relative to full length Pax5 in LPS 
activated splenic and blood-derived B cells from trout. Based on the relative expression 
pattern of each spliced transcript during B cell activation, we propose a model wherein 
Pax5 isoforms are selective transcriptional activators or inhibitors.
Ig M  and IgT production in trout splenic and blood-derived B cells
In order to correlate isoform usage with activation state of B cells in splenic and blood- 
derived B cells, we first measured the relative ratio of secreted to membrane IgM and 
IgT across 7 days of LPS activation. LPS activation of B cells is known to cause a shift
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towards increased secreted Ig mRNA and protein production. Our studies of the relative 
ratio of secreted to membrane IgM in splenic B cells show an increase in the secreted 
IgM transcript immediately after and throughout activation. This confirms that splenic B 
cells react predictably towards LPS treatm ent in trout. Conversely, the relative ratio of 
secreted to membrane IgM in blood-derived B cells decreases after LPS activation and 
there is shift towards increase in membrane IgM. This too is in agreement with previous 
studies, where blood-derived B cells were found to be less responsive to LPS treatment 
and have low potential for generating Ig secreting plasma cells (Zwollo et al, 2008).
In order to confirm that the trend observed in Ig transcript amplification was a true 
reflection of LPS activation, total secreted IgM was measured for LPS activation splenic 
and blood-derived B cells using ELISA. These studies were performed by a graduate 
student, Maggie Barr. ELISA studies showed that in both splenic and blood-derived B 
cells a gradual increase of secreted IgM could be detected after 2 days of LPS activation, 
consistent with known effects of LPS activation. It was noted using flow-cytometric 
analysis of blood-derived B cells that while the number of secreted lg+ cells increased 
gradually post-activation; there was also a corresponding increase in membrane lgM+ 
cells (data not shown). This addresses why the relative amplification of secreted to 
membrane IgM in our semi-quantitative studies for blood-derived B cells was always 
less than 1.
We also performed semi-quantitative studies on the relative ratio of secreted and 
membrane transcripts of a recently identified IgT immunoglobulin isotype. Relative
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amplification of secreted IgT in splenic B cells increased immediately after LPS activation 
and remains elevated throughout. In the blood, the relative amplification of secreted IgT 
remains unchanged during the initial days of LPS activation but increases suddenly after 
day 3. This is in agreement with delayed Ig response observed in trout blood-derived B 
cells (Zwollo et al, 2008).
The average amplification of total membrane and secreted IgM was greater than that of 
IgT, consistent with reports that the subset of IgT producing B cells are lower than those 
that produce IgM (Hansen et al, 2008). Based on these studies, we concluded that LPS 
stimulation of splenic and blood-derived B cells does indeed induce B cell activation.
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4.1 Alternatively spliced PaxS isoforms which lack complete Paired 
domain (PD)
In our study using trout B cells, two types of alternatively spliced Pax5 transcripts were 
cloned that lack exon 2. These A exon 2 transcripts contained either exon la  or exon lb , 
named Pax5/laA2 and Pax5/lbA2 respectively. Trout A2 isoforms have an incomplete 
PD and are hypothesized to have impaired DNA binding ability.
Alternatively spliced Pax5/A2 with exon la
From all clones containing Pax5 sequence, laA2 was by far the most abundant 
alternatively spliced Pax5 species, where almost 30% of clones sequenced were laA2  
(see Chapter 3 Results - Table 3.1 for a complete list of clones). This is in agreement with 
our semi-quantitative studies in splenic and blood-derived B cells where, barring the 
full-length isoform, laA2 has the strongest relative amplification of all the alternatively 
spliced variants. Our studies on splenic B cells showed an increase in the relative 
amount of laA2 after 6 days of LPS activation. Interestingly, blood-derived B cells also 
show an increase in the relative amount of Pax5/laA2 after 6 days of LPS activation. This 
suggests that the laA2 isoform may play a role in the genetic events associated with 
terminal B cell differentiation.
Alternatively spliced isoforms of Pax5 lacking part of the paired domain have been 
reported in mouse studies (mouse Pax5b and Pax5e), where skipping of exon 2 leads to 
a shift in the reading frame and a premature stop in exon 3 (Zwollo et al, 1997).
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Messenger RNAs with a premature stop codon close to exon junctions are normally 
targeted for degradation by non-sense mediated decay (Hillman et al, 2004). It is likely 
that mouse laA2 transcripts use a second downstream ATG start codon located inside 
exon 3, and yield isoforms with a truncated paired domain. This implies that these 
isoforms may behave as dominant negative co-repressors of Pax5 activity by competing 
for co-factors necessary for normal Pax5 function. Western blot analysis could detect 
mouse laA2 isoforms (Pax 5b and 5e) in mouse B cell lines showing that these 
alternatively spliced Pax5 transcripts are translated (Zwollo et al, 1997, Lowen et al, 
2001).
The laA2 isoform has also been reported in human B cells, where differences were 
observed between the relative expression of human laA2 transcript in healthy donors 
and patients with multiple myeloma (Borson, 2002). However, due to a high degree of 
variability between the relative expressions of laA2 between individuals, no consistent 
pattern could be established in both normal and multiple myeloma patients. Recently, 
another group established a relative expression pattern of laA2 in normal human B cells 
by using micro-fluidics technology to enhance the sensitivity of detecting amplified 
transcripts by RT-PCR (Arseneau et al, 2009). Arseneau et al noted that in both 
lymphoma and normal B cells the full length isoform was more abundant than laA2, and 
is in agreement with our previous studies in mice. Arseneau et al also showed polysomal 
association of human laA2 transcripts with ribosomes in EHEB cells, suggesting that the 
human laA2 transcript is translated. In a related study, Santoro et al (2009) noted a 
greater incidence of the laA2 isoform and single point mutations in B cell pre-cursor
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acute lymphoblastic leukemia (BCP-ALL) cells, but were unsuccessful in elucidating a 
consistent relative expression pattern of laA2 that was characteristic for ALL Santoro et 
al reported that 29 of 100 ALL patients had detectable amounts of laA2 by quantitative 
RT-PCR. In these patients the median ratio of full-length Pax5 to laA2 was 25:96, 
implying a higher relative amount of the alternatively spliced isoform in ALL patients. 
This directly contradicts the Arseneau study and thus yet, no conclusions can be made 
about aberrant laA2 isoform expression and disease incidence.
Recently, a similar exon 2 skipping pattern was reported in amphioxus Pax2/5/8; the 
evolutionary ancestor of vertebrate Pax5 (Short & Holland, 2008); demonstrating 
conservation of the laA2 isoform along the vertebrate lineage. However, no comments 
were made about the relative abundance of laA2 in amphioxus tissues.
Mouse, human and amphioxus laA2 are analogous to trout laA2 in the pattern of exon 
2 skipping. As in mouse laA2, exon 2 skipping in trout Pax5 leads to a shift in the reading 
frame and a premature stop in exon 3 (nucleotides 248-250). This likely results in the 
use of a second ATG start codon (nucleotides 221-223), located in exon 3. The 
expression pattern of trout laA2 isoform during LPS activation suggests that it may also 
function as a dominant negative co-repressor of target downstream genes, like CD19 
and blk. The down-regulation of these target genes may contribute to the de-repression 
of genes involved in the B cell terminal differentiation program like Blimpl and Xbp-1, 
by Pax5 (See introduction, figure 1.1). Thus the laA2 isoform may be associated with 
processes that trigger the terminal differentiation program.
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Zwollo et al, 1997 performed functional studies using EMSA assays of mouse Pax5b and 
Pax5e using high-affinity Pax5-binding sites to demonstrate that these isoforms lacked 
DNA binding ability in-vitro. In a follow up study on the function of mouse Pax5 A2 
isoforms (Lowen et al, 2001), co-transfection of the Pax5e isoform along with full length 
isoform synergistically enhanced the transcriptional activity of the full length isoform in 
a dose dependent manner. This suggests certain Pax5 isoforms may auto-regulate Pax5 
activity in B cells.
Alternatively spliced Pax5/A2 with exon lb
Trout Pax5 with exon lb  sequence was serendipitously cloned in a previous library 
screen (Zwollo et al, unpublished data). Preliminary studies performed to amplify exon 
lb  using RT-PCR revealed a second amplicon whose size differs from the full-length by 
approx 180 nucleotides. This difference is approximately the size of exon 2, suggesting 
that this second amplicon arose from a Pax5/lbA2 transcript (cloning studies and 
sequence analysis o f lbA 2 are yet to be performed). Our studies on the relative 
amplification of lbA2 in trout B cells also showed an increase immediately after LPS 
stimulation. This elevation peaks at day 3 for spleen. In contrast the relative amount of 
lbA2 in the blood almost doubles following LPS stimulation and remains elevated, 
unlike in the spleen. The increased expression of the lbA2 isoform during activation of B 
cells suggests that it may also be involved in the genetic regulation of terminal B cell 
differentiation, similar to the laA2 isoform.
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Studies on alternatively spliced Pax5 with exon lb  are extremely scarce. Recently, 
Arseneau et al (2009) used micro-fluidics technology to obtain high-resolution 
separation of PCR amplified Pax5 transcripts. Arseneau et al reported a human lbA2 
spliced variant that could be detected in B cells from chronic lymphoblastic leukemia, 
lymphoma and healthy patients. In each case, the full-length was amplified in greater 
relative amounts than lbA2, which is agreement with our studies in trout. Their data 
suggested that lbA2 amplification differed in CLL, lymphoma and healthy patients, 
however, the researchers did not comment on performing relative amplification studies 
for this isoform.
The Pax5 lb  exon has been reported in human and mouse studies, but there is a dearth 
in the literature on its functional significance. The suppression of exon lb  containing 
human Pax5 in REH cell lines showed an increase in CD19 mRNA and cell surface 
expression (Robichaud et al, 2008). CD19 is a component of the B-cell receptor (BCR) 
complex and plays key roles in cell signaling events surrounding B-cell proliferation and 
differentiation. Suppression of exon lb  containing Pax5 also lead to an arrest in 
proliferation and increased susceptibility of B cells to apoptosis. Based on these studies, 
we hypothesize that trout lbA2 isoform functions differently from laA2 during terminal 
differentiation. The sustained expression of lbA2 even during later days of activation in 
trout suggests that this isoform may be involved in the survival of B cells as they 
terminally differentiate into plasma cells. Transfection assays will have to be performed 
to test the function of lbA2 on Pax5 activity.
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Structural analysis of Pax-5 A2 isoforms
NMR and X-ray crystallography studies of the highly conserved paired domain have 
provided interesting insight about Pax paired domain structure and its mechanism of 
DNA binding. Studies by Xu et al (1999) in Pax6 showed that the highly conserved Pax 
paired domain is bi-partite in structure and is composed of two helix-turn-helix (HTH) 
motifs separated by a short linker region. The N-terminal HTH motif, referred to as PAI 
in the literature, contains two conserved cysteine residues that control the PAI sub­
domain's interaction with DNA in a redox-regulated manner. Oxidation of the conserved 
cysteine residues by gluthionylation completely abrogates DNA binding ability (Xu et al, 
1999). The C-terminal HTH motif, referred to as RED in the literature, forms contacts 
with DNA independently and regardless of the redox state (Cao et al, 2005). 
Additionally, a p-hairpin at the N-terminal and the linker region provide specific contacts 
at the minor groove level and stabilize DNA binding by PAI and RED (Xu et al, 1999). 
Recently, Codutti et al (2008) reported that the Pax-8 PAI and RED domains retain a fair 
degree of tertiary structure even when unbounded by DNA. Interestingly, Pax-5 A2 
isoforms are predicted to lack both conserved cysteine residues in the PAI sub-domain 
and the N-terminal p-hairpin. This drastically reduces the available DNA binding 
interface for the truncated paired domain, suggesting that A2 isoforms may be unable 
to adopt sufficient contacts on DNA that enable docking into the minor groove to ensure 
stable DNA binding.
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Other alternatively spliced transcription factors with altered DNA-binding
Deletion of paired domain encoding exons is relatively new to the Pax group of genes 
and has been extensively studied in only one other member -  Pax6, which is expressed 
in the developing olfactory bulb and eye. Use of alternative promoters control the 
expression of paired domain containing Pax6 and the paired domain lacking 'Paired-less' 
Pax6 (Kim & Lauderdale, 2006). Unlike Pax5, Pax 6 isoforms contain an intact DNA 
binding homeodomain. Thus, 'Paired-less' Pax6 retains its DNA binding ability even 
without a paired domain. However, over-expression of paired-less Pax6 caused a 
micropthalmic phenotype in Pax-6(+/+) and Pax-6(+/-) mice, suggesting that a delicate 
balance between both Pax-6 isoforms is necessary for normal eye development.
Alternatively spliced isoforms with altered DNA binding ability have also been reported 
in the zebrafish Oct-3 like transcription factor pou2 (Takeda et al, 1994). POU domain of 
transcription factors are important genetic regulators during early development. 
Alternative splicing of the pou2 gene yields isoforms that either contain the DNA binding 
POU domain or contain incomplete POU domain structure (t-pou2). As a result of this 
splicing pattern, t-pou2 lacks DNA binding ability and over-expression of this isoform 
lead to complete or partial developmental arrest due to incomplete gastrulation. This 
provides further evidence for neofunctionalization of alternatively spliced isoforms and 
warrants further investigation of Pax5 isoform function on overall Pax5 activity in B cells.
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4.2 Alternatively spliced Pax5 isoforms that lack complete Trans­
activation Domain (TD)
Alternatively spliced Pax5/A8
Our studies in trout B cells are the first to report the A8 isoform in vertebrates other 
than humans, since analogues of A8 have not yet been discovered in murine and 
amphioxus systems (Zwollo et al, 1997, Short and Holland, 2008). Although deletion of 
exon 8 in Pax5 does not shift the reading frame or stop codon usage, the resulting 
isoform resembles full-length but lacks most of the minimal trans-activation domain (34 
amino acid deletion) (Dorfler and Busslinger, 1996) (see Chapter 3 -  Results: Figure 3.1 
fo r location of minimal TD). Based on this structural analysis, we predict that the A8 
isoform functions as a transcriptional repressor of Pax5 activity. Trout A8 clones were 
obtained from splenic B cells and represent only 8% of clones with Pax5 sequence, 
suggesting that this isoform may be relative rare in freshly isolated splenic B cells (see 
table 3.1 for a complete list of clones). This is in agreement with our semi-quantitative 
studies, where full-length Pax5 is always amplified in greater relative amounts than A8 
transcript in both freshly isolated and LPS activated splenic and blood-derived B cells. In 
the spleen, the relative amplification of A8 increased gradually throughout LPS 
activation and peaked at day 6. Interestingly, blood-derived B cells also showed a 
gradual increase in the relative amplification of A8 during LPS activation, but unlike the 
spleen the relative ratio remained elevated even after 14 days of LPS activation. This
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suggests that, like the A2 isoform, A8 isoforms may also be involved in the 
transcriptional regulation of terminal B cell differentiation.
The A8 isoform was first described by Borson et al (2002) in patients with multiple 
myeloma (M M ), where (like trout A8) skipping of exon 8 conserves both the reading 
frame and stop codon usage. Borson et al noted that in a total of 6 M M  patients and 3 
normal patients the full-length isoform was predominant and only trace amounts of A8 
isoform was detectable through RT-PCR analysis. This is in agreement with our own 
studies in trout splenic and blood-derived B cells. Borson et al also reported that Pax5 
isoform expression profiles differed in normal and M M  patients but sample limitations 
and variations between individual patient's isoform patterns prevented the 
establishment of a distinct expression profile for each. Consequently, Robichaud et al
(2004) attempted to use RT-PCR analysis to establish an isoform expression profile for B 
cell lymphoma patients and noted that in 8 of 11 patients tested the full-length isoform 
was predominantly expressed, whereas in the remaining three A8 was the most 
predominant isoform. Although a consistent expression profile for Pax5 isoforms in 
lymphoma patients could not be established, Robichaud et al used western blot analysis 
to show that the A8 isoform was indeed translated.
Following with the theme of studying Pax5 isoform expression in B cell lymphomas, 
Oppezzo et al (2005) found that A8 isoforms may regulate AID (activation-induced 
cytidine deaminase) expression in chronic lymphoblastic leukemia (CLL) B cells. In 
normal B cells, AID initiates somatic hyper-mutation and class-switch recombination
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during early B lymphogenesis. Oppezzo et al reported that the full-length isoform was 
predominantly amplified in CLL B cells with constitutive AID expression. However, full- 
length amplification was reduced in CLL B cells without constitutive AID expression and 
the emergence of A8 isoform was detectable in 33 of 54 patients. This suggests that A8 
isoform functions as a transcriptional repressor by competing with full-length Pax5 for 
binding sites on the AID promoter.
Sadakane et al (2006) also reported the presence of full-length and A8 isoform in 14 
children with acute lymphoblastic leukemia (ALL) and healthy donors using RT-PCR and 
western blot analysis. More recently, Santoro et al (2009) noted that full-length Pax5 
was often the only detectable isoform in cord-blood and bone marrow-derived 
progenitor cells from healthy patients, and that A8 isoform was detectable only in 
mature B cells from peripheral-blood.
Robichaud et al (2004) performed functional DNA binding studies to show that the A8 
isoform could efficiently bind DNA. Interestingly, the trans-activation ability of A8 
isoform was comparable to full-length human Pax5. This is unexpected since more than 
50% of the TD is missing from the A8 isoform, suggesting that important trans-activation 
elements may reside in regions outside those encoded by exon 8. Alternatively, deletion 
of 34 amino acids from the TA domain might alter protein folding and overall 3- 
dimensional protein conformation at the C-terminal end, thus mask important elements 
in the inhibitory domain.
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Taken together, these results suggest that although the A8 isoform is present in lower 
transcript levels relative to full-length, A8 isoform probably functions as a transcription 
factor that represses Pax5 activity in normal and malignant B cells.
Other alternatively spliced transcription factors with altered trans-activation
Skipping of trans-activation domain coding exons has been reported in one other 
member of the Pax family -  Pax-7. The transcription factor Pax-7 helps convert multi- 
potent stem cells to the myogenic lineage and is vital for skeletal muscle myogenesis 
and regeneration (Buckingham and Relaix, 2007). Mao et al (2008) report a A8 spliced 
variant of Pax-7 in chick cells, that results in a 22 amino acid deletion in the isoforms TD. 
QT-PCR studies for the full-length and A8 variants in developing chick embryos showed 
that they had similar expression profiles until day 12, where A8 amplification was 
highest. Co-transfection and luciferase reporter studies performed by Mao et al showed 
that this A8 isoform had lower trans-activation potential than both full-length Pax7 and 
an empty vector used as control. This suggests that Pax-7 A8 isoform probably also 
functions as a transcriptional repressor during chick muscle myogenesis.
Alternatively spliced isoforms with truncated trans-activation domains frequently show 
reduced or complete loss of trans-activation ability, as is the case for p63 isoforms 
(Petitjean et al, 2008). p63 proteins are responsible for the development of stratified 
epithelia during bone morphogenesis and are structurally similar to the p53 tumor 
suppressor family of proteins. It has been demonstrated, in vitro and ex vivo, that Pax5 
directly represses p53 expression through a Pax5 binding site in its un-translated first
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exon (Stuart et al, 1995), though no such evidence has been presented for p63. 
Alternative splicing of p63 produces isoforms that lack an N-terminal trans-activation 
domain and these isoforms act as dominant negative inhibitors of isoforms that possess 
the intact trans-activation domain (Yang et al, 1998). This inhibition is thought to be the 
result of accumulation of inactive hetero-oligomers or competition for specific response 
elements on DNA binding sites (Westfall et al, 2003). W e suggest that this mechanism of 
inhibition is precisely what A8 isoforms employ to negatively regulate Pax5 activity in B 
cells.
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4.3 Alternatively spliced PaxS isoforms that lack complete Inhibitory 
Domain (ID)
Alternatively spliced Pax5/A9a
In our search for alternatively spliced variants of trout Pax5 with deletions at the 3' end, 
8% of clones containing Pax5 sequence had a deletion of complete exon 9 (Pax5/A9a) 
(for a complete list of clones refer table 3.1). Exon 9 encodes 29 amino-acids at the C- 
terminal end of Pax5, which compose of a 21 amino-acid region where C-terminal 
elements from of the TA domain overlap with N-terminal elements of the ID domain and 
an additional 8 amino-acids from the N-terminal part of the ID domain (Dorfler and 
Busslinger, 1996) (See Chapter 2 -  Results: Figure 3.1). Skipping of exon 9 conserves 
both the reading frame and stop codon usage, and the resulting isoform incurs 
truncations in both the TA and ID domains. Since removal of inhibitory elements from 
the ID domain may be counteracted by removal of activating elements from the TA 
domain (or vice versa), it is not feasible to predict the trans-activation/inhibitory activity 
of the A9a isoform without functional data from reporter gene expression/transfection 
assays.
Our relative amplification studies in trout splenic and blood-derived B cells indicate that 
A9a is produced in minute quantities relative to full-length in these tissues. In blood- 
derived B cells, the relative ratio of A9a increases marginally during LPS activation and 
peaks around day 3. A9a amplification was undetectable in most days of LPS activated 
splenic B cells, except day 2. At this point it is unclear if the A9a isoform is involved in
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regulatory processes that govern terminal differentiation of B cells; however, previous 
reports about the human A9a isoform may help shed some light on this matter.
Pax5 A9a isoforms were first reported by Borson et al (2002) in normal and malignant 
human B cells, where different isoform profiles were observed in each case. 
Consequently, Robichaud et al (2004) reported that human A9a isoform could be 
detected by Western blot, indicating that A9a is indeed translated. In all human cell lines 
tested by Robichaud et al, the full-length isoforms predominated over A9a, as is 
evidenced in our studies in trout B cells. Robichaud et al observed that activation of 
several B cell and primary lymphoma cell lines with the mitogens PHA and 
PMA/ionomycin always lead to reduced amplification of full length and different 
patterns of isoform expression, though no distinct pattern could be elucidated for each. 
Sekine et al (2007) studies on the amplification of human Pax5 isoforms in human cord 
blood-derived B cell progenitors also concluded that the full length form was most 
predominant, and that A9a amplification was detectable only after one week of co­
culture.
Finally, Arseneau et al (2009) reported that multiple C-terminal isoforms, including A9a, 
could be detected in 10 chronic lymphoblastic leukemia patients using RT-PCR. 
Arseneau et al also reported anti-N-terminal Pax5 antibodies could detect a 40kDa 
protein in western blot studies that could either be A8 or A9a (since the predicted 
molecular weight for both isoforms is 40kDa). Furthermore, polyribosomal association
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analysis suggests that A9a mRNA is probably recruited to the translation apparatus, 
where it is translated into protein form.
In vitro mutagenesis and transient transfection experiments by Dorfler and Busslinger 
(1996) showed that removal of inhibitory domain elements enhanced the trans-activity 
of Pax5 by 8 fold. This suggests that Pax5 isoforms with truncated inhibitory domains 
would have greater trans-activity than the full-length form. In striking contrast to this 
experiment, Robichaud et al (2004) found that human A9a isoforms could bind DNA and 
induce expression of a luciferase reporter construct at levels a little lower but somewhat 
comparable to that of full-length Pax5. This implies that truncation of the inhibitory 
domain does not relieve its negative regulation on trans-activation domain function. 
Recently, Sekine et al (2007) also tested the trans-activation potential of human Pax5 C- 
terminal isoforms using a luciferase reported fused with high affinity Pax5 binding sites. 
A9 isoforms showed a 7 fold induction of luciferase expression over controls, while full- 
length isoform showed a 9 fold induction. These data support the view that A9 isoform 
is a slightly less potent trans-activator when compared to full-length.
Cryptically spliced isoforms Pax5/A9b and Pax5/A9c
Our studies report for the first time two cryptically spliced variants of Pax5/A9, unique 
to trout, that use alternative 5' donor and 3' acceptor sites. The first variant (A9b) uses a 
5' splice acceptor that is 12 nucleotides upstream of the exon 8 /9  junction and a 3' 
splice donor site at the normal exon 9 /10  junction. This unique splice pattern does not 
alter the reading frame and the resulting isoform would lack 33 amino-acids at the C-
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terminal end of Pax5 composed of: 4 amino-acids from the TA domain, 21 amino-acids 
containing elements of both the TA and ID domains and 8 amino-acids from the N- 
terminal part of the ID domain. Comparison of the primary protein structure of A9a and 
A9b isoforms reveals that an additional 4 amino acids of the TA domain are lacking in 
A9b. Only 8% of clones containing Pax5 sequence were A9b, suggesting that it is rare in 
abundance. This conclusion is supported by our semi-quantitative studies where A9b 
amplification is undetectable in splenic and blood-derived B cells, where full-length Pax5 
is predominantly amplified.
The second cryptically spliced variant (A9c) uses a 5' splice acceptor that is 12 
nucleotides upstream of the exon 8 /9  junction and a 3' splice donor site that is 54 
nucleotides downstream of the exon 9 /10  junction. Like in A9b, the splice pattern for 
A9c conserves the reading frame and the resulting isoform would lack 51 amino-acids at 
the C-terminal end of Pax5. These residues are composed of a 4 amino-acids from the 
TA domain, 21 amino-acids containing elements of both the TA and ID domains and 26 
amino-acids from the N-terminal part of the ID. Almost 30% of clones containing Pax5 
sequence were A9c, suggesting that it is more abundant than A9a and A9b. However, 
our semi-quantitative studies were once again unable detect A9b amplification in LPS 
activated splenic and blood-derived B cells and full-length Pax5 was predominant.
The lack of A9b and A9c amplification in LPS activated splenic and blood-derived B cells 
suggests that expression of these spliced variants may be limited to specific B cell 
developmental stages in other immune tissues, like the anterior and posterior kidney.
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We predict that the A9b might have a marginally lower trans-activity than A9a due to a 
deletion of 4 additional amino acids from the TA domain. Alternatively, we predict that 
A9c might have greater trans-activity than A9a, since almost a third of the ID is removed 
in A9c. It remains to be seen if the cryptically spliced A9b and A9c isoforms do exhibit 
altered trans-activity.
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4.4 Model of Pax5 isoform mediated regulation of the B cell program
Based on our PCR studies in trout B cells and the resulting predictions on isoform 
function, alternatively spliced isoforms of trout Pax5 can be broadly classified under two  
categories: transcriptional activators (Isoforms: A9c; and possibly A9a and A9b) or 
transcriptional inhibitors (Isoforms: laA2, lbA2 $nd A8).
Figure 4.1 (a)
Pax-5 is o fo rm s : Trans-activato rs
B lineage c o m m itm e n t:
* E b fl (TF)
* (kzf3 (A iolos) (TF)
Pax5/A9c
Pax5/A9a
Pax5/A 9b
BCR-sienaling:
*  CD19(R)
* CD79a (Ig a) (R)
*  BLNK(ST)
C ell-cvc le /P ro life  ration: 
*  p53  (TF)
S om atic  H y p e r-m u ta tio n : 
*  A icda  (A ID )
Figure 4.1 (b)
Pax-5 isoform s: Inhib itors
..... 'N
P a x 5 /la  A2
— 1
P a x 5 /lb  A2
Pax5/A8 — 1
Lineage inap propria te  genes:
*  N o tch -1  (T-ceil fa te ) (TF)
* csflr (m acrophage fa te ) (TF)
M u lti-p o ten cy :
*  Flt-3 (TF)
■ Adhesion &  M igration: 
' Cd47 (R)
: Emb (R)
Term inal D ifferentia tion:
*  B lim p-1  (Plasma cell) (TF)
* X b p -1  (TF)
Figure 4.1 Model of Pax5 isoform mediated regulation of the B cell program, (a) Pax-5 isoforms A9a, A9b 
and A9c function as trans-activators that directly or indirectly induce the expression of genes involved in 
B-lineage commitment, BCR-signaling, cell cycle and proliferation and somatic hyper-mutation, (b) Pax-5 
isoforms la  A2, lb  A2 and A8 function as transcriptional repressors that directly or indirectly inhibit the 
expression of genes involved in other lineage commitment programs, multi-potency, adhesion /  migration 
and terminal differentiation. In parenthesis (TF) = transcription factor, (R) = receptor, (ST) = secretory tail. 
Boldface = Genes that are direct targets o f Pax5, Italics = Genes that are under Pax5 control in mature B 
cells.
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Pax5 isoforms with putative trans-activator function:
Based on semi-quantitative analysis and data from the literature, isoforms A9a, A9b and 
A9c are most likely to induce transcriptional activation in target genes. Genes involved 
in commitment of lymphoid progenitors to the B lymphocyte lineage like Early B cell 
factor (Ebfl) E2a and Aiolos are reported to be both regulated by Pax5 and also exert 
regulatory influences on Pax5 expression. The early B cell factor promotes the 
commitment of lymphoid progenitors to the pro-B cell stage (Roessler et al, 2007). 
Roessler et al found Pax5 binding sites on the Ebfl promoter implying a direct mode of 
regulation by Pax5 and its isoforms. On the other hand, Ikzf3 (Aiolos) plays an important 
role in the pre-B cell and mature B cell stages of differentiation and is controlled by Pax5 
(Nera et al, 2006). A9 isoforms of Pax5 may help induce and sustain the expression of 
these transcription factors during early B cell development. Pax5 binding sites have also 
been found on genes for integral components of the BCR-signaling complex -  namely, 
CD19 and CD79a and BLNK (Kozmik et al, 1992, Nutt et al, 1997, Schebesta et al, 2002). 
BCR signaling is a tightly regulated process that provides the necessary cues for B cell 
differentiation towards mature B cell state. Pax-5 has also been suggested to be 
involved in the direct regulation of cell-cycle through tumor suppressor p53 (Stuart et al, 
1995). Finally, Pax5 isoforms may also regulate the expression of activation-induced 
cytidine deaminase (AID) which is responsible for somatic hyper-mutation and class 
switch recombination in developing B cells. Taken together, isoforms A9a, A9b and A9c 
may contribute to Pax5 control of important regulators of the B cell program.
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Pax5 isoforms with putative Inhibitory function:
Pax5 repressive activity has been best documented in the suppression of non B lineage 
genes such as Notch-1, an important T-cell fate inducer (Souabni et al, 2002), and csflr, 
which induced macrophage fate (Tagoh et al, 2006). Recently, Pax5 was also reported to 
repress the multi-potency inducing transcription factor flt3, thus restricting the 
lymphoid progenitors to the B cell lineage (Holmes et al, 2006). Pax5 also represses 
migration and adhesion receptor genes CD47 and Emb (Carotta et al, 2008), implying 
that Pax5 activity is pivotal for the migration of progenitor B cells and commitment 
towards mature B cells stage. Finally, Pax5 also represses genes involved in terminal 
differentiation of B cells in to plasma cells through B lymphocyte inducing maturation 
protein (Blimpl) and X-box protein (Xbpl) (Mora-Lopez et al, 2007). Pax5 isoforms laA2  
and lbA2 may contribute to repressive activity as dominant negative co-repressors since 
both isoforms are predicted to have impaired DNA binding ability. Pax5 isoform A8, 
however, may engage in a more direct regulation of the above genes.
4.5 Evolutionary Conservation of Pax5 isoforms
An interesting observation can be made about the conservation of certain isoforms 
across evolutionary time. Comparison of alternatively spliced transcripts in various 
organisms has revealed that predominant splice variants are well conserved and rarer 
isoforms are less conserved (reference Lareau et al, 2004). This suggests that conserved 
isoforms are functionally important. Alternatively spliced isoforms of Pax5 have been 
reported in mammalian systems (in mice and humans), in amphioxus (a basal chordate)
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and now, in teleosts (O. mykiss). The mutually exclusive use of exon la  or lb  has been 
reported in all 4 systems (Busslinger et al, 1996, Short & Holland, 2008).
Alternatively spliced variants of Pax5 with exon la  and deletion of the paired domain 
coding exon 2 are conserved from basal chordates to mammals (Zwollo et al, 1997, 
Borson et al, 2002, Short & Holland, 2008). Interestingly, alternatively spliced variants of 
Pax5 with exon lb  and deletion of exon 2 have been reported in humans (Arseneau et 
al, 2009) and now in trout, but are absent in mice and amphioxus. Similarly, 
alternatively spliced variants that lack exon 8 or exon 9 have been reported in humans 
and now in teleosts but not in mice or amphioxus -  although, two splice variants of 
mouse Pax5 (mouse Pax5d and Pax5e) were reported to lack exons 6-10 that encode the 
TD and ID (Zwollo et al, 1997) and 7 different C-terminal isoforms of amphioxus Pax5 
encode truncations of the TD and ID (Short & Holland, 2008).
A common effect of alternative splicing is altered localization of the resulting isoform 
(Chi & Epstein, 2002). Human Pax5 possesses a nuclear localization sequence (NLS) in 
exon 5 (encoded by nucleotides 585 to 603) that interacts with the nuclear transport 
protein importin a l  (Kovac et al, 2000). Alternative splicing of exon 5 can produce an 
isoform lacking NLS and would not be transported into the nucleus after translation. 
Unfortunately, our search for trout Pax5 isoforms with deleted NLS coding exon 5 
returned no results. Also, reports of Pax5 isoforms in other organisms support the view 
that exon 5 is always constitutively spliced. Many novel and rare isoforms of Pax5 have 
been reported that are unique to the organism it was reported in but are largely absent
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in other species, either because they have not been discovered yet or are no longer 
produced. For example, mouse Pax5d and Pax5e have a deletion of exon 6-10 and 
instead possess a shorter novel sequence at their 3' end (Zwollo et al, 1997). Similarly, 
multiple C-terminal isoforms have been reported in humans that have a deletion of 
consecutive exons, A7/8, A8/9, A 7 /8 /9  (Robichaud et al, 2004, Arseneau et al, 2009). 
These isoforms have not been found in other systems, suggesting that they are not 
conserved. These isoforms are translated, as shown in western blot and polysomal 
analyses, but their function is yet to be determined. It is likely that these isoforms may 
be tissue specific or limited to finite stages of B cell development and activation.
4.6 Future Directions
In this study, we cloned six alternatively spliced variants of trout Pax5 and studied their 
relative expression in splenic and blood-derived B cells. A preliminary study of the 
relative amplification of these isoforms in B cells obtained from the anterior kidney 
revealed a complex pattern of isoform expression. We attribute this complexity to the 
observation that the anterior kidney houses multiple populations of developing B cell 
(Zwollo et al, 2008). To overcome this barrier, the study will be repeated on tissues that 
have been separated by mass/density on Percoll gradients, as has been previously 
described (Zwollo et al, 2005). This will improve the resolution with which we can 
measure the relative amounts of spliced variants in B cells from the anterior kidney. 
Since B cells in like stages of development are separated together using Percoll 
gradients, relative isoform amplification would also reveal potential associations
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between isoform expression and B cell developmental stages. These isoforms can then 
be used as markers of B cell development.
Another area of interest lies in establishing relative isoform transcript levels in normal 
and malignant B cell lines using a quantitative real-time PCR or a semi-quantitative RT- 
PCR approach. Establishment of an isoform expression pattern in B cell lines would 
provide important clues about potential association of isoforms with B cell lymphomas 
and other lymphocyte diseases.
There is some concern that alternatively spliced Pax5 mRNA transcripts detected far 
exceed those reported as translated protein. Not all human isoforms are readily 
detected by Western blot analysis. Arseneau et al (2009) recently described a polysomal 
association analysis that identifies translated mRNA. This technique relies on the fact 
that translated mRNAs can be separated from un-translated messenger transcripts by 
virtue of their weight added on by ribosomes. Ribosomes attached to the translated 
RNA make them denser and allow for separation of the polysomal fraction of translated 
mRNA. Detection of Pax5 spliced transcripts within this pool of translated mRNA would 
indicate if it is translated.
Due to design limitations, we were unable to screen for deletions/truncations of exon 
10 and the 3' UTR of trout Pax5 using a nested PCR strategy. Alternative exon 10 usage 
has been reported in the basal chordate amphioxus (Short and Holland, 2008). 
Alternative splicing of the un-translated region has been known to alter the stability, 
localization and efficiency of translation of pre-mRNA transcripts (Kim et al, 2008).
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Interaction of Pax5 isoforms with alternatively spliced 3' ends with the gene expression 
of downstream targets can potentially influence the kinetics of B cell proliferation and 
differentiation.
Functional 'in-vitro' Studies
To further investigate the functional role of each alternatively spliced isoform, EMSA 
studies of each isoform with target Pax5 binding sites from CD19 promoter can be 
performed to test DNA binding ability. Pax5 that possess an intact paired domain are 
known to possess DNA binding ability, and are hypothesized to function as dominant 
negative repressors of Pax5 activity. In our studies, 4 Pax5 isoforms possess an intact 
DNA binding domain; each must be tested for efficient DNA binding so that their role in 
B cell activation can be elucidated.
The trans-activation potential of each isoform must be evaluated using transient 
transfection or co-transfection assays and a reporter gene system, such as the CAT or 
luciferase assays. Based on the deletion of certain exons we have made predictions 
about the trans-activity of each Pax5 isoform and classified them as activators and 
repressors (or co-activators and co-repressors). Evaluating the trans-activation ability of 
an isoforms is the first step towards understanding the role of Pax5 isoforms in the 
genetic regulation of the B cell.
Using RNAi, micro-RNA or ribozyme suppression system to selectively knockout isoform 
production, as recently described by Robichaud et al, 2008, may be a useful tool to 
study the role of Pax5 isoforms in B cell activation and terminal differentiation events.
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Analysis of functional role of Pax5 isoforms would help tease apart Pax-5's complex regulatory 
control over the 140 or more down-stream target genes involved in B cell development.
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1. Multiple Alignments of Human, mouse and trout full-length Pax5. cDNA
sequence of mouse and human Pax5 exon junctions were used to predict trout 
Pax5 exon junctions.
Exon 1 (/
N,
\TG)
10 20 X
Human Pax5 cDNA A T G G A T T T A G A G A A A A A T T A T C C G A C T <: c T
Mouse PaxS cDNA A T G G A T T T A G A C. A A A A A T T AP C ,C G A C T c c TTrout PaxS cDNA A I G G A | 1T A G A G p ■ c g |a ]E! tl_£J
tfumin Pax5  cDNA\ 
Miu>e Pax5 cDNA 
Trout PaxS cDNA
tinman Pjxs cDNA 
fAou>ePaxS c it iA  
Trout PaxS ctMA
tinman PaxS cDNA 
Ktrnze PaxS cDNA 
Trout PaxS cDHA
Cj G G  A A .n
E x o n  1 E x o n  2
\c c  c x r c x  c c x  g  g a t x
[c G G A C C Af~1c A G G A C A
A C C A G G G A
CV
C X T  G G  A CG
C A T G G A G G 
A C A T G O  A G_G
0 G AA T G G A
70 60
G T G 'A T T  C A G C T T G G'G G G 'G G T T T T T G T G 
G T G A A T  C A G C T I  G G G G G G G T T T T T  G 
G I G A A T C  A Gf ~ [T P |G  Gf~[G  G| |G T | [ T T p ~|G
m r x x r ]
T G A A T] 
T G A A |
G T G A A T C A G C T T G G G G G G G T T T T T G T G A A T
106 110 120
G G A C G G C C A C T C Z T \ J T a  I  O T a " G  T C c ^  c C A T ]
G G A C G G C C  AC  T C C C  A G A T G I A G T C C  G (  CA |
G G] [G G C ( [ " ]<: T C C (  A G A T G T| [O T f~|C Of
G G A C G G C C  A C  T C C C A G A T G T A G T C C G C  C
Humm PaxS cDNA 
KknsePaxb cDNA 
Trout PaxS cONA
A G G A T A G  I G G A A U  T O  C T r A f C " A A G  < T f G"t T
A G G A T A G !  G G A A C I  T G C Pl C A I  C A A G G T G I  C
,i G G A T A w T G G A A . T C* " T  C A T \  A A G G i ( T T T
160 170_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ? ^ S |
H u rm n  PaxS cDhA i a - g g t t  c t  g c  g  a  c a  f r m i T o T T ' ^  m T c :  
H iteP ax S  d m  [ AG G C C C T G C G A C A T C T C  C A G G C A G C T T C G G  
Trout PaxS cD*\A f jp p |C C C T ( - n < -  A H A  T (  T ( | - ~ l c n c  A G c t |  |c G Gj
Cc T G C G A C A T C T £ C A g G C A G C T T £ & 0
Human PaxS clahA 
IAh&o PaxS dJNA 
Trout PaxScD*\A
1?C x c 2K
G T C A G C C A I  G G I  I  G I  G T C A G C A A A A I  I  C I T  
G I C A G C  C A T G G T T G T  G T C A G C A A A A T T  C I T  
G T C A G [~ K  A] |G O f l T  G T G T C A G C A  A p l- *  T p “fc T
G T C A G C C A T G G T T G T G T C A G C A A A A T T C T  T
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Human PaxS cDNA
Mo if. e PaxS citiA G G C
Trout PaxS cDNA
t b BG G C
Hurrvn PaxS cDNA c c :
Mo i / .  o PaxS cCtiA c c G
Trout PaxS cDNA c c c
B
* *  ‘  * :  *
G G  G G I M A  T I  G G  A G G A T C C  A A A C  C A A A G 
G G G G I  G A T  I  G G A G G A T C C A A A C C A A A G
G G G G T G A I  T G G A G G A T C C A A A C C A A A G
G C* (j 6 t (; A T t G C* A G & A t c c A  A A C C A A A &
liurmn PaxS cDNA 
M b  u s e  PaxS cDJNA 
Trout P jxS  cCNA
2to  ore xo
[ T T i f o  c c X T 'a  r r r r a T r r o T o o A  a a a a a k
G T T G C C A C  □ (  C C A A A G I  G G T G G A A A A A A T C 
G T T G C [~1A C y  C C C A A A G T G G T G G A p l *  AP 1 *  T c
C* T  I  G  C  C  A  C  A  C  C  C  A  A  A  G  I  G  G  T  C - G  A  A  A  A  A  A
Hurrvn Paxb cDNA 
Khi&ePaxS cDNA 
Trout Paxb cDNA
G C T G A 
G C T G A 
C C f l O A
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T T l l A  a  a c g  c c a a a  A l l c  c c a c c a t g
T A C  A A A C G C C A A A A C C  C P ]  A C C A T G
T A C A A A C G C C A A A A C C C C A C < A T G
G  A  V  T  A  C  A  A  A  C  G  C  C  A  A  A  A  C A I  G
Hurrvn Paxb cDNA 
M u te  PaxS cDNA 
Trout Pax S cDNA
M3 350
i  t  i  c  e c T r c . ”c a T : v T  x r r c n r r r r t X T . " *  r  e
I  T T G C C T G G G A G A T C  A O G G A C C  G G C T G
T T |~~lG c c t g  g  g  a g  a  t [ [g |~>  A c I |Ol Ic t | |t t  g
T  T  T G C C T G G G A G A I C A G G v A c  C G G C  T G T T G
L J t t ]  
V t g
Hurrvn Paxb cDNA 
M)it,o PaxS CitiA 
Trout PaxS cDNA
Hurrvn PaxS cDNA 
Mo i t  o Paxb citiA  
Trout Pjxb cDNA
373 3S3 39C
G C A G A G C G |  |G I  G T G T G A C A A t  G A C A C | | G  T G
G C A G A G C G A G T r ] T  G I  G A C A A T G A C A C I  G T
G C P ]G A G P |G  A G T G T G T G A C A A[ [G A C A
G C A G A G C G A G T G T G T G A C  A  A  T C-  A  C  A
SCO
T T I J a g  c g  t c a g M t c c a  t c a
C C C A G ( G T ( A G C T ( (  A K A  
C c C A G| |C> T C A G C T C | [A T C A
C
Exon 3 Exon 4 
JT3 \ y
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t u t t t i
c I  g t  Gl 
~ ] T G T |
T G T O
T T  C  ( T T n T T C T
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G G A T C A T (
A C A G G A T C A T T
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G G A C f l A  A A G T f~fc A G C A G C C
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K ] C  GI  ^ C  IG] [Cl  [G A C[~|C A G G T f ] *  <■
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5X* SiZ
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T C C A T C A G P ]G  G C A T C C T G G G C A T C A C C T C C  
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Jrcut Pjx S cDNA
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A
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A A 7 G G  ^ 1 A C  I  C D
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Human PaxS cDNA
Me 6  e Paxb cDNA
Trout Paxb cDiVA
human Pax 5 cDNA 
Ml ■ t6 o Paxb c it* A 
Trout Paxb cDNA
iiunun Paxb cDNA 
fAotsoPaxS citiA  
Trout Paxb cDNA
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MoisePaxS cDNA 
Trout Paxb cDNA
Human Paxb cDHA 
Ki iho Paxb cLtiA 
Trout Paxb cDNA
Exon 6 Exor 7
A C A C A G C  A G C A G  
A C A C A G C A G C A G
C T G G A G G T  GC  
C I  G G A G G I  G C
T G G A C C G C  
T G G A C C G C
|C i |C | |C A G C A G H t | |g  a  c-I
r n  G' T T T G A 6  A 61 \Z A 1G . W  A T <!
G T G T T T G A G A G|  jC A G C  A C  I  A C  T C |  [G A C A T C
G I V ’ T T G A G A G R C A O C A C T A C T C W G A C A T C
A  76 njcleotide gap in troa: Pox5 exon 7 (absent in mouse anc human Pax5) %
T T C A C C A C C A C  
T T C A C C A C C A C
G A 
G A A
U C . i t  C A A GC C 
C C C A T C A A G C C A
G A  
G A
T T C A C C A C C A C R G A R C C C A T C A A G C C M G A R
300
C A G A C C A| C A G A G I  A I  I  C A G C C A T G G C 
C A G A C C A C A G A G T A T T C A G C C A T G G C 
C A G A G T A T I  C \ ~]Q  C C A T G G C
u a u a u u a C A O A O i A T T C A O C C A T G G C T
Exon 7 Excn 8
I  C
IT
r T T T T r C T X  G T G G 
C T G G C T G G [ ] G  G
C T ]~~1g  c f~1 G 0  T G 0
C T G G C  T G G T G G
[C  T G G A G A
JC T G G A G A
| T G G A -■ G A
340
C X  t  G A A[_JC C C
C A I  G A A A G  C C
"7 a  I  g  A A A [~]C c
E G A .  A T  G A A A G C  C
Hunun Paxb cDNA 
MolsoPaxb citiA  
Trout Paxb cUtiA
SSO 360
~7T~Z—A C C—c—Z—Z—X~Z—c—c—C*
C A C C C
C C H
z r c T T P J T
G C T G A C
k s n s r ~
G C T G
A GG G G 
A C A A G
900 39C 900
Human Paxb cDNA I t  c g g  g a  g c a  g t  g  t  |_J t c a g g c c c  M e  a g t c c
M u te  PaxS itiA  |T C G G G A G C A G] |G T T C C A G G C C C  A C  A G T C C
Trout Paxb cDHA fC i V l C  G[ 1C A G T G T T C C V I C  G C C C A C A G T C C
C- A G C A G T G 7 I  C C A A C. T
Human Paxb cDt\A 
Ml) if. e Paxb cENA 
Trout Paxb cDNA
T A C C C 
T A (  C (
i C H i .
9»5 920 900
IA I H  T G A C A G G C C G i l o  A C T T G T cT  
A T T G T ]~ lA  C A G G C C G A G A C T T G G C G
A C 
H A G T
~ K  ■* 9 ° r i t  c- A C. A e n r f -
A C A G G C C G A G A C T T G
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Exon 8 .  Exon 9
Human Pctxb cDHA A G C A C
KintoPaxb c it iA A G C A C
frout Paxb ci}>\A A G C A C
MO 9*0 960
rc rn t c c C G G G T A C C C T C C A C A C
A C C C T C C C  F IG  G G T A C C C T C C A C A C  
A C ( C T C C ( € G  O n  I  A c (  (  Y lC  C A C A (  
V A C  C" C Y “ C ' £ "C C* G G ; A c t C  T c t  A t ‘ A £
Human Paxb cDNA 
Kin t o  Pa xb cQVA 
/rouf Paxb cL'SA
Human Pm  b cDNA 
KintoPaxb C itiA  
hou t Paxb ciM A
Human Paxb cDNA 
Kb i t  e Paxb c it iA  
frou t Paxb cDNA
f 4urmn Paxb cDNA 
KintoPaxb c it iA  
frout Paxb cDNA
Human P&b cth\A  
Kb i t  o Paxb c it iA  
frout Paxb cDNA
970 9*0
<rrc~c~ccrcTG'ri'cr^ATAiiGGc a g c t  
G T C C C C C C C G C T G G A C A G G G C A G C  
G T C  (  c (  c C1 Ic n o  o n e  A G G G C A G C
?9C
T T T  C G s. T G C’  A C A G G 0  C A
T A  e r e ]  
T A C T C 7 ]  
T A C T C T|
1010
G C A C  C G A C G C I  G A C A G G G A T G  G I  G C C I  G 
G C A C  C G A C G C  T G A C  A G O G  A T  G G T  GC C T  G 
G Cj  [C] T G A ( H O  p r i A  T O G i f l t  CI lG
A V. 1 v. I 
Exon 9^ .Exon 10V::;
G C A C C G A C  G C  T G A C  A G G G A T G G T G C
A G I O  A 
A G I  G A
t o t i c a
A G T G A D T T T T C
tote
1030 1040 1050
T I T T  C C G G G A G I  C (  (  I  A C A G C C A (
T T I  T C H O  G H A  
T T T T C C O  G O A
G T C C C T A C A G C ' C A C  
G I - C C C I _ aJ [£  C A C
G G G A G  i C C C  T A C A G A C
107
r n r T T n r s n r x T T T T n r T
C C T C A G T A T T C p |T  C 
C C T C A G T A T T C  C | | (. A T T c C«T c vA
T T C T T C G A  
T A C A A [ l G  A 
t a P |a  A C G A
. A . A A . v.* A B
1060
T T 'T T 'C T :  
T C p j l  C* G 
I C C  T G G
T T T T T T T  C (! i  A A (  (  (  
A G G T T C C C C A A C C C  
A G|~ ] t T f~ |c C P A  A C C C 
A G O .  T C  C C C A A C  C C
HOC
G G G C T G t t T G
T G G
me
G G G C T G C T T G
p o n e  i  G n i n c . i i o n e
V G C* G C T G C T T O .  1 J “  '
human Paxb cDMA 
K tu to  Paxb c it iA  
frout Paxb cDHA
Human Paxb cDAA 
KintoPaxb c it iA  
frou t Paxb cl>NA
1100 1130
C A A C  A G O A C  T A T G G G T C T C T C  C I  G G G  G X T G
A A v G G G i TTT T9 0  n u c le o t id e  in s e r t io n  i r  t r o u t  P a x 5  ( a b s e r t  i r  r r o u s e - ’b u r r a n  P a x 5 )
11 !C 1160 V
G A C- A I ' C C- C. A I  C. T T C C T C T C. C. C. C T C T T <
G A G TT G G T T T T T T G G G TTT
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Human Paxb cDNA
M ihoPaxb ci t iA
Trout Paxb cDNA
Human Paxb cDNA 
Moleo Paxb c iTiA 
Trout Paxb cDNA
Human Paxb cDNA 
f,bi&e PaxS citiA  
Trout Paxb cDNA
Human Paxb cDNA 
Mouse Paxb cENA 
Trout Paxb cDNA
G C C A C* C C ■ A T A T ' a T T C A T A  T G C A A G
r r A v  C
tJOO
A O A .  G G G A - A G A I G .  A A G G C  K  C
rr>; .v . ;r.\:
c c --
c c
c c G
T T T t T T T T M a  g c  g c t  g c M g  c c c g a g  g a 
I A C  T A i  T A C . H C Q C  T G C A G C C C G A  G G J
C C T A C T  A f l T  A C A G C G C V lO  C Af“ k  1 [G A
C C v T A C T A T T A C A G C G C T G C A v C C C G A
g ~ ~ ]
Al  
G_GJ
G G A
1240 12SG 12tC
g T M g c c c c a c c t g c  L J gT  
G C G G C C C C  A C C  f l ^  C C G C 
G C G Gf |C C 1 |C T G  C C | fC
C C C A C C T G C C G C  
Exon 10 (TGA)
G C
G C C A C T G C C T  
G C C A C Q g  C C T 
G C(~fA ( T G  C C T T T j
V O C C A C T G C C T C C
1270 ____ 1
I A T G A C C G T C A C T G A
I . U G A C  C O T C  AC I  G A
A H O  A C C G|  jC A C T G A
A T G A C C G T C A C T G A
12SC 2?:
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2. Formatted multiple alignment of full-length trout Pax5 and Pax5/laA2 clone (contains
exon la  with deleted exon 2 (Nucleotides 47-216)- E23A0a_T3_492426).
Sense Primer (tPax5.’E1wt.S) fff
irmx P8xb CUNA [a T O G A A G I  A G A G G C  C G A G G O T  C A T O
to  r  I  P3AOa 73 49P42Hsoq  " " ] &  T A G A G G  C C G A G G O  T C A T G
T G T T G 
T O T T G
A T G G A A G T .U  A i  i  ,J “ & A i  d d T . A f G 7 G I
Exon 1 Exon 2 (Nudeotide 47)
Trout RtxS COMA 
FOT_r?3AOs T3 49 P 4 P 6 iO q
TrotX f&*5 CDNA
tO  f tSJA O a 73 49?4 PH soq
A G G f U G U T G l T c i r n G G A  C A T G G A G G G|  
A G G C C G G G A C G A G C A G Gf
A G G C C G G G A i G A G C A o G A G G A C A T G G A G G G
G I  G A A T C A G T I  A G G A G G C G T O T T C G T G A A C
>00 *»0 tOB
Ttvdt Pub err,'A [g c- c a  g g c c c c t  c c c a  g  a  t  g  t  g  c. T 0  C G A A c c-|
FOt_£23AOi_ I3 ^ 4 9 P 4 P & s e q ..................................................................* .............................................................
G G C A G G C C C C T C C C A G A T G T G G T G C G A A C G
iroat text, cUNA |C G A A l t  G T A G ' a T c  I  G G  C I  C V c T I T a — ^ ^ T r T ]
P01_ E23AOA T3 49P4PC S O Q . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
C G A A T C G T A G A G C  T G G C  I C A C C A A G G G G T C
trout ( * * ' ,  C ON A Ic G C f r H  g T ^ T a T  c T c  T T t  A C A G C T C T Z Z ]
tO  I  [ ? 3 A 0 ^ 7 3  4 9 P 4 P 6 s e q .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  -  -
C G C  C C C  7 G T G A 7 A T C  T C  7 C G A C  A G C  7 C C G G
>SC 000 0t3
Tr'vjt Pi  <S COKA | G T C A G T C A C G G A T G T G T C A G C A A 0  A I  A C T gT
f O L . f _ 7 . M O a  _ 7 3 ^ 4 9 2 4 2 6  S f S f .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   - ......................... . . . . .
G T C A G T C A C G G A  T G T  G T  C A  G C A  A G A  T  A  C T  G 
Exon 2 Exon 3 (Nudeotide 216)
Troot Paxb cONA
t o t  J P 3 A 0 4  73 49P 4P 6  soq
froiX fbxS CDNA
tO \ t?3A O i 73 49P4PH Soq
rnma con  a
to  r._ f?3AO*_ 73 4924X  soq
JfOOt Rixb cONA 
f O U 2 3 A O *  73 49?4 PH soq
|G G G A G ^ I t  A f  T A I O T g A C A 6  G A A G T A T  C C_ o ' f  
| T  A C T A T G A G A C A G G A A G T A T C C G T
G G G A G G I A C  t a T G A G A C  A G G
0*C
A A G T A  T C C  G T 
073
C C C 0  G  0  G  T G  A T T G  0  A G  0  A T C C A A A C C A A A G
C C C  G G G G T  G A T T G G A G G A T C C A A A C C A A A G
C C C G G G G 7 G A T
ZiC
T G G A G G A T C 
: . v
C A A A C C A A A G
J33
G T T G C T  A C  A C C C A A A G T G G T G G A T A A G A T C
G T T  G C T A C A C C C A A A G T G G T G G A T A A G A T C
G T T G C T  A C  A C C  
3tC
C A A A G T G G 7
7
G G A 7 A A G A T C
233
G C C G A C T A C A A A C G C C A A A A C C C C A C C A T G
G C C G A C T A C A A A C G C C A A A A C C C C A C C A T G
G C C G A C 7 A C A A A C G C C A A A A C C C C A C C A T G
159
frout ffexi. CON A
r o i  . 123A O * T3_ 4 9 2 4 2 6  soq
TfOUt r a * 5  CDNA
T 0 1 723210* T3 4 9 2 4 2 6  soq
trout to*S> c ON A
TO L  (2 3 A O * 72L  49 24  26  seq
Trout PgxTr CDNA
TOT T23AO* 13 4 9 2 4 2 6  te g
Trout P S x S  CON A 
fO J _ L 2 M O A  1X .A 92426 .iO q
Trout. f 9x 5 CON A
TOT [ 2 . 1 4 0 J  T3 4 9 2 4 PCsoq
Trout r a x S  CON A
TO f „ L23AQt_ I X  49 2 4 2 6 . io q
Trout ra<5 cOVA 
fO t„L ? jA O *. I J L  4 9 2426 . seq
Trout rax& ciJVA
« ?  r  t 2 .v ia 3 73 49242c  soq
Trout r a x 5  C O V A  
f O t_ T23A O * 13. 49242CSt>q
TroU  r t s x i  cUNA
TOT J 2 3 A 0 4  T3_ 49 242C  SOq
TfOUt r a x S  CON A
TO f_ C21A03 T3 4 9 2 4 2C SOq
t  t  c o  c c t  o  g  V a '"g a  f T " o  a T a T T H ' cT T tT T
T T C G C C T G G G A G A T A C G A C A C A G A C T A T T G
T T C  G C C T G G G A G A T A C  G A G A C A G A C  T A  T T  G
jrc  joo 3sc
G C T G A G A G A G T  g T g T G  "A’ C A“ c " g " A ^  A ^ f o T T f  
G C T  C A G A G A G T  G T  G T G A C  A A C  G A C A G T G T T
G C T G A G A G A G T G T G T G A C A A C G A C A C T G T T
Exon 3 Exon 4
c c'Ta 'g T T  t  c a g  c t  c t  a  t  c  a  a  c a  g | g  a  t  c a  t  c
C C C A G T G T C A G C T C T A T C A A C A GI G A T C A T C
C C C A G T G T C A G C T C T A T C A A C A G G A I C A T C
Antisense Primer (tPax5/E4.AS)
JTC ±tC y .  4S0
| c C A G C  A G C  C T C C G G G T T  A g 'I 
l c  C A G C A G C C T C C G G G T C A 01
A G G A C I  A A A G T 
A G G A C T A A A G T
A G G A C T A A A  G T C C A  G C A  G C C I C C  G O  G t  C A
jtc jr p  jsc
[ T c " A G GA~C'~C, "T,"C"T C~T C T G C T C A T A A C C T 0 G C 6[
T C A G G A C  C T C  T C  T C  T G C  T C A T A A C C  T G G C G
J f f  SOQ Sf3
| T C G T  C "t~ a'~G~C~G~ T~~C G A C A C A G 0  T T T C  C G T g T
T C 6 T C 6 C  T A G C  G T C G A C A C A G G  I  T T C C G - C G
|G T G A C C A' G' T -G — ~T~C ~ G ~ rT ~ G ~ G  C T C C T C C T A C 1
G T G  A C C A  G I G  A C  T C G G C  T G G C  T C  C T C  C T A C
sm
|T  (  C A T C A G C T c T A T f T f T G O A  A T C A G C  T C  X |
T C C A 7 C A G C G G C A T T C T G G G A A T C A G C T C A
IG C T A A C~G A C G G C A A G C G G A A G A G A O A C  "o T T f
G C T A A C G A C G G C A A G C G G A A G A G A 0  A C G A T
t ’C 63S
C C A G G A G T C I  C C T C T A G C C A A I  G G C |
G C C C  7 C C A G G A G T C  T C C  T C  T A G C C A A T G G C
$40 iSC OS
A A G G G C G
|C A T G O T C t  A O] |A G G G C G| j G A C T T C C T G  A~G~G|
A
C A 7 G G T C C A G & A G G G C  G S . G A C  7 T C C  7 G A G G
t~c too esc
|a  a  g  c a  g  a  t  g a g  a  g  g  g  g  a  c  c t  c t  t  c t  c g  c c t~[
A A G C A G A T G A G A G G G G A C C T C T T C T C G C C T
160
T'C
Trout PaxS cDNA |C A  G C A  G A  T T G A  G A  C A  T  C A G A G T A  T  T C G O C C |
FO f_  E23A 0a T3. 49 2426 . soq
C A G C A &  A T T G A G A C A T C A G A G T A T T C G G C C  
'SO 740 7 sc
Trout PaxS cDNA |A  T G G C T C T A G C C C- G T G G A T T G O A C- G A G A T G|
FO I _  L23A 0a T3_ 4 9 2 4 2 6 . soq
A T G G C T C T A G C C G G T  G G A T T  G G A G G A G A T G
~ct? 770 7SC
Trout PaxS cDNA |A  A A A  C C A A T C T G G C C A A T  C C A G G C- T C A C- C C-|
(O  f _  L23AOa T3_ 49 2 4 2 6 .  Seq
A A A A C C A A T C T G G C C A A T C C A G G G T C A G C G  
7$c aoo etc
TroiX PaxS cDNA |G G G G A G C 7 A G G A G C C A G T G T T C C G G G C C C A|
FO l _ L 2 2A 0a  r JL 49 2426 . soq
G C- G &  A C- C T A G G A G C C A G T G T T C C G G G C C C A  
see- esc &*c
TroiX Pans cDNA | C A G T C C T A T C C  A C T G C C A G G T C G A G A C C T C I
FO 1 l2 3 A 0 a  T3_ 492426 .soq
C A & T C C T A T C C A C T G C C A G G T C G A G A C C  T C 
SSC SSO 87C
rroix Paxs c d n a I T G C A G C A C  C A C C C  T C C  C C G G C T A C C  C C C  C A |
FO f_ L 23A 0a T3_ 492426.SOq
T G C A G C A C C A C C C  T C C C C G G C T A C C C C C C A  
esc sec see
TroiX PaxS cDNA |C A C G T C C C C C C A A C G G G C C A G G G C A G C T A C |
FO f _ L23AOS T3_ 4 9 2426 . soq
C A C G T C C C C C C A A C G G G C  C A G G G C A G C  T A C  
$io sac
TroiX PaxS CDNA | T  C T  G C C T C C T C A C  T G A C T  G G T A T  G G T A C  C C |
FO l _ L23A 0a T3_ 4 9 2 4 2&.scq
T C T G C C T C C T C A C T G A C T G G T A T G G T A C C C  
$40 SSC SSC
TroiX PaxS cDNA I G G A G G A G A T T T T T  C C G G G A G T  C C  C T A T T  C C |
FO r_ L23A 0a T3_ 4 9 2426 . Seq
G G A & G A G A T T T T T C C G G G A G T C C C T A T T C C
$ 7 0  SSC SSC
Trout. PaxS CDNA I C A C C C T C A C- T A T T C C A C A T A T A A C G A G T C C 1
FO T_ F23A 0a T3_ 4 9 2 4 2 6  soq
C A C C C I  C A
~ | A T T C C A C A T f
G T A T T C C A C A T A T A A C G A G T C C
fCCC fC*C *020
Trout PaxS CDNA | T G G A  &  A T 1  T C C A  A  A  C C C C A G C  C T G T  T A G T G |
FO J_£23AOaL T3_ 49242.6 seq
T G G A G A T T T C C A A A C C C C A G C C  T G T T A G T G  
1030 1040 'CSC
Trout PaxS c d n a  [T T T  C A A C  A G G A C T a T ~G G O T C T C I  C C T O G  0 T |
FO r_ F21A 0a T3, 4 9 2 4 2 6  soq -  - -  "  -  -  - -  - -  -  -  •  - | T G G G |
T T C C A A C A G G A C T A T G G G T C T C T C C 7 G G G G
161
fca? tcro ioso
TroiX Pax5 ci)MA | A C G G A G A T C G G A T G T T C C T C T G G G C T C T T C |
iQ T _ l2 3 A 0 3  T 3 _49 242 €so q
A C 6  5  A  5  A  T C 6  6  A  T 6  T T C C T C T G G 6  C T C T T  C 
* 0 5 0  t t f O
r.fritc c m  a  | a  c c  g  c c a  g c c a  g  a  c  g  g  g  a  c a  g  a  t  g  c a  a  g  g  g |
f0 1 _ L Z 3 A 0 i n _  49242&.SOq
A C C G C C A G C C A G A C G G G A C A G A T G C A A G G G
? ,*20  # 130 * 1 4 5
f r a u f  A J X 5  ciXk'A | T C G C C G T A C T A C T A C A G C G C G G C A T C G A G X |
FQ 1_£23A03 I3 _  492425 . soq
T C G C C G T A C  T A C  T A C  A G C  G C G G C A T C  G A G A
??S0 > * £ 3  t f  7 3
IftMJC «3X5 CfJNA [g g ~g  g c g g g  a  c c "g  T c T c T c a ' c g g c  X a  r  t g ' c "c |
f 0 r _ L ? 3 A 0 - i  7J_49>42G .S 4?(?
G G G G C G G G A C C G G C T G C C A C G G C A A C T G C C
ffSC n x  toss
TroiX 1*3X5 CON A | T C  C G C  C T A C  G A C C  G C  C A C T  G A |
iO t_L23A O a 13_49242C.SOq
T C C G C C T A C G A C C G C C A C T G A
162
3. Formatted multiple alignment of full-length trout Pax5 and Pax5/A8 clone (with deleted
exon 8 (Nucleotides 832-931) - b04_a5_ 504022).
TS 20 20
Tree: *2 *5  cDSA  1a t  g  g  a  a  g  t  a  g  a  g  g  c c g  a  g  g  g  t  c a  t  g  t  g  t  I  o l
bCd_s5_ S04022vecscreen. sec
A T C- G A  A  G T A G A  G G C C C- A  G G G T C A T G T G T T  G
4C SC €0
Tree: *2x5  c D \A  |.A G G C C G G G A C G A G C A G G A G G A C A T G G A G G G |
b0d_a5_504G22veescte&Lseq
A G G C C G G G A C G A G C A G G  A G G A  C A  T  G G A  G G G
Tree: *2x5 cDSA | g  T G A A T C A G T T A G G A G G C G T G T T C G T G A A C
bCd_ 3 5_ S0&022vecscreen. sec
G T G A  A  T  C A  G T  T  A G C- A G G C G T G T T C G T G  A A C
roc ire  rco
Tree: *2x5 cDNA | G G C A G G C C C C T  C C C A G A T G T G G T G C G A A C G[
bC'd_3 5_S04Q22vccscfcenjseq
G G C A G G G C  C C  T C C C A G A T G T G  G T G C G A  A C G
T 140
Tree: *2x5 cDS4 
bCd_35_5C4C22\, ocecreor sec
|C G A  A  T C G T  A  G A  G C T  G| C A C C A  A G G G G T
A T C C A C T G I G G A  A T_
"■X I~c
'20
"
V
rso
Tree: *2x5 cDS4 c G C C C T T G A T A T C T C T C G A C A  G C T C C G g |
oCA_ 3 5 CA022v~czc.''eec. sec c G C C C I I A to r
C G C C G A  T A  T C T C I  C C- A  C A  G C T C C G G
IX , 200 210
Tree: *2X5 CDMA | g  T  C A G T C A  C G G A  T  G T G T C A G C A A G A T A  C ~ T g \
b04._aS_504022vecscreenseq - .........................................................................................................................
G T C A G T C A C G G A T G T G T C A G C A A  G  A  T  A  C T G
Tree: *2x5 cD\ 4 
bCd_sS_ 504022\
[ G G  G A G G T A  C f  A T G A G A C A G G A A G T A T C C G T |
C- G G A G G T A  C T A  T G A G A C A G C- A A G T A T C C G T
CSS CSC C ”C
Tree: *2x5 cDNA | c C C G G G G T G A T  T G G A G G A T C C A A A C C A A A~G
b04_a5_504022vecscteen^eq .........................................................................- - -.. - ...................................
C C C G G G G T G A T T  G G A G G A T  C C A A  A  C C A  A A G
Tree: *2x5 cDSA
tr  if.bC4_35_5C4C21
w r ~ < r c " T — i r T T - r r A  o t  g o t  g g a t a a g a T t i
G T T G C T A  C A C C C A  A A  C* T  C  G T  G G A  I  A  A  G A T
Tree: *2x5 cDSA | G C C G A C T A  C A A A C G C C "a ' r f l c T c T A T c T T G l
604_as_ 50dQ22vecscfeenseq - - - -
G C  C G  A  C T A  C A  A  A C G C C  A  A A A C C C C A  C C A  T G
163
T re n t *3 x 5  cD \ 4 ff~T~C" G ic C T G G G ~ A G  A t  A C  G A G A C  A G A C  T A T T p]
bC4_2 f _  J 04022vecscreen. see . . . . .
T C G C C G G G A G A  T A  C G A G A  C A G A  C 7  A X T G
3~C CSC CA?
Trent *3x5  c D \A | G C T G A G A G A G T G T G T G  A C A A C G A C A G T G T T
cC4_2 5 _ 504022vecs creen.seq
G C T  G A  G A  G A  G T G 7  G 7  G A N. A  A  C G A  C- A  G 7 G 7 7
£OG 4f<? 43?
Trent *3x5  cD.\A l C C C A  G T G T C A G C T C T  A T c A A C A G G A  T C A T C
b 02_  sS _5  Q4022vecscrecn - - -
c C C A  G T G T C A G C 7  C 7  A  7 - A  A  C A G C- A  7  C A 7 C
•iSC 44C 45?
Trent *2x5  cDXA |A  G C- A C T A A A G T C  C A G C A G C  C T A G
bC'd_3S_ 5Q4Q22vecsc*sen.seq
A G  G A  C  T A  A  A  G T C C A  G C A  G C C 7 C C G O G T C A  G
4SS 470 43?
Trent *3x5  cDX4 | T C A  G G A  C C T C T  C T  C T G C T C A  T  A  A  C C T G G C Gj
bCd_ 3 S_ 5 CSC22vecscreen sea - ..................... - - - - ........................... - . . . ........................... - - -
T C A  G G A r- c 7  C T C 7  C 7 G C T C A 7 A  A  C C 7  G G C G
•iSC see S10
Trent *3x5  cDX4 G T A G C G T C G A C  A C  A C G T T T C  C G C G
bC4_3 5_5Q 4Q 22vecscfeenseq
T C G T  C G G 7 A  G C G 7  C G A  C A  C A  G G  T  7  T C C G C G
sec ssc S40
Trent *3x5  cDSA G T G A C C A G T G A C T C G G C 7 G G C I  f  C T  C C T A C|
bC2_ 3 5_ J  C 2C22\ eescreer: .sec - . . . . . - - - ........................... -
G T  G A  C C A G 7  G A C T C G G C G G C 7  C C T C C X A C
ssc see 5~<?
Trent *3x5 cDSA T C C A T C A G C G G C A I  T C T G G G A A T C A G C 7 C A
oC2_3S_ 5  C4022\-ecscreensec;
T C C A  T  C A  G C G G C A  7  7  0  7 G G G A A  T C A  G C T C A
SSC see tCO
Trent *3x5 cDS'A G C T A A C G A C G G C ' A A G C G G A  A  G A G A G A C G A  T|
b0d_3S_ 5Cd022vecscreer; sec | t |
C- C T A  A  C G A C G G C A  A  G C G G A  A  G A G A  G  A  C G A  7
Sic sec S3?
Trent *3x5 c D \4 G C C  C 7  C C I G A I C I A G C C A  A  T G G C |
b Cd_ 3 5_ 5  CdG22\> ecscreenseq G N  K  K  N  N c G c  -
G C C C 7  C c - 5 G A G 7 C 7 C C C 7 A G C C A A T G C- C
S4S ssc SSC
Trent *3x5 CLfS 4 | C A T G G T C C A G G A G C- G C G G G A C T T C C  T  G A G G|
dC4_ 3 5_ 5  C'4.022i. ecs ere e n ^e q .................. - - -
A A  7  G G T c C A  G G A G G G C G G G A  C T T C C 7 G A  C- G
6TC SSC SA?
Trent *3x5 c D \A A A G C A  G A T G A G A G G G G A C C I  c T  T C T C G C C 7  |
A A  G C A  G A T G A G A G G G G A c C 7  0 7  T C T C G C C T
164
Trout *2x5 cDNm (c a  o  c a  g  a  t  t  g  a  o  a  c a  t c a  g  a  g  t  a  t  t  c g  o c c 1
b04_aS_ 5C£022ueczcreer? z e e ..........................................................................................................................
C A G C A G A T T G  A G A C A T C A G A  G T  A  T T C G G C C
Trout *3*5 cD-MA 
b04_ i  5_ 5 C-lC22ueczcree n seq
Trout *3x5 cDNA 
oC-l_a 5^504022veczcreefi :ez
[ a  t  g  G ( " T (  t  a  g  < c g  g  t  g  6  a  t  T T T a ' q  G 'a X T t T I
A T G G C  T C T A G C C C C T O C A T T 6 C A C C A C  A T G
Sense Primer (:Pax5/764 S)
m3C
C A A T C T G G
I a  c c a a t c t g g
c C A A T C c A G G G T C T f ,  C G
c C A A T C <: A G G G T C A (,  C G
A A A A C C A A T C T G G A A A G C G
Trout PaxS cDSA 
eCe_35_5C-iC22', eczcree' see
Trout *2x5 CDS4
bCJ_ 35_5 CJ022x ec: cree -  zeq
G C G C U C  T A G G A G C C A 
G G G G A G C T A G G A G C C A
SCC S*f!
GfGTTCCGOGTcT a 
G T G T T C C  G G G C  C C A
G G G AG T A G G A G C A G i  G 
Exon 7
C G G G C A
rXcTTT
C A G T C C T
$00
C T A T  C C A C T G 
T  C C A C T G
C A G C T A T
T:
C A P  G|
Exon 8 (Njcleotide 831) 
3*2
C G A G A C C T C l
T G C C A G G T C G A G A C
$50 350 8 -0
Trout *2x5 cDNA l l G C  A G C A C  C A C C C T C C  C C  G G C  T A C C  C C C C A |
bCS_ sS_S C4C22vtczcreen zee
T G C A G C A C C A C C C T C C C C G G C T A C C C C C C A  
SSC i f f  900
Trout *3*5 CDSA |( A C G T  C C C C C c  X ^  G G 'G C T ' A G C G C A G C T A C l
o€'d_o5_ 5 Q4Q22i eczcreerzee
C A C G T C C C C C C A A C G C - G C C A G G G C A G C T A C
91C $ X  920
Trout *2x5 cDSA | l  C T G C C T C C T C A" "c“ f  g T F t T g  T A T  G G T A C C C |
t>CJ_ 3 5_ 5CJ022v eczcreer sec
T C T G C C  T C C T C A C T C A C  T G G T  A T G G T A C C C
E x o n  8 E x o n  9 ( N j c l e o t i d e  931)
y  940 350 350
Trout *3x5 cD&A [o  g |a  G G A G A T T T T T (  C G G G A G I  C C (  T A T T (  C
oCJ_ 3 5_ 5C4022vecscreen sec | a G G a G a T T T T T C ( 0 G G a 0 T C C C T a T T C C
G G  A G O  A G  A T X T  T T C C G G G A C * T C C  C T A T T  C C
9T0 33C 990
Trout *2*5 cDS’A C A  C C C T  C A G T A T T  C C A C A T  A T A A C G A  G T C C
b04_s S_504022vecscre*n zee C A C C C T C A G T  A T T C C A C A T A T A  A C G A G T C C
C A C C C T C A  G T A T T C C A  C A T A T A  A C G A  G T C C
1000 TfffC
Exon 9 Excn 10 
rex
Trout *3x5  cDSA T G G A G A T T T C C A A A C C C C A G C C T G T T A I G T G
oC4_ z5 _ 5  C4022uecscreen. zee T G G A G A  I  T T C C A A A C C C C A G C C T G T T A  | G T G
T G G A G A T T T C C A A A C C C C A G C C T G T T A G T C-
Trout *2x5 cDSA
bCd^a 5_ 5QdC22veczcreen zee
•C X  t 040 1C 50
T T C C A A C A G G A C T A T  G G G T C  T C T C C T G G G G
t t c  c a a c a g g a c t a t g g g t c  t c t c c  t g g g g
T  T  C C A A C A G G A C T A T C* G G . C T C C T G G G G
165
Tree: ^3*5 cDSA
bCS_ s5_5 CJC£~\ ecscreen :*g
Trout *2x5 cDSA 
bC4_iS_50402 2vec:creer, seq
'X ' fST? 1 c&c
It G G A G A T  C G G A T G T T C C  T (To (TGTfTTTc 
C G O  A O A T  C C G A T C T T  C C T C T  G O O C  T C  T T  C
R C G G A G A T C G C A T G T T C C T C T G G G C  
Artiiserse Primer (tPax5'1 104.AS)
A C C <, | C C A  G C C A G A C G G G A C A G A T ° lA C C <Ac C A G C c A G A C G G G A C A G A T ±1
T C
O G G I
g_g |
A C C G C C A G C C A G A C G O G A C A G A T G M A U G G
* n JC 11 40
Trout *3*5 cDSA | T C  G C  C G T A C T  A C T  A C  A G C  G t  G G C  A T  C G A G  A|
T C G C C G T A C T A C T A C A G C C C G G C  A T C G A G A
ueo tiro
7(Cut *3x5 cDSA Ig g g g c  g g g a c  c g G m C C A C I C T  G C  Cl
tCJ_ s5_5 C4C22vec. creen re- 1 c  C- A a [t ] ■ (  C A C A T T G G
G G G O C C G G A C C O F, y. 7 K C C A C R K Y K R C T G C C
T18C TfSC tsoo
Trent Pax 5 cDSA | T C C G C C T A C G A C C G C C A C T G A|
bC4_ 35_ 504C22vee3cr&er seq
I C C GC C T A C G A C C G C C AC T O A
166
4. Formatted multiple alignment of full-length trout Pax5 and Pax5/A9a clone (with
deleted exon 9 (nucleotides 932-1018) -  E9180a3_497320).
Trenr Psx5 cD\A
E9! 80a3_d9732Q\ecsm esc
Trent Psx5 cD.\4
E9 i 8033_d9732(h ecsf dlz&z
1C 20 sc
( a  T &  G A  A G T  A G A G G C C G A G G G T C A T G T G T T C-]
A  T  6  G A  A  G I  A  G A G G C C G A  G G G  T  C A  T  G  T  G T  T  G
-iC so sc
l A G &  C C G G G A C G A G C A G G A G G A C A T  G G A G G G|
A  G G C C G G G A  C C* A  G  C A G G A  G  G A C A T G G A G  G G
TV 30 SC
Trent *sx5 cD.\A
E9 f 80s3_d97320veccm. esc
Trent *3x5 cDS'A
E9 i 8Q33_d9732C\ecsfn.sec
Trent AsxS cDX4
E9180s3_d9732Cieccn esc
A  A  C
A A
| G T G A  A T C A G T  T A G G A G G C G T G T T C G T G
G T  G  A  A  T  C A G T T A C  C* A G C C G 7 G T T C G T  G
too no 12c
| G G C A G G C C C C T C C C A G A T G T G G T  G C G A A C G|
G G C A G G C  C C C  T C  
rsc
|C G A A T  C G T  A G A C
C A G A T G T G G
C G A A T  C G
C T C A C C A  A G & G G T
T  C C A C T  G T G G A  A T
A G A G C T  G S. V  V A C
G C G A  A  C G
ISC
7
R W G G R R T V  
*
Trent PsxS cDSA c g c c e It G
E9 f 80s3_dQ7320veccrr> esc C G C C C l T
T  G A
t_gT
I  a 7 C T C I  C G -> C A G C T C C G C-l
C C Y  T R T G A
fSO
A  T C  T C  T C G A  
.XV
C A G C T C C G G
n c
Trent *3x5 cDSA
E9 f 8035_d97320iscc/n
A C G G T t- ^ ' t ' g T T X  g  c a  a  'g  a  t  A C t ~g [
G  T  C A  G T  C A  C G  G A T  G T G T C A  G C A A G A T A T  G
7rct;r cDS'A 
E9 '80a3_d9732C\\
|G  G G A G G T  A C T~A ~ T & A G A C A G G A A G T A T  C C G T |
G G G A G G T  A  C T  A
250
T G A G A A G G A
-eV
A G T A T C C G T
Trent *3x5 cD\‘A
E9 \ 3Q3S_d5752C%eccrn.csc
Trent *3x5 cDSA
E9 < 80sS_d97320i-sccrr‘ esc
Trent *3x5 cD\A
E9180s3_49732(hreccsmesa
C C C G G G G T  G A T T G G A G G A T C C A A A C C A A A ~G|
C G G G G T G A T I  G  G A  G G A  A A  C C A A  A  G
see
r&~f~T~C- C T A  C A C C C A A A  G T G G T G G A T A A G A T c j
G T T G C  T A C A C C  
SIC
C A  A A G G G T C-
53?
 G A T A  A  G
SSC
|G  C C  G A C T  A C A A A C G C C A A A A C C C C A C C A T  G|
G C C G A  C T  A C A  A  A  C G C C A  A  A A  C C C C A  C C A  7  G
167
SJC ssc ssc
Treat *3x5  cDXA [ t  T c g " C'  c  T G G G a T I T a  C G a  G a ~c a 'g  a " c  - t a  f  T " g 1
E9130s3_ 497320vecsm. sea
T T C G C C T G G G A G A T A C C A  C- A C A G A C T A T T G 
3T0 3^0 sec
Trear *3x5  CDS4  |G  C T G A G A g  a  g  t  g  t  g  t  g  a  c  a  a  c g  a  c  a  g  T C- t  T I
Ed f 80a3_497320vecsm.seq.................................................. - ..............................................
G C 7 G A G A G A G T G T G T G A C A A C G A C A G T G 7 T
-toe *10  433
Treat PsxS CDS4  |c C C A G T G T C a  G C f  c f  A T C A  A C A G G A t " C  a ' t T I
E9180a3_d97320vecsmseq................................................................................................................
C C C A G T G T C A G C T C T A 7 C A A C A G G A T C A 7 C
Treat *3 x5  cDNA [ a ~ g g  a c t  a  a  a ' g  t c c  a  g" c  a  g  c c t  c c  g  g  g  t  c
E9i8033_d9732C % -ecsm .seq  - - - - ....................................................................................................................................
A G G A C 7 A A A G T C C A G C A G C C  T C C  G G G T C A G
•JtC fTO
Treat *3x5  C D \ 4  j 7  C A G G A C C T C T C T C T G C  T (  A  I  A A C C T G G C G|
E91S0s3_49732Ovecs.rn .s e q ............................................................ ...............................................................
7 C A G G A C C  T C  T C  T C  7 G C  7 C A T A A C C T G C- C 0
Treat *3x5 cDSA 
E9 i 803S_49732C\ecsm sea
7 C G T C G G T A G C G T C G A C A C A G G T T T C C G C G
Treat * s t5  cDNA [5 T o T n  " a  G T G a  C I  C G G C T G O  C 'T  c" C t " C C i : a l
E9 1 8 0 a 3 „d 9 7 3 2 0 v e c s m s e q
Treat *3x5  cDSA
E9 f 8 0 s 3 _ 4 9 7 3 2 0 v e c s tn s e a
Treat *3 x5  cD .\4
E9 < 3  Os 3_ 4  9 732Q vecsm .sea
Treat *3 x5  cDN4
E9 f 8 0 3 3 _  4 9 7 3 2 C \e csm .se a
Treat *3x5  cDXA
E9 t 80s 3_49732 Ciecsrn sea
Treat *3x5  cDS4
E 9 18 0 sS _ 4 9 7 3 2 (h e cs rn .se a
G T G A C C A C - T G A C T C G G C  T G G C T C C  T C C 7 A C
| T C C A T  C A G C G  G C  A T I  C T G C- G A A T C A G ( :T ( ' ~ v [
7 C C A 7 C A G C G C- C A 7 T C T G C- G A A T C A G C T C A
f s f  S M  SSC
| G C T A A C G A C G G C A A G C G G A A G A G A G A C G A l |
G C T A A C G A C G G C  A A C* C C- G A A G A C* A C- A C C - A T
e tc  see ssc
| GC C C T C C  A G G A G T C T C  C T C  T A G C C  A A T G G C l
G C C C 7 C C A G G A G T C T C C 7 C 7 A G C C A A T G G C
|C A T G G T C C A G G A G G G C  G G G A C T f  C C T G A G~G|
C A T G G T C C A G  C* A G G G C G G G A C T 7 C C  T G A G C-
r r  s s c  ssc
A A G C A G A T G A G A G G G G A C C T C T T C T C G (  C T |
A A G C A G A T G A G A G G G G A C C  7 C T T C  T C G C C  T
490 SCC StO
T  C G T C G G T A G C  G T C G A C A C  A G G T T T C  C G C o|
168
IX* 710
Trout ~2i 5 cDSA 
E9 f 8Qa3_A97320vecst
[ < A G C  A G A T T G A G A 1 c G G C C
1 c G G C c
Trcui Pat 5 cDSA
£91S Qa3_ A 97 SZCSe zzm zee
Trcvz PsxS cDSA 
£91S0a$_497 SZO^ecs/nzeq
Trcvt Pax 5 cDSA 
£9f 80a 3_ A 9732CS ec5Jv zee
Trout Patx$ cDNA
£ 9 ! £0aS_A973£Checs/n zee
Treez PaxS cDSA 
£9 ' S0a3_A9"32Cv*cz/n zee
~ T  T G G A G G  A G A T G]
Jv V O C  C T C  T A G C C G G T G G A T T G G A G G A G A T G
l A A A A C C A A T C T O O C C A A T C C A O O G T C  A G C G|
A A A A C C A A T C T C 6  C C A A T C C A C G C I  C A O C C
a
7.9C *X >  $13
| G G G G A G C T A G G A G C ( A G T G T I C C G G G C C C A |
C G C G A G C T A C G A C C C A C 7 C T T C C G G C C C C A
SX &.V SA*
[C~A~G T~C~~C~T A T C C A C T G C (  A G G T C~C a ' V a ^ ' T T cI
C A G T C C T A T C C A C T G C C A G G T C G A G A C C T C
Sense Primer (tPax5,'360 S)
sis: $60
| T G C  A G C  A C C A  < C < T C C < C G G C T A £ £ £ c £ a
C T A C c c c c C A
7 C- C A G C A C C A T C C C C G O l
Trcvt Pat 5 cDSA 
£ 9 1 Sd33_A9?32Cxeczrn zee
< A C G T C C < C <  
C A C G T C C  c c c
m o  $90 900
C A A C G G G C C A G G G C T g T T T T
c a a c g g g c c a g g g c  a  g  c  t  a  c
C A C G C C C C C A A C G G G C C A G G G C A G T A C
sic sco sa:
TrceZ Pax 5 cDSA
£9 * S0a3_A9 732Qvecsm zee
T C T G C C T C C T C A C  T G A C T G G T A T G O T  A C C C  
T C T G C C T C C T C A C T G A C T G G T A T G G T A C C C
T C v v C C  T C C  T C A C  T G A C  T G G T A T G G T A C C C
Excn 8 Excn 9 (nucleotide 931)
V  $*o ssc se:
Trcvt *3x5 cDSA GIG A G G A G A T T T T T C C G G G A G T C C C T A I T C  C|
£918033_d9?32(beczrr> zee I f i l ................. - ..................... ... ...................................................... ...
G G A G G A G A T T T T T C C G G G A G T C C C T A T T C C  
$TC SSC SSC
~rcvz PaxScONA |C A C C C T C A G T A T T C C A C A T A T A A C G A G T C C |
£9 1 80a3^d97320rtcz/nstq
C A C C C :  C A C T A :  T C C A C A T A 7 A A C G A O T C C
(Niucleo’ude 1018)Exon 9 Excn 10
icec id o  \ fz z c
Trcvt *2x5 cDSA [ T G G A G a  T T T C C a  a  a  C C C C a  G C C T G T T a  GI T  G
7 G G A G A T T T C C A A A C C C C A C* C C 7 G T T A G T C  
1C30 10*0 1-3S3
Trout Pax 5 cDSA 
£9 ISQaS^A^TSZCxeczmzee
T T C  C' A A  C A G G  A C T A T  G G G T C T  C T C  C ' T C G G G  
T T  C C A A C  A G G A C  T A T  G G G T C  T C T C C T  G G G G
7 T T C A : A G G A C T A T G G C* 7 r 7 . 7 . . 7 G G G G
169
Treat P&5 cDK*
59 < 3 0s3_ J  P 7S2Qv e csw*
Treat *3*5 cDSA 
59 t8033_d9?32C\e csrn
Treat *3*5 cCSA 
E918Qa3_d97320*ecsm
Treat *3*5 cD\A 
591 3033_S9732C\ ee:,n
Treat *2*5 cDSA
59 f 8033_4Q735(S ecerr
•esc *arv i:se
A C G G A G A T C G G A T G T T C C T C T G G G C T C T T C  
A C  G G A G A T  C G C A T G T T C  C T C  T G G G C T C T T Crec
A C G G A G A T C G G A T G T T C C  T C  T G G G C  T C  T T  
Arv.isense Primer (tPax5/1104.AS)
V v o g• Cvt itie
A C C G C C A G C C A G A C G G G A C A  G A T G 
A C C G C C A G C C A G A C G G G A C A  G A T  G
C G
C A A G O C
A G C C  A G A C  G G G A C A C- A T G C A A G G G
f*3B t f  JO HJC
|T ( o c  c c I  A f n r n T u a a o c  a t  c 0 X 0 7a
T C G C C G T A C T A C T A C A G C C* C G G C A T C G A G A 
? rsc irtO
G
:# c  a
ETC C G G C  T G C  C A C G G C  A A C T G C |
A A ..................................- - - . . .................................T
G G C G X R A C C G G C T G C C A C G G C A A C T G C V
G G G C G 
G G G C G
••sc
:*e
T C C
T C C
T C C
rc~l Frl fo] fcl | G C C A  C T G A|
-A[cl ItJ- M c-|cJ [0 Cf
R C M T T S G R C V G C C A C T G A
170
5. Formatted multiple alignment of full-length trout Pax5 and Pax5/A9b clone (with
deleted exon 9 (nucleotides 920 to 1018) -  A10_T3_504027).
1C CC SC
Trout 7-3x5 c D K A  | a T G G A A 0 T A G A G G C C G A G G G T C A I  G T G T 7 Gj
4 10_ T3_ SO 4027. sea
A :  G C A A G 7 A  G A G G C C G A C- G G T C A T G T G T T  G
«iS SC €C
Trout " 'J o  C i. *»4 ]a  G G C  C G G G A C G A G C A G G A G G A C A T G G A G G G |
4!Q_T3_S0402?.c*c
A G G C C G G G A C G A G C A G G A  G G A C A T G G A G G G
7 3  SC 90
Trout 73x5 CDXA |g  T G a  a  T C a G T T A G G A G G C G T G T T C  G T G A A C l
4 10_ T5_ SO4027. sec
G T G A A :  C A  G T T A G G A G G C G T G T T C G T  G A A C
<CC 110 120
Trout 7-3x5 CDSA |G G C A G G C C CC T C C C A G A T G T G G T G C G A A C G|
4!0_T3_504027.cec
G G C A G G C C C C  T C C C  A G A T G T G G 7 G C G A A C G
'SC 14C ISC
Trout Z3xS cD \4  |c G A a  T C G T a  G a G C T G G C I  C A C  C A A G G G G T C |
AW_T3_S04027.c* q
C G A A  T C G I  A G A G C  T G G C  T C A C C A  A G G G G T C
-SC 170 ISO
Trout 7-3x5 CDSA |C G C C C C T G T G A T A T C I  C T C G A C A G C T C C G G
4 ! 0_T3_SQ4027.sk :
C G C C C C  T G T G A T A T C  T C  T C G A C A G C  T C C G G
'SC 2CC 21C
Trout 7sx5 CDS 4 |G T C A G T C A C  G G A T G T G T C A G C A A G A T A C T  G|
4W_T3_S04027seo
G 7  C A  G 7 C A C G G A T G 7 G T C A G C A A G A T A C T  G
22C 23C 2-iC
~rout 73x5 CDS4 |G G G A G G T A C T A T G A G A C A G G A A G T A T C C G T |
4!Q_T3_SQ4027.c* q
G G G A G G T A C T A T G  A G A C A G G A A G T A T C C G T
CSC CSC CTC
T ro u t 73x5  CDS4  Jc C C G G G G T  G A  T  T  G G A  G G A  T  C C A  A  A  C C A  A  A  G
A10_.T3_S04027.seQ
C C C G G G G 7  G A  T T G G A G G A 7 C C A A  A  C C A A A G
CSC CSC see
Tro u t 73x5  cDSA | G T  T  G C T  A  C A C  C C  A A  A  G T  G G T  G G A  T A  A  G A T  C |
4 ! 0_ T3_S04027.csc
G 7 7 G C 7 A C A C C C A A A G 7 G G 7 G G A 7 A A G A T C
31C 3CC SSC
Trout 7-3x5 CD\4 |G C C G A C T A C A A A C G C C A A A A C C C C A C C A 7 G
A10.J3_S04027.seq -----------------------------------------------------------------------------------------------------
G C C G A  C 7 A C A A A C G C C A A A A C C C C A C C A  T G
171
3<£C 35 l  360
Trout K3X 5 cDSA ] t t c  G C  C T G G G A G A T A C  g  a  g  a  c a  g  a  c t a t t g
4 10_ TS_ 504027. S*J
T T C G C C T G G G A G A  T A C G A G A C A G A C  T A T  T G
370 3SC 390
Trout '3 *5  c D \4 |C* C T  G A G A G A G T  G T G T  G A C A A  C C- A C A G T G T  T
A!0_T3_S04027.oecj
G C I  G A G A G A O T G T O I  G A C A A C G A C A G T G T T
■iOO ~1C 42C
Trout ' 3x5 cD .\4 |c C C A G T G T C A G C T C T A T C A A C A  G G A T C A T C |
4W_T3_S04027.seQ
C C C A G T G . C A G C T C T A T C A A C A G G A T G A T C
Trout '3 x5  CDS 4 | a  G G A  C T A A A  G T  C C A  G C A G C  C T  C C G G G T G A G
A:0_T3_S04027.oeo
A G G A C T A A A G I  C C A G C A G C C 1 C C G G G T C A G
■ISO -i70 -iSC
Trout ' 3x5 cDSA J T C  A G G A C  C T C  T C  T C  T G C T C  A T  A  A C  C T G G C  G|
AtC_T3_S04027.seq
T C A G G A C C T C T C T C T G C T C A T A A C C T G G C G
"roc: '3 x5  CDS' 4 I t  C G T C G G T A G C G T C  G A  C A C A G G T  T T C C G C G
AtQ_T3_SQ4Q27ses
T C G T C G G T  A G C G T C  G A C  A C  A G G  T I  T C C  GC G
Trout '3 x5  cDNA 
4 t  Q_ T3_ 504027. o?c
S3C S^C
I g t g a c c a g t g a c t c g g c t o g c t c c t c c t a c
G T G  A C C  A G T G  A C T C G G C  T G G C  T C C  T C C  T A C
f 5;  SSC s~c
Trout '3 x5  cDXA | T C C A T  C A G C G G C A T T  C T G G G A A T C A G C  T C A |
AI Q_ TS_ SO402 7. sea
T C C A T C A G C G G C A T T C T G G  G A A T C A G C T C  A
.'rout '3 x5  cD.\4 JG C T A  A C G A  C G G C A A G C G G A  A G A  G A G A C G A T
A10_ T3_504027. seq
G C T A A C G A C G G C A A G C G G A A G A G A G A C G A T
f f 0 soc
Trout '3 x5  cDSA |C- C C c T C c A G G A G T C T C c T C T A G C C A A T G G C
AW_TS_SQ4Q2 /.sea
G C c T c w A G G A G 1 V I W c T C I A G c A A T G G C
SSC tfi"
Trout '3 x5  cD.\4 Ic A T G G T c C A G G A G G G c G G G A C T T C C T G A G G
4 1 Q_ T3_ S04Q2 7. sea
A - G G - - C A G G A G G G - G G G A C T - •- C T G 4 G G
Trout '3 x5  c£?.\‘4  |a  A G C A G A T  G A G A G G G G A C C T C T T C T C G C C T
A1Q_T3_SQ4Q27.seo
A A G C A G A T G A G A G G G O A C C T C T T C T  C G C C I
172
~0C 7tc '.V
Treat *3 x5  C a \~  | c  A  G C A  G A  T T G A  G A  C A  I  C A  G A  G T A I  T C G G  C C 1
■U0.T3_SQdC27.seQ ------------------------------------------------------------------------------------------------------
C A G C A G A . . G A O  A C  A T  C A O A C T A T  7 C G G C C
Treat °3*5  c r V 4  | a T G G C  T C  T  A G C C G O T  G G A T T  G O A  G O A  G A T  G |
4 / 0_ 73^50402  7.
A T G C C T C T A G C C G G 7 G G A T T C C A G C A C A T G
T« 770 "SC
Tree: K ix f  c £ \ 4  {A  a  a  a  c  c  A  a  I  C I  G G C C A  a  t  c  c  a  g  G G I  C A  G C G |
4 0_ T3_ SC 402 7. zee
A A A A  C C A  A T C T G G C  C A A T C C A G G C* T C A G C C*
see s.q
Trev: '-3*5 cD m  I g g g g a g c  t  a  g  g  a  g  c c a  g  t  g  t  t  c c g g g c  C C  a !
4  J 0_ 73_ SQ4Q27. s *q
G G C G A G C  T A G G A G C C A G T G T C 0  G G C C C A
S-CC S3C 5-iC
Trent *3 x3  I c a g t c c t a t c c a c t g c c a g g t c g a g a c c t c j
At0m.T3_S04Q27.seq
C A G T C C  T A T C C  A C  T O C C A C G T C O A G A C C  T C
Sense Primer (:Pax5/860 S) 
ssc ssc V s * c
Trcvt *3x5 cDSA |T G C A G C A C c | C C C 7 C C C C 0 G C T A C C c  C C C A
4!C_TS_SQ4Q2Z:ez G T G C G Gj C C G C G C T A C c C C c C A
T G C A G C A C C K V  5 c K S c c S s V — A c £ c c £ £  A
SSC ssc see
Trent *3x5 cDX4 C A C G T c C c c c C A A C G G G C C A G G G C A G C T A c
A!0_T3_S04027.oeq C A C O T c c c c  c C A A C G G G C c A G G G C A G C T A C
c A C G T L L L c  c C A A C G G G C c A G G 0  c A G C A  C
310
Exon 8 (ruclec'ide 920)
!0 sec
Trent *3x5 cDS4 T C T G C  C T C C T C A C T G A C T
°
G T A T G O T A C  C C J
4!0_T3_SC4027e*G T C T G C c t C C T C A C T G A C T 0
T c T G C c c C T C A c T G A C T G C* T A T O G T A C c c
Exon 8
> <
Exor 9
340 SSC sec
Trot’f *3*5 c£.V4 * - A G G A G A T T T T T C C G G G A G T C C C T A T T c c l
- I t  CL T 3_5 0 4 0 2 7 . sea
G 0  A G G A C A T T T T T C C G G G A C- 
§70 SSC
C C C A T T C C 
SSC
Trc-cf ?3X5 C D NI |C A C C C T C A G T A
4 10 _  T3_S 04Q 27. sect
A T A T A A C 0  A G T C C 1
C A C C C T C A G T A T T C C A C A T A T A A C G A G I  C C
Exon 9 Exon 10
'COO m e > f
Trent *3x5 cDS4 |T  G G A G A T T T C C A A A C C C C A  G C C T G T T A  0 T *
4 10_T3_S04Q27.seq -  ' -  .  ■ 3 T G
'C3C 1040 'CSC
Trent *3 x5  c<?.V4 
& W _ T 3 „S 0 4 Q 2 7 .o e q
T T C C A A C A G G A C T A T G G G T C T  C T  C C T G  G O G  
T T C C A A C  A G G A C  T A T G G G T C  T C  T C  C T G G G G
T 7 C A A :  A G 7 C* G C- 7 C C T G G G G
173
Trcvt PcxS
4 1 £L T3_50d027. zee
Trcvt *3*5 cDN* 
l!Q_T3_SC402?.zeq
Trcvt *3*5 cDSA 
*!C_T3_SQ402Zz#s
Trcvt *3*5  cDA4 
Jif0_T3.SC4027.zee
Trcvt *3x5 cDSA 
A!0_T3„SQd027.seq
fOS3 TZ7C 10SC
A C G G A G A T C G G A T G T T C C T  C I O  &  G C T C T T C 
A C G O A  G A  T  C G G A T G T T  C C T C T G G G C T C T T  C
A C G G A G A . C G G A 
Antisense Primer (tPaxSi'l 104.AS) 
V g *
G T T C C T C T G G G
t t SC
I  C I  T C
A C C 0  C C A G C C A & A C G G G A C A G A I  G|
A C C  G C C A  G C C A  G A C G G G A
A C C O C A G C A G A C G G G A
T  [ X]  
C A G A T  g |  [aJ
G G 
G G
me
G
A G A T G M A X G G 5
T C G C C G T 
G A A T T C C
A C 
A C
rrjc m e
f  A C A G C G C G G C A T  C G A Q ~
K M R V V S V A
T T G
W W Y K A C A C C C C G O C A T C G A C A
**>.* tree f#70
|G  g  g  g  c g  g  g  a  c c  g  g  c t  g  c c a  c g "g  c a  a  c t  g T c I
G G G G C G G G A C  C G G C  T G C  C A C G G C A A C  T G C  C
1190 119C rCOC
[ K C G C C T A  C G A C C G C C A  C I  ~ G a ]
T C C G C C T A C G A C C G C C A C T G A
174
6. Formatted multiple alignment of full-length trout Pax5 and Pax5/A9c clone (with
deleted exon 9 (nucleotides 920 to 1072) -  E9160al_T3_497317).
10 20 30
Trout PaxS cDSA | a  t  g  g  a  a  g  t  a  g  a  g  g  c  c  g  a  o  g  g  i  c  a  t  g  t  g  t  t  g ]  
p3xB-de!9c
A T G G A A G T A G A G G C C G A G G G T C A T G T G T T  G 
40 50 SC
TroutPsx5cDXA | a g g c c g g g a c c a c c a g g a g c a c a t g g a  g T T g  
PsxS-ds:9c
A G G C C G G G A C G A G C A G G A G G A C A T G G A G G G  
TC_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  50
Trout Psx5 cDNA |G  T G A  A  T  C A  G T  T  A  G G A  G (■ C G T  G T  T  C G T  G A  A~C~[
p3xS-de!9c
G T G A A T C  A G T T A G G A G G C G T G T T C G T  G A A C
100 HO 120
Trcut 3sx5 cDXA |G  G C A  G G C C C C T C C C A G A T  G T G G T G C G A A  C~G
P3xS-ds!9c
G G C A G G C C C C T C C C A G A T G T G G T G C G A A C G
ISC 140 ISO
Trcut PlxS cDSA |C G A  A  T  C G T  A  G A  G C T  G G C T  C A  C C A  A  G G G G T ~ T [
p3xS-ds!9c
C G A A :  C G T A G A G C  T 6 G C  T C A C C  A A G G G G T C
ISO 170 ISC
Trcut P&5 cDXA |c G C C C C T  G T  G A  T  A  T  C T  C T  C G A  C A  G C T  C C G~"g|
PsxS-dslQc
C G C C C C  T G T G A  T A T C  T C  7 C G A C A G C  T C C G G
15C 200 210
Trcut PsxS cDXA |G  T C A  G T  C A  C G G A  I  G I  G T C A  G C A  A  G A  T  A  C T~G~f
p3xS-de!9c
G T C A G T C A C G G A T G T G T C A G C A A G A T A C T G
220 230 24C
Trcut PSxS c£W 4 |G  C G A  G G T  A  C T  A T  G A G A C A  C  G A  A  G T  A T  C C G T |  
P3x5-ds!9c
G G G A G G T A C  T A  7 G A G A C A G G A A G T A T C C G T
230 2S0 270
Trcut PsxS cD\A  [c  C C G G G G T  G A  T  T  G G A  G G A  I  C C A  A  A  C C A  A  a T T
p3xS-de!9c
C C C  G G G G T G A T T G G A G G A T C C A A A C C A A A G
aso 3a
Trcut PSXO CDWA |G  T  T  G C T  A  C A C C C A A A G T  G G T  G G A T  A A G A  T~Tf 
P3x5~ds!9c
C T T G C T A C A C C C A A A G T G G T G G A T A A G A 7  C
31C 320 330
Trcut Pax5cD N A  |G  C C G A C T A C A A a  c g  c c a  a  a  a  c c c  c a  c c a  t ~ g
P3x$-de!9c
G C C G A C T A C A A A C G C C  A A A A C C C C A C C A T G
175
j - ; JSO sso
Treat Pox 5 cDX4 
? 3 xS -d e !9 c
Treat *3*5 cDX4 
P3xS-de!9c
Treat PixS cD.V4 
p3xS-dei’9c
Treat PsxS cDS'A 
P3xS-Qe!9c
Treat PsxS cDSA 
23xS-2e!9c
T I C  G C C T G G G A G A T A C G A G A C A G A C T A T T G
C G C C  T G G G A G A I  A C G A G A C A G A C T A T I G  
37V 333 3SC
G C T G A G A G A G T G T G T G A C A A C G A C A G T G T T
G C T G A G A G A G T G T G T G A C A A C G A C A G T G T T
40C 41Q 430
C C C A G T G T C A G C T C I  A T C A A C A G G A T C A T C |
C C C A G T G T C A G C T C T A T C A A C A G G A T C A T C
• ta r  440 450
A G G A C T A A A G T C C A C- C A G C C T C C G G G T C A g |
A G G A C T A A A G  T C  C A G C A G C C  T C  C G G G T C A G
4€C 470 4SC
T C A G G A C C T C T C T C I  G C T C A T A A C C T G G C G[
T C A G G A C C  T C  T C  T C T G C T C A T A A C C T G G C G  
490 500 510
Treat P3xS cDNA 
?3xS-ae!9c
Treat PoxS cDSA 
P3x5-de!9c
Treat P3x5 cD.\'A 
PaxS-ae!9c
Treat P ix5 cDMA 
~’3xS-3e!9c
Treat *3xS oD\’A 
P3xS-de!9c
Treat Pix5 cDSA 
p3xS-de!9c
T C G T  C G G T A G C G T C G A C A C A G G T T T C C G C G
T C G T C G G T A G C G T C G A C A C A G G T T T C C G C G
530  530 540
t o T G A C C A G T G A C T C G G C T G G C T C C T C C T A CI
G A C C A G T O  A G G C 1 G G C  1 C C T C C  T A G  
550 570
T C ' C A T  c a g c  G G C A T T C T G G G A A T C ' A G C T C A
T C C A 7 C A G C G G C A T T C  T G G G A A T C A G C  T C A
r f C 500
G C T A A C G A C G G C A A G C G G A A G A G A G A C G A T
G C T A A C G A C G G
€70
A A G C C- G A A C- A G A G A C G A T 
600 630
| GC C C T C C  A G G A G T C T C C  T C T A G C C  A A T C» G~C
G C C C C A G G A G T C  T C C  T C  T A G C C A A T G G
54C 650 SSC
C A T G G T C  C A G G A G G G C G G G A C  T T C  C T G A G G
C A T G G T C C A G G A C G G C G G G A C T T C C T  G A G G
Treat PoxS cD\'A 
PsxS-Q€!9c
A A G C A G A T G A G A G G G G A C C T C T T C T C G C C T
A A G C A G A T G A G A G G G G A C T T C T C G C C T
176
TOO 710 7 X
Trout PsxS cDMd |c a  g  c  a  g  a  t  t  o  a  g  a  c a  t  c  a  g  a  g  t  a  t  t  c g  g  c c|
PaxS-delQc
C A O C A G A T T C A C A C A T C A C A C T A T T C C C C C
SO  743 7SC
Trout PsxS cD \A  | A T G G C T C T A G C  C G G T G G A f f T o  A G G A G A T G|
P3xS-a*l9c
A T G G C  T C  T A G C C G G T G G A T T G G A G G A G A T G
760 770 S C
Trout PsxS cDNA | a  a  a  a  C C A a  T C T G G C C A A T C C A G G G T C A G C G|
Psx S-de<Qc
A A A A C C A A T C T G G C C A A T C C A G G G T C A G C G
*SC 330 SIC
Trout PsxScDNA I g g g g a g c  t  a  o  g  a  g  c  c a g t g t t c  c g g g c c c a |
PjxS-O e'Q c
G G G G A G C T A G G A C- C C A G T C* T T C C G G G C C C A
SCO S30 S4C'
Trout PsxS cDNA [C A G T C C T A T  C C A C  T GC C A G O T  C G A G A C C T Cj
p3xS -de!9c
C A G T C  C T A T C C  A C  T G C C A G G T C G A G A C C  T C
SSC
Trout PsxS cDNA T 
P3xS-de>9c
G C 
G C
V C C M S Y W U V & T S 
MO
Sense Primer (iPax5/860 S) 
S6C S
G G
ssc 9CC
Trout PsxS Ci 
PsxS~de!9
5 cDNA j c A C G T C C C C c k  A A C  
: c [ C A C G T C C  C C C  C A A C
C C A G G G C A G C T A C 
I G G C C A G G G C  A  C C T A C
C C C C A A C K G 6 C C A O G O C A G C T A
Exon 8 (nucleotide 920)
Trout PsxS cDHA 
P3xS-de:9c
910 SCO /  93C
T c T g T T t T T T c T I :  t  g  a  c  t  g of f  a  t  g  g  t  a  c c c|
T C T G C C T C C  T (  A C T G A C T G C
T C  7 G C C  T C C  T C A C T G A C T G C T A T G C T A C C C
Trout Psx 5 Ct?V4 
PsxS-defffc
Excn 8 Exon 9
940 950 9SC
O A O O A O A T T T T U C C O G A O T C C C T A  i J Q ]
5 C. $
C G A G G A G A T T T 
970
T C G G G A G 
MO
C C C A T T C
99C
Trout PsxS cDSA |C A C C C T C A G T A T T C C A C A T A T A A C G A C T C C]
P3xS-ae!9c
c a c c c t c a g t a t t c c a c a t a t a a c g a g t c c
Exon 9 Exon 10
rOOC 1010
Trout PjxS cDNA | t  g"g a " g X t  t t c c a a a c c c c  u r c T o i  T
P3xS-3&9c 
T G G A G A T T T C C A A A C C C C A G C C T G T T A G T G
e iu 
\ /  r a »
■Jo T oj
Trcut 9*xS cDNA 
$-Qe9c
*330 *-343 «CSC
A G G AC T A  T' G G G T  C T C T C C T G G~G g1
T C C A A C  A G G A C  T A T G G G T C
177
C T C C T G G G G
Trcvt ?3xS cDNA 
PsxS-de'Qc
Trout PzxS cDNA 
P3xS-de:dc
Trout Psx(S cDNA 
P3xS-ae:9c
Trout PixS cDNA 
PjxS-delQc
Trout Pjx5 cDNA 
P3x5-de!9c
•060
Ia c o g a g  a  t T o g a
t 070
-£ j"
Exon 10 (nt 1072) 
rOSC
W c T c T T
^ |G C T C T T
A C G G A G A T C G G A T G T  T C C  T C  T O G G C  T C  T T C
Antiserse primer (tPax5/1104.AS) 
ujto 1110
A C C G 
A C C G
A G C C A G A C G G G A C A G A T 
A G C  C A G A C G G G A C A G A T
A
A
G G 
G GPa  c c  g c t  .U - !  i  A A t £ £ £ A ■ A £ A ? o m a k g g  g
1100 1130 11*0
c [g|  [g g c a  t  c g a  g a]
t B g
T C G C C G W A Y I  A C Y A C A G Y G S G G C A T C G A G A
|T  C G C C G T A C
T M C
A C A G 
A C A G
11SC 1160 1170
[g" g~g~g~ c -g ’g g a  c c g g c t  g c c a c g g c a a  c t  g c c |
G G G G C  G G G A C C  G G C  T G C C A C G G C  A A C  T G C C
1130 1190 130C
f t  C C G C C T A r  G~A C~C G C C A C T~G~a|
T C C C- C C T A C G A C C G C C A C T G A
178
